ReachMD CME: Recent Episodes
ReachMD
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
CME credits: 1.00
Valid until: 16-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/ADT-Intensification-The-Evidence-You-Cant-Afford-to-Miss/57196/
This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 16-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/Winning-the-Battle-Against-Side-Effects-Adverse-Event-Management-in-HSPC/57198/
This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 16-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/Molecular-Profiling-in-mHSPC-Informing-Treatment-Selection/57199/
This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 16-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/Targeting-PTEN-Why-It-Matters/57200/
This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 16-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/Case-Implementing-ADT-Intensification-in-mHSPC/57197/
This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 16-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/De-Novo-mHSPC-Recognizing-the-Patients-Who-Need-More/57195/
This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 0.75
Valid until: 08-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/leadoff-hitter-spotting-high-risk-players/56435/
This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.
Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.
CME credits: 0.75
Valid until: 08-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/crossing-home-plate-building-a-winning-team-culture/56441/
This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.
Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.
CME credits: 0.75
Valid until: 08-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/turning-the-double-play-comprehensive-secondary-prevention/56440/
This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.
Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.
CME credits: 0.75
Valid until: 08-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/extra-innings-sustaining-victory-beyond-the-first-game/56439/
This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.
Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.
CME credits: 0.75
Valid until: 08-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/small-ball-wins-games-combination-therapy-for-goal-attainment/56438/
This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.
Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.
CME credits: 0.75
Valid until: 08-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/swing-for-the-fences-ldl-c-as-the-power-hitter/56437/
This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.
Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.
CME credits: 0.50
Valid until: 23-07-2027
Claim your CME credit at https://reachmd.com/programs/cme/ongoing-trials-in-oral-targeted-strategies-in-breast-cancer/57228/
Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
CME credits: 0.50
Valid until: 23-07-2027
Claim your CME credit at https://reachmd.com/programs/cme/serena-6-acting-on-esr1-mutations-in-advanced-breast-cancer/57229/
Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
CME credits: 0.50
Valid until: 23-07-2027
Claim your CME credit at https://reachmd.com/programs/cme/elevate-elacestrant-plus-capivasertib-in-advanced-breast-cancer/57227/
Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
CME credits: 0.50
Valid until: 29-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/all-hands-on-deck-multidisciplinary-coordination-for-smarter-perioperative-care/57093/
This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.
CME credits: 0.50
Valid until: 29-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/before-the-scalpel-identifying-candidates-for-perioperative-immunotherapy/57086/
This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.
CME credits: 0.50
Valid until: 29-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/choosing-the-path-forward-a-real-world-dialogue-on-perioperative-immunotherapy/57089/
This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.
CME credits: 0.50
Valid until: 29-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/partnering-through-treatment-preparing-for-immunotherapy-in-the-perioperative-setting/57090/
This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.
CME credits: 0.50
Valid until: 29-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/turning-evidence-into-action-applying-perioperative-data-to-real-world-practice/57091/
This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.
CME credits: 1.00
Valid until: 26-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/the-15-minute-med-check-making-aims-and-td-screening-routine-in-psychiatry/56643/
Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 26-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/treating-the-complex-patient-td-management-in-older-adults-and-medically-fragile-populations/56647/
Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 26-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/shared-decisions-real-patients-patient-centered-td-and-antipsychotic-strategies/56648/
Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 26-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/when-movements-steal-lives-td-burden-stigma-and-the-therapeutic-alliance/56641/
Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 26-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/subtle-vs-syndromic-distinguishing-td-from-other-dimds-in-the-neuro-clinic/56642/
Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 26-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/closing-the-gap-equity-disparities-and-access-to-td-diagnosis-and-care/56644/
Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 26-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/not-all-vmat2s-are-the-same-understanding-the-pkpd-differences/56645/
Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 26-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/from-eps-to-personalized-td-treatment-matching-vmat2-moa-to-the-patient/56646/
Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 07-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/her2-breast-cancer-with-brain-metastases-rethinking-first-line-treatment-in-the-adc-era/56518/
What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.
CME credits: 1.00
Valid until: 07-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/managing-brain-metastases-through-multidisciplinary-team-collaboration/56522/
What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.
CME credits: 1.00
Valid until: 07-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/egfr-mutated-nsclc-with-brain-metastases-navigating-adc-treatment-decisions/56521/
What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.
CME credits: 1.00
Valid until: 07-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/sequencing-systemic-and-local-therapy-in-her2-overexpressing-metastatic-nsclc/56520/
What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.
CME credits: 1.00
Valid until: 07-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/first-line-management-of-hrher2-low-breast-cancer-with-brain-metastases/56519/
What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.
CME credits: 1.00
Valid until: 07-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/brain-metastases-management-from-detection-to-multidisciplinary-care/56517/
What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.
CME credits: 1.00
Valid until: 01-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/beyond-biology-environmental-and-lifestyle-influences-in-ibd/56891/
This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.
CME credits: 1.00
Valid until: 01-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-microbiomes-role-in-ibd-management/56892/
This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.
CME credits: 1.00
Valid until: 01-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/putting-it-all-together-challenges-addressed/56894/
This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.
CME credits: 1.00
Valid until: 01-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/ibd-beyond-symptoms-what-community-gis-need-to-know/54127/
This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.
CME credits: 1.00
Valid until: 01-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/pathophysiology-of-ibd-the-war-within/56889/
This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.
CME credits: 1.00
Valid until: 01-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/genetic-susceptibility-in-ibd-from-risk-genes-to-clinical-impact/56893/
This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.
CME credits: 1.00
Valid until: 01-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/targeting-inflammation-in-ibd-localized-vs-systemic-strategies/56890/
This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.
CME credits: 1.00
Valid until: 15-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/Catching-Demodex-in-the-Act/56703/
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 15-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/closing-the-loop-structured-follow-up-and-patient-communication/56708/
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 15-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/Key-Takeaways-and-Practice-Integration/56710/
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 15-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/return-and-revisit-a-38-year-old-patient-returns-for-follow-up-after-lotilaner-treatment/56709/
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 0.75
Valid until: 28-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/nps-agitation-evidence-and-emerging-mechanisms-of-management/56766/
This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
CME credits: 0.75
Valid until: 28-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/nps-psychosis-circuits-treatment-and-new-hope/56765/
This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
CME credits: 1.00
Valid until: 15-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/the-missed-diagnosis-a-45-year-old-software-engineer-who-complains-of-dry-eyes/56705/
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 0.75
Valid until: 28-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/Amyloid-Therapies-in-Practice-Not-All-Are-Created-Equal/56761/
This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
CME credits: 0.75
Valid until: 28-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/unseen-impact-of-nps-in-ad-domains-and-burden/56764/
This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
CME credits: 0.75
Valid until: 28-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/tau-therapies-and-clinical-translation-mechanistic-approaches/56762/
This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
CME credits: 1.00
Valid until: 15-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/moving-beyond-lid-hygiene-evidence-based-treatment-strategies/56706/
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 15-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/the-neverending-journey-a-66-year-old-patient-who-has-undergone-several-rounds-of-tea-tree-oilbased-treatment/56707/
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 15-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/At-the-Intersection-of-DB-DED-MGD-and-Other-Forms-of-Blepharitis/56704/
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00
Valid until: 19-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/56979/
This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
CME credits: 1.00
Valid until: 19-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/
This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
CME credits: 1.00
Valid until: 19-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/
This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
CME credits: 1.00
Valid until: 19-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/
This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
CME credits: 1.00
Valid until: 19-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/
This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
CME credits: 1.00
Valid until: 19-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/
This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
CME credits: 1.00
Valid until: 19-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/when-blockers-fall-short-in-ohcm-time-for-a-new-approach/54838/
This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
CME credits: 1.00
Valid until: 19-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/
This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/shared-goals-shared-gains-align-with-patient-preferences/54776/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/escalate-with-intention-stepwise-target-anchored-moves/54773/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/the-2-point-signal-apply-2-point-rule/54777/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/fcrn-same-class-different-pathsspot-agent-differentiators/54778/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/target-locked-in-gmg-why-t2t-matters/54768/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/minimal-by-design-define-mse-endpoints/54769/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/turning-flares-into-function-flag-uncontrolled-disease/54770/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/when-to-begin-fcrn-initiation-criteria-key-evidence/54771/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 24-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/the-igg-clock-redose-using-igg-kinetics/54772/
This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/igan-soc-strengths-and-limits/54682/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/april-uncovered-an-upstream-driver-in-igan/54680/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-igan-disease-modifying-agents/54684/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/targeting-lower-proteinuria-levels-shifting-the-goalpost-in-igan/54686/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 1.00
Valid until: 10-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier escalation at persistent proteinuria ≥0.5 g/day, even in the absence of rapid eGFR decline. Notably, these guidelines recommend a simultaneous, dual-pathway approach, combining optimized supportive therapy (RAAS inhibition, SGLT2 inhibitors) with the timely introduction of immunomodulatory or disease-modifying agents in high-risk patients. However, real-world practice across Asia has not yet caught up. Explore this series for practical strategies to support patient selection and the integration of emerging agents into individualized care.
CME credits: 0.75
Valid until: 04-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/So-You-Think-You-Want-a-TKI/54102/
This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.
CME credits: 0.75
Valid until: 04-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/Who-Needs-a-TKI-Identifying-the-Right-Candidates/54101/
This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.
CME credits: 0.75
Valid until: 04-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/To-Implant-or-to-Inject/54100/
This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.
CME credits: 0.75
Valid until: 04-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/TKI-The-New-TKO-for-Retinal-Diseases/54099/
This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.
CME credits: 0.75
Valid until: 04-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/The-Struggle-Is-Real/54098/
This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.
CME credits: 0.75
Valid until: 13-02-2027
Claim your CME credit at https://reachmd.com/programs/cme/when-gdmt-isnt-enough-understanding-residual-risk-in-patients-with-hfref/51036/
Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support. For cardiologists, the challenge is twofold: accurately identifying high-risk individuals without overt clinical deterioration and knowing when and how to intensify therapy in patients who appear stable but remain vulnerable. Recent data show that soluble guanylate cyclase (sGC) may provide significant reductions in CV death and all-cause mortality, particularly in individuals with moderately elevated NT-proBNP (≤6,000 pg/mL). These findings are especially important because this population is far more common in routine cardiology practice and has historically been overlooked in discussions of additional therapy. However, cardiologists often underestimate risk in these ambulatory patients and may hesitate to add therapies when GDMT appears to be working well. Tune in to learn best practices for patient selection and the implementation of added sGC therapy.
CME credits: 0.75
Valid until: 13-02-2027
Claim your CME credit at https://reachmd.com/programs/cme/do-not-delay-timing-triggers-and-identifying-the-right-patient-for-additional-therapies-in-hfref/54633/
Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support. For cardiologists, the challenge is twofold: accurately identifying high-risk individuals without overt clinical deterioration and knowing when and how to intensify therapy in patients who appear stable but remain vulnerable. Recent data show that soluble guanylate cyclase (sGC) may provide significant reductions in CV death and all-cause mortality, particularly in individuals with moderately elevated NT-proBNP (≤6,000 pg/mL). These findings are especially important because this population is far more common in routine cardiology practice and has historically been overlooked in discussions of additional therapy. However, cardiologists often underestimate risk in these ambulatory patients and may hesitate to add therapies when GDMT appears to be working well. Tune in to learn best practices for patient selection and the implementation of added sGC therapy.
CME credits: 0.75
Valid until: 13-02-2027
Claim your CME credit at https://reachmd.com/programs/cme/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/
Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support. For cardiologists, the challenge is twofold: accurately identifying high-risk individuals without overt clinical deterioration and knowing when and how to intensify therapy in patients who appear stable but remain vulnerable. Recent data show that soluble guanylate cyclase (sGC) may provide significant reductions in CV death and all-cause mortality, particularly in individuals with moderately elevated NT-proBNP (≤6,000 pg/mL). These findings are especially important because this population is far more common in routine cardiology practice and has historically been overlooked in discussions of additional therapy. However, cardiologists often underestimate risk in these ambulatory patients and may hesitate to add therapies when GDMT appears to be working well. Tune in to learn best practices for patient selection and the implementation of added sGC therapy.
CME credits: 0.75
Valid until: 13-02-2027
Claim your CME credit at https://reachmd.com/programs/cme/safety-clinical-integration-and-the-emerging-fifth-pillar-in-hf-practice/54635/
Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support. For cardiologists, the challenge is twofold: accurately identifying high-risk individuals without overt clinical deterioration and knowing when and how to intensify therapy in patients who appear stable but remain vulnerable. Recent data show that soluble guanylate cyclase (sGC) may provide significant reductions in CV death and all-cause mortality, particularly in individuals with moderately elevated NT-proBNP (≤6,000 pg/mL). These findings are especially important because this population is far more common in routine cardiology practice and has historically been overlooked in discussions of additional therapy. However, cardiologists often underestimate risk in these ambulatory patients and may hesitate to add therapies when GDMT appears to be working well. Tune in to learn best practices for patient selection and the implementation of added sGC therapy.
CME credits: 0.75
Valid until: 13-02-2027
Claim your CME credit at https://reachmd.com/programs/cme/gdmt-is-working-fine-why-add-more-therapies-the-clinical-rationale-for-layering-therapies-in-patients-with-hfref/54632/
Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support. For cardiologists, the challenge is twofold: accurately identifying high-risk individuals without overt clinical deterioration and knowing when and how to intensify therapy in patients who appear stable but remain vulnerable. Recent data show that soluble guanylate cyclase (sGC) may provide significant reductions in CV death and all-cause mortality, particularly in individuals with moderately elevated NT-proBNP (≤6,000 pg/mL). These findings are especially important because this population is far more common in routine cardiology practice and has historically been overlooked in discussions of additional therapy. However, cardiologists often underestimate risk in these ambulatory patients and may hesitate to add therapies when GDMT appears to be working well. Tune in to learn best practices for patient selection and the implementation of added sGC therapy.
CME credits: 0.75
Valid until: 29-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/mechanistic-evolution-in-ras-therapy-on-state-and-multi-selective-targeting/54120/
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.
CME credits: 0.75
Valid until: 29-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.
CME credits: 0.75
Valid until: 29-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.
CME credits: 0.75
Valid until: 29-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.
CME credits: 0.75
Valid until: 29-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.
CME credits: 0.75
Valid until: 29-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.
CME credits: 0.75
Valid until: 29-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/unmet-need-second-line-outcomes-remain-poor-for-nsclc-and-pancreatic-cancer/54118/
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.
CME credits: 0.75
Valid until: 29-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/treat-to-target-are-we-there-yet/51485/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/tailoring-treatment-can-you-select-the-best-therapy/51483/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/severity-assessment-can-you-pin-the-stage-on-the-patient/51481/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/switching-strategies-switch-or-staywhats-your-call/51487/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 19-03-2027
Claim your CME credit at https://reachmd.com/programs/cme/remission-can-you-prove-it/51486/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/all-sides-of-the-joint-integrated-tgct-care-across-specialties/48912/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/patient-perspective-navigating-tgct-treatmentsurgery-vs-systemic-therapy/48911/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-safety-equation-managing-adverse-events-associated-with-csf1r-inhibitors-in-tgct/48910/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/applying-the-evidence-tgct-treatment-insights-for-sports-medicine-physicians/48909/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-in-focus-interpreting-data-on-next-generation-csf1r-tkis/48908/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/surgical-crossroads-practical-considerations-for-optimizing-treatment-in-tgct/48907/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-in-focus-interpreting-data-on-systemic-therapy-targeting-csf1r/48906/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-csf1r-code-targeted-pathways-and-tailored-choices/48905/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-scalpel-when-tgct-surgery-isnt-the-solution/48904/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-tumor-thats-not-so-tiny-understanding-the-impact-of-tgct/39305/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Treatment-of-Hepatic-Encephalopathy-Primary-vs-Secondary-Prophylaxis/39791/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Treatment-of-Hepatic-Encephalopathy-When-What-How-and-Why/39790/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-oreatment-of-overt-hepatic-encephalopathy-whats-in-the-pipeline/39794/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Current-Treatment-of-Hepatic-Encephalopathy-Is-It-Meeting-Our-Patients-Needs/39793/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Optimizing-Care-of-the-Hospitalized-Patient-With-Overt-Hepatic-Encephalopathy/39792/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Minimal-Hepatic-Encephalopathy-Hiding-in-Plain-Sight/39787/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Minimal-Hepatic-Encephalopathy-A-Covert-Operation/39788/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/The-Slippery-Slope-of-Overt-Hepatic-Encephalopathy/39789/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 0.50
Valid until: 14-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/looking-ahead-integrating-cdh6-targeted-therapies-into-ovarian-cancer-treatment-paradigms/37866/
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
CME credits: 0.50
Valid until: 14-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
CME credits: 0.50
Valid until: 14-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
CME credits: 0.50
Valid until: 14-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-insights-from-early-trials-of-cdh6-targeted-therapies/37669/
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
CME credits: 0.50
Valid until: 14-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Case-Applications-in-Multidisciplinary-Care-for-Endometrial-Cancer/39298/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Applications-in-Multidisciplinary-Care-for-Cervical-Cancer/39297/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Managing-Immune-Related-Adverse-Events-in-Cervical-and-Endometrial-Cancer/39296/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Evidence-Base-for-Treatment-Strategies-for-Endometrial-Cancer-After-Disease-Progression-and-Interdisciplinary-Collaboration/39295/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Evidence-Base-for-First-Line-Treatment-Strategies-for-Endometrial-Cancer-and-Delivering-Guideline-Concordant-Care/39294/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Role-of-Predictive-Biomarkers-in-Endometrial-Cancer/39293/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Evidence-and-Guideline-Based-Treatment-for-Advanced-Metastatic-Cervical-Cancer/39292/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Screening-for-Cervical-Cancer/39290/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 31-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Interdisciplinary-Management-of-Gynecologic-Cancers/39286/
This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-patient-clinician-connection-in-managing-ckd-ap/36302/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/is-ckd-ap-hiding-in-your-dialysis-center/36299/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/kappa-opioid-settings-real-world-evidence-insights/36300/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/improving-sleep-and-mental-health-in-patients-with-ckd-ap/36301/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/ckd-ap-beyond-the-surface/36294/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/quantifying-ckd-ap-tools-for-better-care/36295/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/ckd-ap-or-something-else-decoding-the-diagnosis/36296/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/ckd-ap-treatment-tool-kit/36297/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 24-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/elevating-ckd-ap-care-new-frontier/36298/
Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-unmet-therapeutic-needs/39665/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-tipping-the-balance/39660/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/you-cant-diagnose-mhe-unless-you-diagnose-cirrhosis/39661/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-an-ominous-sign/39666/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/diagnosing-minimal-hepatic-encephalopathy-theres-an-app-for-that/39662/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/treatment-of-overt-hepatic-encephalopathy/39664/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-an-ominous-sign/39278/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-whats-sarcopenia-got-to-do-with-it/39663/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 1.00
Valid until: 23-10-2026
Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/the-clinical-spectrum-of-hepatic-encephalopathy/39304/
This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.
CME credits: 0.75
Valid until: 07-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/
The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75
Valid until: 07-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/
The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75
Valid until: 07-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/
The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75
Valid until: 07-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/
The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75
Valid until: 07-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/
The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75
Valid until: 07-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/
The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75
Valid until: 07-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/
The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75
Valid until: 07-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/
The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 1.00
Valid until: 19-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-managing-adult-and-pediatric-patients-with-fsgs-latest-data/37186/
Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.
CME credits: 1.00
Valid until: 16-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/Anatomical-Outcomes-from-the-LIGHTSITE-III-Trial/35947/
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
CME credits: 1.00
Valid until: 16-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/Integration-of-Photobiomodulation-Therapy-into-the-Age-Related-Macular-Degeneration-Treatment-Landscape/35951/
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
CME credits: 1.00
Valid until: 16-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/Patient-Centered-Care-and-Integration-of-Photobiomodulation-Therapy-into-Clinical-Practice/35950/
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
CME credits: 1.00
Valid until: 16-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/Best-Practices-for-Optimized-Photobiomodulation-Treatment-Effect-Candidate-Selection/35949/
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
CME credits: 1.00
Valid until: 16-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/Sustaining-Visual-Benefits-of-Photobiomodulation-in-Dry-Age-Related-Macular-Degeneration/35948/
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
CME credits: 1.00
Valid until: 16-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/Real-World-Evidence-of-Photobiomodulation-Efficacy-in-Ocular-Indications/35952/
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
CME credits: 1.00
Valid until: 16-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/Clinical-and-Safety-Outcomes-from-the-LIGHTSITE-III-Trial/35946/
This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
CME credits: 0.75
Valid until: 22-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-for-perioperative-icis-in-locally-advanced-hnscc/36593/
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
CME credits: 0.75
Valid until: 22-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/rationale-for-combining-radiation-and-immunotherapy-in-resectable-locally-advanced-hnscc/36592/
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
CME credits: 0.75
Valid until: 22-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-landscape-of-resectable-locally-advanced-hnscc/36576/
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
CME credits: 0.75
Valid until: 22-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/applying-perioperative-icis-in-clinical-practice/36634/
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
CME credits: 0.75
Valid until: 22-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-in-the-perioperative-setting/36635/
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
CME credits: 0.75
Valid until: 22-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
CME credits: 0.75
Valid until: 22-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-collaboration-facilitates-multimodality-therapy/36636/
This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/next-generation-innovations-the-future-of-celmods-in-myeloma/36575/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/molecular-magic-decoding-the-unique-mechanism-of-celmods/36562/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/data-dive-clinical-evidence-behind-celmods/36568/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/precision-targeting-matching-celmods-to-the-right-patient-with-myeloma/36569/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/mastering-the-sequence-celmods-across-treatment-lines/36570/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/safety-first-navigating-celmod-associated-toxicities/36571/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/real-world-ready-practical-tips-for-community-oncologists/36572/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/case-application-frontline-insightstackling-newly-diagnosed-myeloma/36573/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/case-application-unlocking-relapsedrefractory-myeloma-with-celmods/36574/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 21-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/why-celmods-matter-in-myeloma/36558/
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/How-to-Build-A-Multidisciplinary-Team-in-HAE-to-Optimize-Patient-Care/35993/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/program-name/35990/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/program-name/35991/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/program-name/35992/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/program-name/35985/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/program-name/35986/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/program-name/35987/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/program-name/35988/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 11-08-2026
Claim your CME credit at https://reachmd.com/programs/cme/program-name/35989/
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/met-and-other-emerging-targets-in-metastatic-nsclc/36152/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/finding-the-optimal-treatment-for-egfr-mutated-metastatic-nsclc/36150/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/her2-driven-strategies-in-metastatic-nsclc/36151/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutic-developments-in-non-targetable-metastatic-nsclc/36153/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/updates-in-limited-stage-small-cell-lung-cancer-ls-sclc/36145/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/novel-therapies-in-extensive-stage-small-cell-lung-cancer-es-sclc/36146/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/applications-of-emerging-data-in-resectable-nsclc/36147/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-current-therapeutic-landscape-in-unresectable-stage-iii-nsclc/36148/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/strategies-in-egfr-mutated-unresectable-stage-iii-nsclc/36149/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
CME credits: 1.00
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCNGuideline® recommendations.
*This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/expert-recommendations-and-key-takeaways/36186/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/stratifying-risk-to-guide-therapy-in-rr-aml/36177/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/molecular-profiling-as-a-cornerstone-of-precision-aml-therapy/36178/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-directions-in-menin-directed-aml-therapy/36184/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-recommended-targeted-therapies-into-rr-aml-management/36181/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-menin-inhibitors/36182/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 25-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/applying-evidence-to-clinical-practice/36183/
This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/aligning-pah-treatment-plans-with-key-care-goals-and-your-patients-priorities/33238/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/managing-travel-with-pah-logistics-medications-oxygen-and-emergency-preparedness/33237/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/proms-role-in-clinical-research-and-contributions-to-pah-patient-perspectives/33244/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/proms-in-clinical-practice-impacting-treatment-decisions/33243/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/a-comparison-of-proms-and-how-to-use-them-in-clinical-practice-for-pah/33241/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/what-challenges-and-triumphs-do-patients-face-while-living-with-pah/33242/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-latest-patient-centered-recommendations-from-the-7th-world-symposium-on-ph/33236/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00
Valid until: 15-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/patient-reported-outcome-measures-proms-valuable-insights-into-the-lived-experience-of-pah/33240/
Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 0.50
Valid until: 09-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/differentiating-neuromodulation-therapies-vns-dbs-ect-tms/35793/
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 0.50
Valid until: 09-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-vns-parameters-keys-to-therapeutic-success/35797/
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 0.50
Valid until: 09-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/qol-matters-brain-stem-stimulation-in-patients-with-unipolar-depression/35796/
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 0.50
Valid until: 09-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/vns-beyond-seizure-control/35795/
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 0.50
Valid until: 09-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/epilepsy-beyond-seizure-impact/35794/
This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/when-and-why-to-use-cac-scoring/35818/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-dose-matters-optimizing-statin-intensity-in-ascvd-management/35816/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/where-does-this-patient-land-making-sense-of-risk-and-ldl-c-goals/35815/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/statins-and-safety-what-the-data-say-about-dementia-cancer-and-more/35819/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/expanding-access-alternative-models-for-delivering-lipid-lowering-therapy/35817/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/bridging-ascvd-care-between-academic-and-rural-settings/35824/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/unmasking-hidden-risk-the-role-of-lpa-in-cardiovascular-risk-assessment/35823/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/personalizing-ldl-c-treatmentnovel-options-that-align-with-patient-preferences/35822/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/target-in-sight-escalating-therapy-to-reach-ldl-c-goals/35821/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 10-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/closing-the-loop-practical-strategies-for-timely-lipid-panel-follow-up/35820/
Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/remnant-cholesterol-the-missing-link-in-ascvd-risk/33226/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 0.50
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/practical-tips-for-glp-1-ra-therapy-success/35830/
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
CME credits: 0.50
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-scale-how-to-tackle-obesitys-comorbidities/35829/
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
CME credits: 0.50
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/treating-obesity-lifelong-strategies-from-lifestyle-to-pharmacotherapy-and-surgery-treating-obesity-lifelong-strategies-ffrom-lifestyle-to-pharmacotherapy-and-surgery/35828/
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
CME credits: 0.50
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/obesity-and-comorbidities-strategies-for-effective-patient-management/35827/
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
CME credits: 0.50
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/obesity-unmasking-the-chronic-disease-beneath-the-weight/35826/
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-road-ahead-whats-on-the-horizon-for-fcs-and-shtg-management/33228/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/targeting-mixed-hyperlipidemia-with-apoc3-inhibition/33227/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/shtg-decoding-the-latest-clinical-trial-outcomes/33225/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/shtg-defining-the-unmet-clinical-need/33224/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/latest-clinical-trial-outcomes-and-breakthroughs-for-fcs/33223/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/apoc3-inhibition-a-novel-approach-to-lowering-tgs/33222/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/fcs-enhancing-the-diagnosis/33220/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/setting-the-bar-guideline-recommended-treatment-in-hypertriglyceridemia/33221/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/evaluating-novel-factor-replacement-strategies-extended-and-ultra-half-life-factors-and-factor-mimetics/35548/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/evaluating-emerging-treatment-options-rebalancing-therapies/35549/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-promise-and-future-of-gene-therapy/35550/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-team-collaboration-in-the-new-era-of-hemophilia-treatment/35554/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/integrating-new-therapies-into-healthcare/35553/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/considering-the-promise-of-new-and-emerging-treatments-for-hemophilia-managing-thrombotic-risks/35552/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/considering-the-promise-of-new-and-emerging-treatments-for-hemophilia-the-need-for-iti/35551/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/an-overview-of-current-and-emerging-treatment-options-for-hemophilia-a-b/35546/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-impact-of-hemophilia-across-patients-lives/35547/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 1.25
Valid until: 30-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/moving-forwardwhat-is-on-the-horizon-personalized-therapies-for-patients/35555/
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
CME credits: 0.25
Valid until: 16-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/
Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.
This two-part programme provides an overview of the different first- and second-line chemotherapy options.
Complete both modules, answer pre- and post-test questions and start earning CME credits.
This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
CME credits: 0.25
Valid until: 16-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/
Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.
This two-part programme provides an overview of the different first- and second-line chemotherapy options.
Complete both modules, answer pre- and post-test questions and start earning CME credits.
This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-advances-in-gmg-effective-tools-and-techniques/32727/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/a-scientific-look-at-fcrn-antagonists-mechanisms-of-action-explained/32730/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-mg-how-fcrn-antagonists-are-changing-mg-therapy/32731/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/traditional-mg-treatments-balancing-benefits-risks-and-side-effect-management/32729/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-for-gmg-tailoring-treatments-based-on-patient-profiles/32735/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/ocular-to-generalized-mg-how-and-why-the-disease-evolves/32733/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/managing-side-effects-in-fcrn-therapy-best-practices-for-gmg/32732/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/living-with-gmg-navigating-personal-professional-and-mental-health-challenges/32726/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-science-behind-fcrn-antagonists-a-deep-dive-into-their-mechanism-of-action/32241/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-fcrn-therapy-addressing-and-reducing-adverse-reactions/32243/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-myasthenia-gravis-crafting-personalized-treatment-strategies/32244/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/fcrn-antagonists-in-myasthenia-gravis-a-new-era-in-targeted-therapy/32242/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/balancing-risk-and-benefit-traditional-mg-treatments-and-medications-to-avoid/32240/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-in-mg-their-role-in-diagnosis-and-treatment/32239/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-gmg-navigating-current-tools-and-approaches/32238/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/life-threatening-events-understanding-and-preventing-myasthenic-crisis/32237/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-symptoms-the-true-impact-of-gmg-on-patients-lives/32235/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 1.00
Valid until: 17-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/understanding-disease-progression-the-shift-from-ocular-to-generalized-mg/32236/
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
CME credits: 0.75
Valid until: 20-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/effective-monitoring-and-management-of-adverse-effects-in-metastatic-escc/29792/
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
CME credits: 0.75
Valid until: 20-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-importance-of-pd-l1-testing-shaping-the-future-of-treatment-in-escc/29791/
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
CME credits: 0.75
Valid until: 20-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/distinguishing-between-anti-pd-1-agents-in-escc-combination-therapies/29790/
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guidelines-concordant-care-for-advanced-nsclc-with-second-line-targeted-therapies/29136/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-and-practice-changing-directions-in-nsclc-within-the-perioperative-and-locally-advanced-settings/29137/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-behind-emerging-targeted-therapy-strategies-in-patients-with-metastatic-nsclc/29138/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-optimizing-patient-care-in-nsclc/29139/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-oncology-learning-center-from-guidelines-to-practice-lung-cancer/29133/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-first-line-treatment-of-advanced-nsclc-with-targeted-therapies/29134/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/guidelines-recommended-targeted-therapies-as-second-line-treatment-options-for-patients-with-metastatic-nsclc/29135/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/application-of-guidelines-recommended-broad-molecular-profiling-to-patients-with-nsclc/29130/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guidelines-for-immunotherapy-in-the-neoadjuvant-and-adjuvant-settings/29131/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 27-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guidelines-concordant-immunotherapy-in-the-perioperative-setting-of-nsclc/29132/
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
CME credits: 1.00
Valid until: 08-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-a-sleepy-patient-behind-those-numbers/29112/
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
CME credits: 1.00
Valid until: 08-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/pbc-target-practice-normalization-is-the-new-norm/29110/
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
CME credits: 1.00
Valid until: 08-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-2/29115/
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
CME credits: 1.00
Valid until: 08-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/pbc-is-risky-business/29109/
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
CME credits: 1.00
Valid until: 08-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/does-your-patient-have-pbc/29108/
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
CME credits: 1.00
Valid until: 08-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-1/29114/
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
CME credits: 1.00
Valid until: 08-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-an-itchy-patient-behind-those-numbers/29113/
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
CME credits: 1.00
Valid until: 08-11-2025
Claim your CME credit at https://reachmd.com/programs/cme/initiating-second-line-therapy-what-when-and-then-what/29111/
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.
CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/her2-testing-strategies-across-tumor-types-amidst-guidelines-gaps/26789/
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-on-targeting-her2-in-her2-expressing-solid-tumors/26791/
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-evaluating-her2-directed-therapies-in-gynecologic-cancers/26792/
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/monitoring-and-managing-treatment-related-adverse-effects-associated-with-her2-directed-agents/26793/
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-ovarian-cancer-treatment-landscape/26794/
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-biliary-tract-cancer-treatment-landscape/26795/
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/significance-of-her2-expression-in-solid-tumors/26788/
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
CME credits: 0.75
Valid until: 30-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/diversity-in-her2-expression-among-gynecologic-cancers/26790/
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-in-newly-diagnosed-cll/26494/
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/breaking-ground-the-latest-data-on-ad-disease-modifying-therapies/26345/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/therapeutic-insights-navigating-the-use-and-challenges-of-disease-modifying-therapies/26346/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/comparative-efficacy-subq-vs-intravenous-dmts-in-alzheimers-disease/26347/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/precision-imaging-mris-critical-role-in-early-mci-ad-diagnosis/26343/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/markers-of-memory-pathological-biomarkers-of-clinical-mci-due-to-ad/26344/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/future-frontiers-the-future-landscape-of-alzheimers-therapeutics/26348/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-subtle-onset-understanding-early-mci-ad-symptoms/26340/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/dementia-on-a-spectrum-preclinical-stages-of-mci-in-ad/26339/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/inequity-and-illness-understanding-mci-disease-course-and-severity-for-racial-minorities/26341/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 25-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/beyond-guesswork-validated-methods-for-mci-assessment-in-alzheimers-diagnosis/26342/
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-anemia/26508/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/pacritinib-for-myelofibrosis-across-the-cytopenic-spectrum/26507/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-to-use-prognostic-risk-scoring-and-symptom-burden-assessment-to-tailor-myelofibrosis-treatment/26504/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-and-when-to-manage-ruxolitinib-failure/26505/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/treatment-options-for-ruxolitinib-intolerance-or-resistance-in-myelofibrosis/26506/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/improving-transfusion-independence-with-jak-inhibitor-therapy/26509/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-supporting-first-line-durvalumabtremelimumab-in-unresectable-hcc/26330/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/empowering-treatment-choice-the-essential-role-of-shared-decision-making-in-unresectable-hcc/26338/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/enhancing-outcomes-in-unresectable-hcc-through-integrated-multidisciplinary-care-models/26337/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-ici-combinations-in-patients-with-unresectable-hcc/26336/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-consult-treatment-options-for-an-unresectable-hcc-patient-who-has-esophageal-varices/26335/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-first-line-ici-combination-regimens-in-patients-with-unresectable-hcc/26334/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/use-of-ici-combination-regimens-in-patients-with-intermediate-stage-hcc/26333/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/selecting-the-optimal-ici-partner-for-first-line-treatment-of-unresectable-hcc-ctla-4-vs-vegf-inhibitors/26332/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-supporting-first-line-atezolizumabbevacizumab-in-unresectable-hcc/26331/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-the-field-of-unresectable-hcc/26329/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/accurate-staging-and-determining-resectability-in-nsclc/24385/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/resolving-practice-barriers-to-consolidative-immunotherapy-in-stage-iii-nsclc/24386/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/differentiating-and-managing-pneumonitis-in-unresectable-stage-iii-nsclc-case-discussion/24393/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-case-discussion/24392/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-with-oncogenic-drivers/24391/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/immunotherapy-approaches-in-unresectable-stage-iii-nsclc-whats-on-the-horizon/24390/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/chemoradiotherapy-toxicities-how-do-they-impact-starting-immunotherapy/24389/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-following-scrt-vs-rt-only-in-stage-iii-nsclc/24388/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/consolidation-immunotherapy-after-concurrent-crt-what-do-real-world-data-show/24387/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
CME credits: 0.50
Valid until: 14-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-changing-covalent-btk-inhibitor-treatment-in-a-patient-intolerant-to-ibrutinib-or-acalabrutinib/24454/
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
CME credits: 0.50
Valid until: 14-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/selection-of-btk-inhibitor-following-frontline-chemoimmunotherapy-in-older-patients-with-comorbidities/24453/
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
CME credits: 0.50
Valid until: 14-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/initial-btk-inhibitor-based-treatment-selection-in-a-treatment-naive-symptomatic-unfit-older-patient-with-comorbidities-and-high-risk-cytogenetics/24452/
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-immunotherapy-related-adverse-events-during-adjuvant-treatment-for-resectable-melanoma/24382/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-resectable-melanoma-outcomes-through-multidisciplinary-care-and-multimodal-treatment-strategies/24383/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-therapeutic-selection-for-a-patient-with-newly-diagnosed-braf-v600e-mutated-metastatic-melanoma/24365/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/first-line-treatment-of-metastatic-melanoma-after-adjuvant-anti-pd-1/24366/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-related-adverse-effects-in-lag-3-combination-ici-therapy-for-metastatic-melanoma/24367/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/patient-case-tailoring-first-line-treatment-for-a-patient-with-metastatic-melanoma-and-impaired-performance-status/24368/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/future-directions-targeting-lag-3-in-melanoma-treatment/24369/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/analyzing-key-data-from-lag-3-combinations-in-the-treatment-of-metastatic-melanoma/24364/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-dermatologists-surgeons-need-to-know-adjuvant-treatment-for-resectable-stage-ii-melanoma/24378/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/unlocking-synergy-exploring-the-interaction-between-lag-3-and-other-immune-checkpoints/24363/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/navigating-adjuvant-ici-treatment-in-stage-ii-melanoma-a-patient-case-presentation/24379/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-dermatologists-surgeons-need-to-know-adjuvant-treatment-for-resectable-stage-iiiiv-melanoma/24380/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-consult-adjuvant-therapy-following-localized-treatment-for-stage-iii-melanoma/24381/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
CME credits: 1.00
Valid until: 23-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-multiple-faces-of-attrv-pn/24134/
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
CME credits: 1.00
Valid until: 23-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/raising-the-red-flag-whats-your-index-of-suspicion-for-attrv-pn/24135/
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
CME credits: 1.00
Valid until: 23-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-attrv-pn-whats-in-your-toolbox/24136/
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
CME credits: 1.00
Valid until: 23-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/attrv-pn-a-complicated-disease-with-a-poor-prognosis/24133/
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
CME credits: 1.00
Valid until: 23-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/shhgene-silencing-therapies-for-attrv-pn/24137/
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
CME credits: 1.00
Valid until: 23-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/advancing-the-treatment-of-attrv-pn-whats-in-the-pipeline/24139/
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
CME credits: 1.00
Valid until: 23-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/attrv-pn-a-family-affair/24138/
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
CME credits: 1.00
Valid until: 23-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/attr-amyloidosis-familial-vs-wild-type/24132/
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
CME credits: 0.50
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/osa-exploring-the-impact-on-morbidity-and-mortality/24190/
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
CME credits: 0.50
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/pre-operative-vigilance-the-role-of-osa-screening-in-surgical-safety/24191/
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
CME credits: 0.50
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/overcoming-hurdles-effective-osa-screening-in-primary-care/24192/
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
CME credits: 0.50
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-to-screen-for-osa/24193/
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
CME credits: 0.50
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/from-awareness-to-action-what-to-do-with-a-positive-osa-screen/24194/
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-acute-and-post-acute-risk-of-vte-in-acute-medically-ill-patients/24227/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-options-are-available-prophylactically-for-my-acute-and-post-acute-medically-ill-patients/24228/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-time-vt-edwards-management-of-extended-thromboprophylaxis-in-the-medically-ill/24229/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-do-the-guidelines-suggest-for-prophylaxis-and-how-do-we-implement/24230/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/right-from-the-onset-dvt-diagnosis-management/24231/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/right-from-the-onset-pe-diagnosis-management/24232/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-time-vte-prophylaxis-post-hip-replacement/24233/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/putting-it-all-together-coordinating-the-multidisciplinary-care-plan-for-the-patient-with-vte/24234/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/risk-assessment-whos-most-susceptible-for-a-secondary-vte-event/24235/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/vte-prophylaxis-in-patients-at-risk-for-a-secondary-vte-event-options/24236/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/mrs-vt-elizabeth-a-case-study-on-the-secondary-prevention-of-vte/24237/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.75
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-effectively-integrate-the-latest-vte-treatment-and-secondary-prevention-guidelines-into-clinical-practice/24238/
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
CME credits: 1.25
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/equitable-health-for-all-improving-care-for-underserved-populations-and-their-unmet-needs/24183/
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.25
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-do-i-prevent-future-hospital-visits-due-to-he/24182/
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.25
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/help-aasld-guidelines-related-to-diagnosis-of-he/24180/
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.25
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/west-haven-criteriameaningfulness-into-clinical-practice/24179/
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/therapeutic-options-for-adh1-and-hypoparathyroidism/24176/
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
CME credits: 1.00
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutics-in-adh1-progress-in-precision-medicine/24177/
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
CME credits: 1.25
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-unmet-need-for-he-therapy-in-the-african-american-community-why-is-this-a-concern/24181/
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.25
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/tackling-the-unmet-need-head-onwhat-does-he-look-like/24178/
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/increasing-adh1-awareness-a-hidden-cause-of-hypoparathyroidism/24174/
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
CME credits: 1.00
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/casr-and-adh1-integrating-biology-and-genetic-screening/24175/
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
CME credits: 1.25
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/hear-my-needs-enhancing-the-patient-and-provider-dialogue/24184/
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.25
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/collaboration-and-management-of-he-establishing-foundation-for-successful-outcomes/24185/
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/another-inadequate-bowel-prep-it-may-not-be-the-patients-fault/17858/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/screening-colonoscopy-in-2024-and-beyond/17855/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/bowel-preparation-regimens-how-do-they-compare/17856/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/bowel-prep-hesitancy-whats-it-all-about/17857/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/new-and-emerging-agents/17863/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/patient-education-telling-is-not-teaching-and-listening-is-not-learning/17859/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/dont-flush-another-colonoscopy-down-the-toilet/17860/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/quality-indicators-how-do-you-compare-part-1/17861/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 20-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/quality-indicators-how-do-you-compare-part-2/17862/
In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-latest-updates-on-the-clinical-and-economic-impact-of-af/19781/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-best-incorporate-latest-guidance-in-optimizing-care-for-the-patient-with-af/24074/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/impact-of-social-determinants-of-health-on-management-of-af/24072/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/latest-guidance-on-anticoagulation-in-af-patient-populations-with-comorbidities/24071/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/latest-guidance-on-anticoagulation-in-special-af-patient-populations/24070/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-10-key-takeaways-for-the-2023-accahaaccphrs-guideline-for-af/19780/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-study-new-guideline-recommendations-into-clinical-practice-for-the-patient-with-af/24073/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/af-screening-risk-factors-and-diagnosis-whats-new/19782/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 15-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/anticoagulation-management-of-af-what-has-changed/24069/
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-ros1-tyrosine-kinase-inhibitors/18158/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/intracranial-activity-of-ros1-tkis/18157/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/later-line-targeted-therapies-for-ros1-fusion-positive-lung-cancers/18156/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/first-line-targeted-therapies-for-ros1-fusion-positive-lung-cancers/18155/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/current-guidelines-and-real-world-evidence-for-ros1-testing-in-nsclc/18154/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-treatment-selection-for-ros1-rearranged-nsclc-patient-with-brain-metastases/18162/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/overcoming-acquired-tki-resistance-with-next-generation-ros1-tki-agents/18161/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/treatment-strategy-of-ros1-rearranged-nsclc-in-tki-naive-patient/18160/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-chemotherapy-and-immunotherapy-in-ros1-rearranged-nsclc/18159/
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/approved-bispecific-antibodies-for-rrmm-review-of-the-pivotal-trials/18057/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-treatment-paradigm-for-rrmm-the-role-of-bispecific-antibodies/18056/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/bispecific-antibodies-the-newest-immunotherapy-on-the-block-for-rrmm/18055/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/clinical-challenges-with-triple-class-or-penta-refractory-mm/18054/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/integrating-bispecific-antibodies-into-clinical-practice/18063/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/step-up-dosing-of-bispecific-antibodies-the-need-for-hospitalization/18062/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/considerations-for-dosing-bispecific-antibodies/18061/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-infections-cytopenias-and-other-aes-related-to-bispecific-antibodies/18060/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/preventing-crs-and-neurotoxicities-related-to-bispecific-antibodies/18059/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00
Valid until: 01-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/efficacy-data-for-bispecific-antibodies-in-rrmm/18058/
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/abc-ich-does-care-bundling-improve-outcomes-for-patients-with-intracranial-hemorrhage/18127/
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/providing-optimal-care-for-the-anticoagulated-patient-with-intracranial-hemorrhage-in-the-acute-care-setting-does-the-patient-need-reversal-repletion-or-surgery/18125/
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/implementation-of-the-2022-ahaasa-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhageare-you-doing-enough/18126/
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-in-the-management-of-intracranial-hemorrhage-in-the-anticoagulated-patient/18128/
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-frontier-of-stroke-diagnosis-rapidai-how-can-artificial-intelligence-improve-acute-care-for-ischemic-and-hemorrhagic-stroke/18129/
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/preventing-ischemic-stroke-in-todays-world/18130/
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/while-antiplatelets-are-goodthey-arent-for-everyone/18131/
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-path-forward-whats-on-the-horizon/18132/
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
CME credits: 1.50
Valid until: 27-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-in-the-management-of-acute-ischemic-stroketia/18133/
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
CME credits: 1.00
Valid until: 05-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/her2-pd-l1-exploring-clinical-characteristics-of-ggej-cancers-in-relation-to-biomarker-positivity/18023/
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
CME credits: 1.00
Valid until: 05-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/incorporating-data-into-practice-late-breaking-highlights-on-ggej-cancers-from-the-2024-gi-congress/18028/
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
CME credits: 1.00
Valid until: 05-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-current-standard-for-first-line-treatment-of-metastatic-her2-positive-ggej-cancers/18026/
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
CME credits: 1.00
Valid until: 05-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/claudin182-an-emerging-biomarker-and-its-significance-as-a-therapeutic-target-in-ggej-cancers/18024/
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
CME credits: 1.00
Valid until: 05-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-current-standard-for-first-line-treatment-of-metastatic-her2-negative-ggej-cancers/18025/
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
CME credits: 1.00
Valid until: 05-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-evidence-supporting-cldn182-targeting-in-frontline-management-of-ggej-cancers/18027/
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/which-biomarkers-do-you-recommend-to-confirm-amyloid-positivity/16338/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-role-of-apoe4-testing-in-alzheimers-disease/16337/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/whats-the-best-way-to-identify-mild-cognitive-impairment-and-early-alzheimers-disease/16336/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/which-amyloid-targeting-therapy-is-best/16335/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-behind-att/16334/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-does-aria-look-like-clinically/16342/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 0.50
Valid until: 24-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/putting-data-into-clinical-practice/17847/
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
CME credits: 0.50
Valid until: 24-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/new-tavr-data-new-tavr-talk-track/17846/
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
CME credits: 0.50
Valid until: 24-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/challenging-tavr-cases/17845/
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
CME credits: 0.50
Valid until: 24-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/its-all-about-patient-identification/17844/
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-types-of-changes-if-any-should-we-expect-with-amyloid-targeting-therapy/16343/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/do-women-respond-differently-to-att-than-men/16344/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-do-you-counsel-patients-about-amyloid-related-imaging-abnormalities/16340/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/is-amyloid-targeting-therapy-worth-it/16466/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-should-we-monitor-patients-on-amyloid-targeting-therapy/16341/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 1.25
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-much-should-we-worry-about-amyloid-related-imaging-abnormalities/16339/
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
CME credits: 0.75
Valid until: 26-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-case-of-arthur-frank-how-do-we-manage-elderly-patients-with-atrial-fibrillation/17991/
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-a-natural-history-lesson/16643/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-is-risky-business/16644/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/walk-a-mile-in-my-shoes/16646/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/treatment-for-primary-biliary-cholangitis-whos-on-first-whos-on-second/16647/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/your-patients-pbc-treatment-long-term-monitoring-and-management/16648/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-treatment-pipeline-for-primary-biliary-cholangitis-sorting-out-the-ppars/16649/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-treatment-pipeline-for-primary-biliary-cholangitis-ibat-inhibition-and-beyond/16650/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 0.75
Valid until: 26-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-do-i-improve-the-ability-to-screen-interpret-and-diagnose-elderly-patients-with-atrial-fibrillation/17989/
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
CME credits: 0.75
Valid until: 26-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-anticoagulation-options-are-available-to-optimize-care-in-the-management-of-elderly-patients-with-atrial-fibrillation/17990/
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
CME credits: 0.75
Valid until: 26-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/putting-it-all-together-coordinating-the-multidisciplinary-care-plan-for-the-elderly-patient-with-atrial-fibrillation/17992/
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/goals-of-treatment-for-primary-biliary-cholangitis-a-balancing-act/16645/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-the-phenotype-it-is-a-changin/16641/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 31-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-vs-primary-sclerosing-cholangitis-do-you-know-the-difference/16642/
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/establishing-a-diagnosis-in-cushings-syndrome-an-individualized-approach/16574/
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/program-name/16576/
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-updates-in-cushings-syndrome/16577/
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/shared-decision-making-in-cushings-disease/16578/
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/cushings-disease-from-diagnosis-to-treatment-selection/16579/
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/cushings-syndrome-comorbidities-a-case-study-of-interdisciplinary-collaboration/16575/
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/could-your-patients-symptoms-be-acromegaly/16563/
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/refining-screening-and-referral-in-frontline-care-settings/16564/
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/making-a-definitive-diagnosis/16565/
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/guideline-and-evidence-based-best-practices-for-treatment-sequencing/16566/
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/understanding-trial-data/16567/
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/best-practices-for-individualizing-treatment-selection/16568/
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-traes-and-minimizing-hyperglycemia/16569/
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-would-you-treat/16570/
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/when-to-screen-for-cushings-syndrome-smart-strategic-screening-approaches/16572/
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
CME credits: 1.00
Valid until: 25-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/tackling-diagnostic-delay-in-cushings-syndrome/16573/
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/comprehensive-anticoagulation-management-for-atrial-fibrillation/17962/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-evaluation-and-diagnosis-of-vte/17973/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/implementing-vte-learnings-into-clinical-practice/17974/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/collaboration-is-key-strategies-for-a-multidisciplinary-approach-to-anticoagulation-management-with-vte/17975/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/oral-anticoagulation-management-in-patients-with-atrial-fibrillation/17961/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-anticoagulation-considerations-for-atrial-fibrillation/17965/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-approaches-to-anticoagulation-for-atrial-fibrillation/17966/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/identifying-patients-at-risk-for-atrial-fibrillation/17959/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/initial-approaches-starting-anticoagulation-treatment/17960/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-diagnosis-initial-evaluation-of-a-patient-with-atrial-fibrillation/17964/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/collaboration-is-keystrategies-for-a-multidisciplinary-approach-to-anticoagulation-management-for-patients-with-atrial-fibrillation/17967/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/identifying-patients-at-risk-for-vte/17968/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/selecting-anticoagulants-for-acute-vte/17969/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.25
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/risk-factors-comorbidities-associated-with-atrial-fibrillation/17963/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/ongoing-oral-anticoagulation-management/17970/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-recognizing-the-signs-symptoms-of-vte/17972/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 19-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/comprehensive-anticoagulation-management-for-vte/17971/
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/addressing-the-unmet-need-in-her2-positive-advanced-solid-tumors-exploring-response-rates-and-duration-of-response/16553/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/targeting-her2-in-advanced-solid-tumors-a-comprehensive-understanding-of-the-rationale-and-potential-benefits/16554/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/testing-for-solid-tumors-tissue-and-liquid-biopsy-approaches-using-ngs-technologies-for-cfdna-and-ctdna-analysis/16555/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/management-strategies-for-treatment-emergent-adverse-events-teaes-in-her2-altered-advanced-solid-tumors/16556/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/cervical-cancer-her2-targeted-adcs-current-status-and-future-directions/16557/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/ovarian-cancer-advances-in-her2-targeted-adcs/16558/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/biliary-tract-and-pancreatic-cancer-her2-targeted-adcs-for-gastrointestinal-cancers/16560/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/bladder-cancer-her2-targeted-adcs-for-genitourinary-cancers/16561/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/ascoesmo-2023-roundtable-contextualizing-the-latest-advances-in-her2-targeted-therapy-for-solid-tumors/16562/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 17-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/endometrial-cancer-her2-targeted-adcs-a-promising-approach-to-address-unmet-needs/16559/
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/are-oxybates-safe-in-narcolepsy-patients/17924/
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/challenges-in-recognizing-and-diagnosing-idiopathic-hypersomnia/17908/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/idiopathic-hypersomnia-insights-a-diagnostic-case-study/17909/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/expert-consensus-on-how-oxybates-influence-cardiovascular-risk-in-narcolepsy-patients/17925/
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/idiopathic-hypersomnia-and-cardiovascular-health-too-much-of-a-good-thing/17910/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/evaluating-and-promoting-health-in-idiopathic-hypersomnia-beyond-sleepy/17911/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/patient-testimonial-a-day-in-the-life-of-an-idiopathic-hypersomnia-patient/17912/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/evolving-treatment-paradigms-in-idiopathic-hypersomnia/17913/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/challenges-in-recognizing-and-diagnosing-narcolepsy/17917/
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/lifes-essential-8-healthy-sleep-with-narcolepsy/17919/
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/epidemiology-of-cardiovascular-disease-in-narcolepsy/17920/
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/lifes-essential-8-diet-paradigm-the-narcolepsy-connection/17921/
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/treatment-options-for-the-management-of-narcolepsy/17922/
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/practical-approach-to-incorporation-of-oxybates-into-clinical-practice/17923/
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/professional-recommendations-of-clinically-validated-tools-used-to-monitor-response-to-treatment-in-idiopathic-hypersomnia/17914/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/evidence-based-discussion-of-the-new-and-emerging-treatment-strategies-for-idiopathic-hypersomnia/17915/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 12-01-2025
Claim your CME credit at https://reachmd.com/programs/cme/which-comes-first-the-stimulant-or-the-oxybate/17916/
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
CME credits: 1.00
Valid until: 20-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-do-clinicians-need-to-know-utilizing-clinically-validated-diagnostic-tools-to-diagnose-ms-earlier/17837/
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
CME credits: 1.00
Valid until: 20-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/transforming-ms-management/17843/
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
CME credits: 1.00
Valid until: 20-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/missed-opportunities-in-multiple-sclerosis-care-increasing-hcp-awareness-of-early-diagnostic-delays/17836/
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
CME credits: 1.00
Valid until: 20-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-complexity-of-early-ms-diagnosis/17842/
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
CME credits: 1.00
Valid until: 20-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-s1p-receptor-agonists-in-ms-strategies-for-disease-management/17841/
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
CME credits: 1.00
Valid until: 20-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/from-prescription-to-personalization-an-hcps-guide-to-tailoring-ms-therapeutic-management/17840/
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
CME credits: 1.00
Valid until: 20-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/advancements-in-mri-technology-improved-diagnosis-and-monitoring-of-ms/17839/
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
CME credits: 1.00
Valid until: 20-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-diagnostic-maze-strategies-for-excluding-ms-disease-mimics/17838/
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
CME credits: 0.75
Valid until: 11-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/overcoming-clinical-barriers-to-lai-administration-identification-of-the-negative-stigma-surrounding-the-use-of-injectable-antipsychotics/16604/
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
CME credits: 0.75
Valid until: 11-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/too-soon-is-not-soon-enough-initiation-of-lais-sooner-to-manage-symptoms-of-suboptimally-treated-schizophrenia/16605/
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
CME credits: 0.75
Valid until: 11-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/whos-on-first-accurate-recognition-of-schizophrenia-candidates-that-would-benefit-from-lai-antipsychotic-therapy/16606/
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
CME credits: 0.75
Valid until: 11-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/identifying-and-managing-nonadherence-to-antipsychotics-in-people-with-schizophrenia/16607/
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
CME credits: 0.75
Valid until: 11-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/new-and-emerging-treatment-paradigms-for-scz-symptom-management-one-size-does-not-fit-all/16608/
This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.
CME credits: 0.75
Valid until: 08-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/balancing-the-scales-the-complementary-roles-of-rcts-and-rwe-in-modern-healthcare/16597/
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
CME credits: 0.75
Valid until: 08-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/distinguishing-between-high-and-low-quality-rwe-a-journal-club-for-the-real-world/16598/
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
CME credits: 0.75
Valid until: 08-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/rwe-supporting-cdk46-inhibitor-use-in-hr-metastatic-breast-cancer/16599/
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
CME credits: 0.75
Valid until: 08-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/unlocking-insights-for-underrepresented-patients-the-role-of-real-world-evidence-in-addressing-limitations-of-cdk46-inhibitor-rcts/16600/
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
CME credits: 0.75
Valid until: 08-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/importance-of-the-patient-perspective-on-rwe-in-formulating-sdm-conversations/16601/
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
CME credits: 0.75
Valid until: 08-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/real-world-use-of-rwe-in-hr-metastatic-breast-cancer-the-oncologist-perspective/16602/
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
CME credits: 0.75
Valid until: 08-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/real-world-evidence-to-expand-knowledge-of-cdk46-inhibitor-related-adverse-effects/16603/
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/clinical-trials-in-hfpef-what-have-they-taught-us/16516/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/epidemiology-and-management-of-left-heart-disease-associated-ph/16517/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/panel-issues-dealing-with-left-heart-disease-in-ph/16518/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-1-and-panel-limitations-of-risk-assessment/16519/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-2-and-panel-cteph-and-ph/16520/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-3-and-panel-right-heart-diagnostics-in-pah/16521/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/panel-discussion-controversies-arising-from-2022-ersesc-guideline-revisions/16505/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-a-62-year-old-male-with-cteph/16506/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/cteph-cted-current-epidemiology-and-trends/16507/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/balloon-pulmonary-angioplasty-issues-and-perspectives/16508/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-thromboendarterectomy-for-cteph/16509/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/panel-discussion-simulated-cteph-case-conference/16510/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/ph-ild-diagnosis-and-management/16511/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-arterial-hypertension-and-connective-tissue-disease/16512/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/screening-diagnosis-and-treatment-of-ph-ild/16513/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/panel-discussion-real-world-issues-in-ctd-pah-screening-diagnosis-and-management/16514/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/hfpef-diagnostic-approach-through-case-review/16515/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/us-perspective-on-escers-guidelines/16504/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 4.75
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/overview-of-major-changes-to-ersesc-guidelines-for-ph/16503/
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/questions-answers-from-the-aha-2023-symposium/16494/
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-path-forward-whats-on-the-horizon/16493/
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/while-doacs-are-good-for-some-things-they-are-not-for-everyone/16492/
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-managing-common-adverse-events-associated-with-second-line-treatment-of-es-sclc/16488/
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-sequencing-therapy-in-es-sclc-in-special-patient-populations/16487/
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-treatment-sequencing-in-platinum-sensitive-relapse-es-sclc/16486/
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-treatment-sequencing-in-platinum-resistant-relapse-es-sclc/16485/
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/while-the-doac-revolution-has-occurred-40-50-of-patients-remain-untreated-why/16491/
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-doac-revolution-what-have-we-learned/16490/
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
CME credits: 1.50
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/panel-discussion-patient-selection-emerging-studies-and-strategies-in-es-sclc/16489/
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
CME credits: 1.00
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-peri-operative-immunotherapy-in-early-stage-nsclc/16497/
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
CME credits: 1.00
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-adjuvant-immunotherapy-in-localized-nsclc/16496/
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
CME credits: 1.00
Valid until: 30-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-update-of-neoadjuvant-therapies-for-resectable-lung-cancer/16495/
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-group-3-ph-pulmonary-hypertension-due-to-chronic-lung-disease/16324/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/video-demo-cardiopulmonary-exercise-testing-in-pulmonary-arterial-hypertension-part-2/16332/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/video-demo-cardiopulmonary-exercise-testing-in-pulmonary-arterial-hypertension-part-1/16331/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/focus-on-ctd-pah-and-rheumatology/16330/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/management-of-pah-update-on-the-therapeutic-landscape/16320/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/overview-of-new-ersesc-guideline-recommendations/16319/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-in-rheumatic-diseases-part-2/16329/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-cteph/16321/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-treatment-of-chronic-thromboembolic-pulmonary-hypertension/16322/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/focus-on-ctephcted/16323/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/link-between-parenchymal-lung-disease-and-ph/16325/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/focus-on-lung-disease-associated-ph/16326/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-ctd-pah/16327/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-in-rheumatic-diseases-part-1/16328/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 4.25
Valid until: 31-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-study-cpet/16333/
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/whats-new-about-gout-rheumatology-perspective/15962/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/whats-new-about-gout-nephrology-perspective/15961/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/gout-beyond-the-joints-whats-the-hidden-danger/15955/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/is-gout-hiding-in-the-nephrology-clinic/15956/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-emerging-therapies-for-managing-gout/15963/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/is-managing-gout-in-the-nephrology-clinic-a-challenge/15957/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/center-of-the-target-which-patients-are-most-likely-to-develop-gout/15958/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/can-you-manage-patients-with-uncontrolled-gout-more-effectively/15960/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/treat-or-refer-who-is-responsible-for-managing-gout/15959/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 1.00
Valid until: 24-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/should-we-look-for-gout-in-the-cardiology-clinic/15964/
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
CME credits: 0.50
Valid until: 20-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/novel-and-emerging-chronic-migraine-therapies/16279/
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
CME credits: 0.50
Valid until: 20-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/migraine-treatment-update-2023/16278/
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
CME credits: 0.50
Valid until: 20-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/medication-overuse-headache/16277/
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
CME credits: 0.50
Valid until: 20-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/new-insights-on-integrating-chronic-migraine-preventatives-in-clinical-practice/16280/
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
CME credits: 1.25
Valid until: 09-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-presentation-management-of-a-patient-with-anticoagulation-and-severe-traumatic-injuries/16240/
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
CME credits: 1.25
Valid until: 09-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/emergency-medicine-and-neurocritical-care-managing-life-threatening-bleeding-in-the-ed/16233/
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
CME credits: 1.25
Valid until: 09-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-presentation-management-of-a-patient-with-anti-factor-xa-associated-intracranial-hemorrhage-ich/16234/
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
CME credits: 1.25
Valid until: 09-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/intracranial-hemorrhage-decreasing-time-to-treatment-to-improve-outcomes/16235/
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
CME credits: 1.25
Valid until: 09-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/delivery-of-an-ich-care-bundle-illustrative-case/16236/
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
CME credits: 1.25
Valid until: 09-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/severe-gastrointestinal-bleeding-who-needs-reversal-or-repletion-for-upper-gi-and-lower-gi-bleeding/16237/
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
CME credits: 1.25
Valid until: 09-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/who-needs-reversal-or-repletion-for-ugi-and-lgi-bleeding-case-presentation/16238/
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
CME credits: 1.25
Valid until: 09-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/trauma-in-the-anticoagulated-patient-decreasing-morbidity-and-mortality-in-severe-injuries/16239/
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
CME credits: 1.00
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/expert-panel-how-does-adt-intensification-for-mhspc-affect-future-therapy-options/16218/
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/expert-panel-selecting-treatment-in-mhspc-which-treatment-for-which-patient/16217/
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/choosing-between-doublets-and-triplets-in-mhspc-what-is-the-data/16216/
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/integrating-evidence-and-cultural-sensitivity-in-patient-centric-insomnia-treatments/16186/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/examining-treatment-options-for-insomnia-from-orexin-to-gaba/16185/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/exploring-the-impact-of-insomnia-on-daytime-functioning-and-cognition/16183/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/patient-perspective-living-with-insomnia/16182/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/utilizing-assessment-tools-in-insomnia/16184/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/sleep-architecture-and-neurotransmitters-of-sleep/16181/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
CME credits: 1.00
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-can-i-do-to-improve-care-of-prostate-cancer-patients-at-risk-for-inequities/16223/
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-current-state-of-disparities-in-prostate-cancer-care/16222/
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-pharmacists-role-in-managing-mhspc-doublet-and-triplet-regimens/16221/
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/how-nurses-and-advanced-practice-clinicians-can-help-patients-navigate-a-new-mhspc-diagnosis/16220/
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.00
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/expert-panel-how-can-we-integrate-patient-preference-data-to-support-shared-decision-making-conversations-in-mhspc/16219/
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
CME credits: 1.25
Valid until: 15-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/highlights-from-singapore-on-immunotherapies-in-metastatic-nsclc/16128/
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
CME credits: 1.25
Valid until: 15-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/highlights-from-singapore-on-immunotherapies-in-early-stage-nsclc/16127/
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
CME credits: 1.25
Valid until: 15-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/highlights-from-singapore-on-targeted-therapies-in-nsclc/16126/
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
CME credits: 1.25
Valid until: 15-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/highlights-from-madrid-on-perioperative-immunotherapy-in-early-stage-nsclc/16130/
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
CME credits: 1.25
Valid until: 15-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/highlights-from-madrid-on-targeted-therapy-for-advanced-nsclc/16129/
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/is-long-term-complement-inhibition-safe-and-effective-in-pnh/16114/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-supporting-first-line-c5-inhibitor-treatment-of-pnh/16112/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-supporting-first-line-c3-inhibitor-treatment-of-pnh/16111/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-would-you-treat-a-newly-diagnosed-pnh-patient/16115/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-impact-of-first-line-pnh-treatment-choice-on-risk-of-thrombosis/16113/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-would-you-treat-a-newly-diagnosed-pnh-patient-with-near-normal-hgb/16116/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/a-look-at-the-numbers-cost-of-durable-treatments-in-retinal-disease/15857/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-durable-treatment-of-dme/15854/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/real-world-outcomes-with-durable-treatments-for-retinal-diseases/15855/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/a-closer-look-at-real-world-strategies-for-treatment-resistant-dme/15856/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/real-world-treatment-of-retinal-disease/15852/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-namd/15858/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-dme/15859/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-treatment-resistant-dme/15860/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 1.00
Valid until: 15-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-durable-treatment-of-namd/15853/
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
CME credits: 0.25
Valid until: 13-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/bridging-the-gap-to-care-what-you-need-to-know-about-attr-cm-amyloidosis/15863/
Once thought to be a rare disease, transthyretin amyloidosis that results in cardiomyopathy (ATTR-CM) remains a challenge to diagnose and treat. In this discussion, Drs. Mazen Hanna and Marianna Fontana provide expert advice on imaging techniques to diagnose ATTR-CM, including recognizing diagnostic “red flags.” They also review recent clinical trial data of current and potential therapeutics for ATTR-CM, so listen in to find out how you can put the evidence into practice.
=
CME credits: 0.50
Valid until: 24-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-fine-print-the-who-when-and-what-to-do-about-aria-in-patients-with-alzheimers-disease-radiology-module/14852/
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a seriesof six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of radiologists in the risk stratification, recognition, and management of ARIA.
Note that the core activity is supplemented by an interactive clinical summary designed specifically for radiologists. This convenient, mobile-friendly tool was developed to assist clinicians in considering how best to implement ARIA guidelines into their own day-to-day practice.
=
CME credits: 1.00
Valid until: 22-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/addressing-patient-management-in-ascvd-risk-reduction-a-collaborative-approach-broadcast-replay/15310/
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
=
CME credits: 1.00
Valid until: 21-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/hiv-and-cardiometabolic-health-whats-the-connection/15676/
This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
CME credits: 1.00
Valid until: 21-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/factors-to-consider-when-thinking-about-switching-a-patients-arv-regimen/15683/
This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
CME credits: 1.00
Valid until: 21-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/managing-art-for-optimal-cardiometabolic-health/15684/
This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
CME credits: 1.00
Valid until: 21-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/patients-high-risk-poor-cardiometabolic-outcomes-switching-regimens-option/15682/
This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
CME credits: 1.00
Valid until: 21-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/art-and-cardiometabolic-health-whats-the-connection/15680/
This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
CME credits: 1.00
Valid until: 21-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/weight-creep-the-overlooked-vital-sign-in-patients-with-hiv/15679/
This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
CME credits: 1.00
Valid until: 21-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/cardiometabolic-disease-in-patients-with-hiv-whos-at-greatest-risk/15678/
This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
CME credits: 1.00
Valid until: 21-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/my-patient-is-stable-on-art-but-has-gained-30-pounds-what-are-my-options/15681/
This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
CME credits: 0.50
Valid until: 16-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/lowering-burden-to-raise-adherence-optimizing-prophylaxis-for-hemophilia-a/15518/
Hemophilia A is an inherited or spontaneously occurring secondary hemostasis disorder caused by clotting factor VIII deficiency, which affects the formation and stabilization of clots. If left untreated, hemophilia A can cause recurrent and disabling bleeding, leading to severe arthropathy or life- threatening hemorrhage. Prophylaxis is well-documented for its effectiveness in preventing arthropathy and life-threatening bleeds, and improving total bleeding rates. However, limitations of modern factor replacement treatment result in suboptimal outcomes, poor adherence to prophylactic regimens, and reduced QoL. Novel and emerging prophylactic therapies can mitigate some of the hindrances of traditional replacement therapy and enhance the overall effect of treatment in hemophilia A.
In this educational activity, expert faculty will review recent evidence from key clinical trials of prophylactic therapies that are expanding the armamentarium of therapeutic choices, including a novel high-sustained factor VIII replacement therapy, a bispecific antibody non-factor replacement therapy, and other emerging therapies. Evaluating patients’ goals and preferences will also be discussed, so clinicians can co-create treatment plans using a shared decision approach to improve adherence and reduce bleeding episodes in patients with hemophilia A.
=
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-burden-of-sickle-cell-disease-for-patients-and-their-families/15705/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/diverse-manifestations-of-sickle-cell-disease/15706/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/a-quick-look-at-standard-treatments-for-sickle-cell-disease/15707/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/why-do-we-need-new-therapies-for-sickle-cell-disease/15708/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/lets-discuss-transplantation/15709/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/cell-and-gene-therapies-for-sickle-cell-disease/15710/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/implementing-the-sickle-cell-treatment-regimen/15711/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/preventative-management-of-sickle-cell-disease-complications/15712/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/making-the-transition-managing-patients-with-sickle-cell-disease-across-the-lifespan/15713/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 1.00
Valid until: 14-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/improving-communication-across-care-settings/15714/
Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.
CME credits: 0.25
Valid until: 07-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/improving-symptoms-in-patients-with-hfref-using-novel-device-therapy/14475/
Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Brian Howard and William Abraham explore data on its positive effects on exercise capacity, functional status, and quality of life. Do you know which of your patients may benefit from BAT?
=
CME credits: 0.50
Valid until: 03-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-fine-print-the-who-when-and-what-to-do-about-aria-in-patients-with-alzheimers-disease-primary-care-module/14850/
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of primary care physicians (PCPs) in the monitoring, recognition, and management of ARIA. This includes an overview of baseline needs surrounding Aβ-DMT, potential presentations of ARIA in primary care, courses of action that may be needed regarding its evaluation/treatment, and communication throughout care.
Note that the core activity is supplemented by an
CME credits: 0.25
Valid until: 30-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/asco-2023-updates-on-targeting-her3-in-breast-and-lung-cancers/15055/
Feeling overwhelmed by the latest NSCLC and breast cancer advances, including novel HER3-targeted agents? Here’s how you can stay up to date.
=
CME credits: 0.25
Valid until: 27-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-hpv-vaccine-announcement-for-children-and-adolescents-hpv-cancer-prevention-starts-with-you/15668/
Healthcare providers face challenges in promoting HPV vaccination, which is now recommended for children at age 9. The good news is that there are scientifically validated, effective methods for promoting HPV vaccination. Tune in to learn more about the 3-step Announcement Approach and discover strategies to address parents' hesitation and optimize cancer prevention.
=
CME credits: 1.00
Valid until: 20-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/incorporating-scientific-advances-into-myelofibrosis-treatment-plans/15090/
MF is a BCR-ABL1–negative chronic myeloproliferative neoplasm (MPN), a collection of heterogeneous cancers that includes primary MF (PMF) and secondary MF that sometimes forms in patients first diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET). The role of the JAK pathway and its aberrant activation in MF has long been appreciated. Importantly, the treatment armamentarium for MF is expanding with the emergence of new agents targeting the JAK pathway alongside other key regulators of immunity and inflammation. As such, treatment selection for MF is increasingly based on patient preference, with consideration given to treatment-related side effects, symptom burden, and transfusion dependency.
This educational initiative will update the interprofessional care team on current and emerging therapies for the treatment and management of MF, including treatment risks and benefits, barriers to adherence, and side effect monitoring and management. These concepts are coupled with education about shared decision-making strategies and other related approaches to achieve increased patient satisfaction, better adherence to treatment plans, and greater treatment engagement, as well as to enhance quality decision-making.
=
CME credits: 1.50
Valid until: 21-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/leveraging-metabolic-driven-treatment-strategies-to-target-the-origins-of-nash/15703/
Experts provide a review of therapeutic interventions for NAFLD/NASH, including key recommendations from the latest clinical care guidelines and the safety and efficacy of emerging agents.
=
CME credits: 0.25
Valid until: 21-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/delivering-change-mechanisms-to-address-racial-healthcare-disparities-in-multiple-myeloma/15610/
Multiple myeloma (MM) is the most common hematologic malignancy among African Americans, so it’s important that healthcare providers are aware of the disparities in the treatment provided to Black patients and White patients with MM. Listen in as Drs. Joseph Mikhael, Brandon Blue, and Monique Hartley-Brown discuss strategies to manage racial disparities and begin closing these gaps to ensure all patients receive the care they need.
=
CME credits: 0.50
Valid until: 21-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-2023-contextualizing-the-evidence-newly-diagnosed-aml-in-difficult-to-treat-subtypes/15571/
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as the newest approved treatments.
=
CME credits: 1.50
Valid until: 21-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-genetic-obesity-management-across-syndromic-monogenic-obesity/15704/
Experts provide a review of genetic causes of obesity, the utility of genetic testing, and evidence for and appropriate use of medications for the treatment of genetic obesity disorders.
=
CME credits: 0.25
Valid until: 20-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/in-the-medical-spotlight-antibody-drug-conjugates-in-advanced-her2-positive-gastricgastroesophageal-junction-cancer/15206/
Gastric and gastroesophageal junction cancers are the third most common cause of cancer deaths globally. In this Chairman’s Perspective, Dr. John Marshall breaks down the latest data from the 2023 World Congress on GI Cancer in Barcelona, Spain, so you can more effectively treat your patients.
=
CME credits: 0.50
Valid until: 19-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-use-of-immunotherapy-in-the-first-line-maintenance-setting-for-metastatic-urothelial-carcinoma/15654/
Survival for patients with metastatic urothelial cancer has increased with the approval of immune therapy, antibody-drug conjugates, and targeted agents. In the maintenance setting, avelumab has become the global standard of care. Do you know how to evaluate and effectively implement immune therapy in the maintenance setting in your practice?
=
CME credits: 1.00
Valid until: 18-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/a-changing-approach-to-tnbc-management-patients-as-partners-in-care/15611/
Despite recent advances, triple-negative breast cancer (TNBC) remains difficult to treat due to a poor prognosis and a small number of effective treatments. Thus, clinicians’ priorities need to be aligned with patient goals and perspectives to ensure optimal care and overcome patient misunderstandings about treatment and clinical-trial options.
Join an expert panel of oncologists and oncology nurse practitioners for an in-depth discussion of patient-centered care practices for TNBC that incorporate and align with patient preferences for treatment. Panelists will also discuss effective strategies for TNBC management and the appropriate incorporation of novel therapies into treatment regimens.
Do you have patients who have been diagnosed with TNBC who could use education on treatment options, clinical trials, and available support resources? Direct your patients to MedLive.com to access the activity, “Navigating Treatment and Support for Triple-Negative Breast Cancer.”
=
CME credits: 0.50
Valid until: 13-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/whats-the-consensus-on-cardiorenal-protection-for-ckd-in-t2d/14595/
Managing chronic kidney disease (CKD) and type 2 diabetes (T2D) with multiple medications has become a challenge, and a multidisciplinary approach is needed to achieve optimal cardiorenal outcomes. Join Drs. George Bakris, Mikhail Kosiborod, and Tessa Laubscher as they discuss initiating consensus-based nonsteroidal MRA therapy in their patients with CKD and T2D.
=
CME credits: 0.25
Valid until: 07-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/applying-evidence-to-practice-what-can-we-learn-from-recent-clinical-trials-of-iv-iron-use-in-hf/15329/
While multiple clinical trials demonstrated a positive impact on patient outcomes with IV iron therapy in patients with HFrEF and iron deficiency, few have addressed the long-term effects of IV iron treatment on morbidity, mortality, and exercise tolerance in these patients. Join Dr. Robert Mentz and Dr. Piotr Ponikowski as they discuss the design of the HEART-FID trial and its potential impact on the clinical applications of long-term treatment with IV iron products in patients with heart failure and iron deficiency.
=
CME credits: 0.25
Valid until: 30-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/hyperkalemia-is-it-still-a-challenge-in-2023/15327/
With more effective ways to manage hyperkalemia, is it still a challenge in 2023? Chairperson Ileana Piña, MD, and faculty members cardiologist Javed Butler, MD, and nephrologist Patrick Rossignol, MD, use case-based vignettes to provide expert analysis regarding hyperkalemia in patients with HFrEF who are on RAASi therapy. Tune in for insights on applying clinical trial data to the unique challenges of complex cases and learn how a guideline-based approach, innovative treatments, and emerging data are achieving successful outcomes in patients with heart failure with hyperkalemia.
=
CME credits: 0.25
Valid until: 29-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-future-of-muscular-dystrophy-management-updates-for-limb-girdle-muscular-dystrophy/15318/
Limb-girdle dystrophy (LGMD) is a group of inherited neuromuscular diseases with at least 34 variants, all affecting muscles of the limb-girdle region. Because LGMD is so variable, it can be hard to detect and there are no FDA-approved treatments currently. Advances in gene transfer therapy have been slow to emerge. However, helping clinicians detect LGMD and know the next best steps is critical to effective management of LGMD, along with identifying patients for clinical trials.
=
CME credits: 1.00
Valid until: 29-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-biological-and-clinical-rationale-for-parp-inhibitor-combinations-as-potential-treatment-for-prostate-cancer/15169/
Prostate cancer is a disease characterized by high genomic instability. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair (HRR), such as mutations in BRCA1/2 and ATM, are associated with response to poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition. The US Food and Drug Administration (FDA) has approved PARP inhibitors as monotherapy for the treatment of previously treated patients with HRR gene-mutated (olaparib) and BRCA mutation-associated (rucaparib) metastatic castration-resistant prostate cancer (mCRPC). Despite the advances with PARP inhibitors as monotherapy, primary and secondary resistances are seen, and evidence suggests that PARP inhibitors should be reserved for mCRPC with BRCA1, BRCA2, or ATM mutations. Now, clinical trials are evaluating PARP inhibitors in combination with other treatments such as androgen pathway inhibitors which may expand the clinical use of PARP inhibitors. When PARP inhibition is combined with novel hormonal therapies, a treatment benefit may be observed regardless of the HRR deficiency status.
This educational activity will review emerging clinical evidence and potentially practice-changing advancements in the treatment of mCRPC with PARP inhibitor combination treatment strategies, especially those that include combinations with androgen receptor targeted agents, to improve understanding of the evolving treatment and management of mCRPC.
=
CME credits: 0.25
Valid until: 27-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-future-of-muscular-dystrophy-management-updates-for-duchenne-muscular-dystrophy/15317/
Duchenne Muscular Dystrophy, or DMD, is considered a rare disease, affecting 1 in 3,500 boy births. But to the patients afflicted-and to the families who love them-it is a painful, everyday experience. Current advances in gene transfer therapy are exciting. Helping clinicians interpret and utilize the outcomes of gene therapy clinical trials is critical to effective treatment and management of DMD, as is the coordination of multidisciplinary teams for the ongoing care of these patients.
=
CME credits: 1.00
Valid until: 27-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/treatment-oab-and-managed-care-professional-balancing-double-edged-sword/15674/
Tune in to this live broadcast on overactive bladder! Experts David Staskin, MD, and Roger Dmochowski, MD, discuss evidence-based best practices in the management and treatment of OAB and integrate challenging case studies throughout the broadcast.
=
CME credits: 0.50
Valid until: 26-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-fine-print-the-who-when-and-what-to-do-about-aria-in-patients-with-alzheimers-disease-emergency-medicine-module/14851/
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of emergency medicine clinicians in the recognition and management of ARIA. This includes an overview of how ARIA may present to the emergency department and what courses of action to treat/manage ARIA may be needed from the hospital care team.
=
CME credits: 0.50
Valid until: 26-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-fine-print-the-who-when-and-what-to-do-about-aria-in-patients-with-alzheimers-disease-closing-module/14853/
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity finishes out the series by first providing an abbreviated outline of what has been addressed across activities 1-5 followed by a multidisciplinary discussion of questions and considerations that may impact the team-based execution of discussed strategies.
=
CME credits: 1.00
Valid until: 23-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/lessening-glaucoma-treatment-burden-sustained-release-therapies-part-2/15195/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 1.00
Valid until: 23-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-glaucoma-treatment-migs-part-2/15197/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 1.00
Valid until: 23-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/lessening-glaucoma-treatment-burden-clinical-cases-part-1/15198/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 1.00
Valid until: 23-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/lessening-glaucoma-treatment-burden-clinical-cases-part-2/15199/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 1.00
Valid until: 23-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/lessening-glaucoma-treatment-burden-with-topical-therapies-the-evidence-part-1/15191/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 1.00
Valid until: 23-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/lessening-glaucoma-treatment-burden-sustained-release-therapies-part-1/15193/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 1.00
Valid until: 23-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/lessening-glaucoma-treatment-burden-with-topical-therapies-the-evidence-part-2/15192/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 1.00
Valid until: 23-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-glaucoma-treatment-migs-part-1/15196/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 0.75
Valid until: 21-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/conversations-about-pah-latest-developments-and-key-insights-for-2023-case-discussion/15399/
Pulmonary arterial hypertension (PAH) is a chronic and progressive condition that affects the pulmonary vasculature, resulting in elevated pulmonary vascular resistance, right ventricular dysfunction, and eventually, right heart failure. It is essential to identify and manage PAH early to improve patient outcomes. This necessitates comprehensive knowledge of the diagnostic criteria and classification of PAH, as well as a care approach based on evidence that incorporates the latest guidelines, advancements, and recommendations from leading professional organizations. In addition, due to the inadequacies of current therapies, it is necessary to critically evaluate novel treatment pathways and new/emerging therapeutic targets for PAH.
In this clinical discussion, you'll hear from two leading experts who will discuss patient cases and discuss how you can optimize PAH treatment plans based on risk stratification and comorbidities and integrate the evidence-based recommendations and treatments in your practice.
=
CME credits: 0.25
Valid until: 20-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/pah-clinical-consult-getting-to-the-heart-of-pah/15504/
Diagnosis of pulmonary arterial hypertension, or PAH, may be delayed because symptoms are nonspecific. And while there have been many advances in terms of available treatments, it remains imperative that providers perform a thorough risk assessment on each patient. In addition, it’s necessary to develop both a multidimensional approach to caring for patients with PAH and a communication plan to use with patients, care partners, and caregivers. If we can improve how we practice, we can improve outcomes and quality of life. Join us!
=
CME credits: 0.25
Valid until: 15-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/patient-centered-communications-and-shared-decision-making-in-the-management-of-obesity/15361/
Obesity and overweight have reached epidemic status in the US. While safe and effective treatment options are available, it remains a challenge for clinicians to initiate conversations about weight with their patients. Learn how to open channels of communication with your patients by watching Dr. Charles Vega interact with a 42-year-old patient using shared decision-making.
=
CME credits: 0.25
Valid until: 15-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/hpv-vaccination-rates-in-mid-adult-and-high-risk-patients-strategies-for-improvement/15430/
HPV vaccination guidance for mid-aged adults (27 to 45 years old) was updated by the CDC in 2019. Unfortunately, very few individuals in the US in this age range have ever been vaccinated for HPV, despite the risk for acquiring an HPV infection that can potentially progress to cancer, most notably oropharyngeal, cervical, and anorectal. Join us as Drs. Anna Giuliano and Joel Heidelbaugh discuss strategies for improving HPV vaccination rates across different populations and provide specifics on how and when to use shared clinical decision-making (SCDM) when offering a permissive recommendation.
=
CME credits: 0.25
Valid until: 14-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/clinical-challenges-of-ibd-management-biologic-failure-and-advances-in-surgery/15522/
In this brief medical minute, Bruce E. Sands, MD, MS, an expert in IBD discusses the clinical challenges of IBD management including biologic failure and surgical management.
=
CME credits: 0.50
Valid until: 14-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-achieving-mucosal-healing/15524/
This Medical Minute will discuss how to identify and target objective measures of ulcerative colitis disease activity to achieve mucosal healing.
=
CME credits: 0.25
Valid until: 14-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/clinical-challenges-of-ibd-management-a-team-based-approach-to-ibd/15523/
In this brief medical minute, two experts in IBD, Abigail Meyers, PA-C and Bruce E. Sands, MD, MS, discuss collaborative and holistic care for IBD management.
=
CME credits: 0.25
Valid until: 14-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/clinical-challenges-of-ibd-management-pregnancy-considerations-and-shared-decision-making/15521/
In this brief medical minute, Abigail Meyers, PA-C, an expert in IBD, discusses strategies to address the clinical challenges of IBD management during pregnancy and engaging patients in shared decision-making.
=
CME credits: 0.25
Valid until: 14-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-management-and-monitoring-of-ibd-treat-to-target-and-therapeutic-drug-monitoring/15520/
In this short medical minute, Bruce E. Sands, MD, MS, an expert in IBD management, discusses the latest in treat-to-target and therapeutic drug monitoring in patients with IBD.
=
CME credits: 0.25
Valid until: 14-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-management-and-monitoring-of-ibd-early-diagnosis-and-individualizing-therapy/15519/
An expert in IBD discusses the latest in early diagnosis, individualizing therapy, and monitoring of IBD. Hear about early signs and symptoms of IBD as well as strategies for individualizing initial therapy in patients with IBD based on available agents and guidelines.
=
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/patient-selection-for-adcs-in-first-line-dlbcl/15183/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/individualizing-frontline-treatment/15177/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-bispecific-antibodies-and-antibody-drug-conjugates-in-fl/15180/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/first-line-treatment-of-adults-with-classical-hodgkin-lymphoma/15175/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/bispecific-antibodies-in-fl/15178/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/nccn-guideline-updates-in-dlbcl/15181/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/application-of-data-from-the-echelon-1-trial/15176/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-fl/15179/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 1.00
Valid until: 12-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/late-stage-bispecifics-and-adcs-in-dlbcl/15182/
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
CME credits: 0.25
Valid until: 09-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.
=
CME credits: 0.25
Valid until: 06-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/strategies-to-reduce-treatment-burden-for-vulnerable-patients-with-diabetic-eye-disease/15355/
Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.
=
CME credits: 1.00
Valid until: 31-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/treatment-the-right-royal-for-the-castle/15120/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 31-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-necessity-of-a-multidisciplinary-roundtable-in-the-diagnostic-workup-of-castleman-disease/15119/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 31-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-realities-of-treatment/15122/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 31-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/hiding-in-plain-sight-could-this-be-castleman-disease/15117/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 31-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/climbing-the-long-winding-stairs-to-the-diagnosis-of-castleman-disease/15118/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 31-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/will-you-accelerate-patient-outcomes/15124/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 31-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-feverish-case-of-the-fatigued-and-fibrotic/15123/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 31-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-and-management-of-castleman/15121/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 22-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-glaucoma-treatment-novel-topical-therapies/15190/
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-impact-and-importance-of-iron-status/15127/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/in-any-case-the-importance-of-iron-repletion/15137/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/enhancing-adherence-with-oral-iron-therapy/15136/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/iron-supplementation-formulations-for-females-with-idida-monitoring-response/15135/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/strategies-to-effectively-manage-id-and-ida-throughout-the-life-span/15134/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/id-and-ida-in-postmenopausal-women/15133/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/all-oral-iron-therapies-are-not-created-equal/15132/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/how-a-womans-iron-status-today-can-impact-a-babys-health-tomorrow-and-through-the-years/15131/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/assessing-and-addressing-idida-the-need-for-guidance/15130/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/pathogenesis-of-id-and-ida-in-reproductive-aged-women-focus-on-heavy-menstrual-bleeding/15129/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 01-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/contributors-to-iron-status-serum-ferritin-tsat-and-hemoglobin/15128/
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
CME credits: 1.00
Valid until: 11-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-necessity-of-a-multidisciplinary-roundtable-in-the-diagnostic-workup-of-castleman-disease/15119/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 11-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/hiding-in-plain-sight-could-this-be-castleman-disease/15117/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 11-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/climbing-the-long-winding-stairs-to-the-diagnosis-of-castleman-disease/15118/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 11-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/treatment-the-right-royal-for-the-castle/15120/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 11-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-and-management-of-castleman/15121/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 11-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-realities-of-treatment/15122/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 11-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/the-feverish-case-of-the-fatigued-and-fibrotic/15123/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 1.00
Valid until: 11-04-2024
Claim your CME credit at https://reachmd.com/programs/cme/will-you-accelerate-patient-outcomes/15124/
This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
CME credits: 0.25
Valid until: 01-02-2024
Claim your CME credit at https://reachmd.com/programs/cme/titrating-and-dosing-device-therapy-for-dre-best-practices-for-optimizing-patient-outcomes/14854/
Vagus nerve stimulation (VNS) therapy is an add-on neuromodulation treatment designed for adults and children diagnosed with drug-resistant epilepsy (DRE). The device delivers mild pulses to the brain through the vagus nerve to help prevent seizures before they start and help stop them if they do. Join Drs. Danielle Becker, John Stern, Deborah Holder, and Ahmed Abdelmoity as they discuss best practices for initiating, titrating, and dosing adult and pediatric patients to optimize outcomes.
CME credits: 0.50
Valid until: 30-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/predicting-type-1-diabetes-using-genetic-testing-or-islet-antibody-screening-are-we-there-yet/14286/
Autoantibody Screening to Identify Risk for Type 1 DiabetesT1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.
CME credits: 0.50
Valid until: 30-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-management-strategies-for-patients-with-adpkd-part-2/13880/
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
CME credits: 0.50
Valid until: 26-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/updates-in-glomerular-disease/14891/
Patients with chronic kidney disease often have a multitude of comorbidities which may present challenges in diagnosis, treatment, and management. In addition, the limitations of currently available treatments may reduce the opportunity for effective improvements in their quality of life. But clinical trial data are emerging, and our understanding about the underlying mechanisms of glomerulonephritis and sclerosis is growing. Find out how these advances could lead to improved outcomes in patients with IgAN, FSGS, and AAV.
CME credits: 0.50
Valid until: 24-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/case-management-strategies-for-patients-with-adpkd-part-1/13879/
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
CME credits: 0.25
Valid until: 17-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/improving-meibomian-gland-dysfunction-with-device-management/14810/
How can more advanced measures improve meibomian gland function to relieve dry eye symptoms and improve refraction? Listen as Dr. Cynthia Matossian and Dr. Jillian Ziemanski discuss additional approaches you can try with your patients.
CME credits: 0.25
Valid until: 16-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/treatment-options-for-invasive-fungal-infections-why-they-dont-always-work/14809/
The changing epidemiology of invasive fungal infections, ongoing antifungal resistance, drug-drug interactions, and few oral agents leave patients with limited viable treatment options. While the antifungal pipeline has been essentially dry for the past 2 decades, several antifungal drugs are now in late-stage clinical development and poised to address these unmet needs. But take heed: They will need to be treated as precious commodities lest they, too, become ineffective due to resistance.
CME credits: 1.00
Valid until: 10-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/individualized-approaches-in-cllsll-meeting-the-needs-of-your-patients-now-and-preparing-for-the-future/14730/
The emerging treatment landscape for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has resulted in improved outcomes for patients. However, challenges remain when selecting the best frontline approach and now involve decisions about using a time-limited option or continued therapy model. Other challenges exist on relapse, so it’s essential that providers understand the disease and patient factors that are critical when sequencing therapeutic agents. Join us in this Streaming National Broadcast that will help you meet the treatment needs of your patients with CLL/SLL both today and in the future.
CME credits: 0.25
Valid until: 10-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/invasive-fungal-infections-more-common-than-you-think/14808/
Despite advances in diagnosis and treatment, as well as the dissemination of clinical practice guidelines, both the threat and burden of invasive fungal infections are increasing and underappreciated. Dr. Peter Pappas and Dr. Thomas Patterson, pioneers in this field, offer their perspectives on why this is the case and how a heightened awareness of invasive fungal infections is the key to improving your practice.
CME credits: 1.00
Valid until: 10-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/bcma-who-and-when-immunotherapies-in-patients-with-rrmm/14729/
Given the complexity of care for patients with multiple myeloma (MM) and the mounting clinical trial data, it is crucial to stay abreast of investigational agents and new data from current agents. Join Drs. Saad Usmani, Sikander Ailawadhi, and Amrita Krishnan as they explore new and emerging ways to close medical gaps in treatment and provide clinically applicable information to optimize outcomes for patients with MM. This enduring program will cover practical case illustrations, recent data released at the ASH annual meeting, and more!
CME credits: 0.25
Valid until: 06-01-2024
Claim your CME credit at https://reachmd.com/programs/cme/tentative-approval-understanding-the-fda-ruling-on-once-nightly-sodium-oxybate/14688/
While most clinicians are aware of a drug being either “approved” or “not approved” by the FDA, many are not familiar with the term “tentative approval.” Leading experts, attorney Sara Koblitz, JD, and Dr. Michael Thorpy, review the FDA approval process, explore how “tentative approval” is currently impacting treatment in the field of sleep medicine, and discuss how “non-drug” issues are related to delayed FDA approval. Review the latest safety and efficacy pivotal trial data associated with once-nightly sodium oxybate and find out if we’re truly on the cusp of a new awakening in sleep medicine.
CME credits: 0.50
Valid until: 30-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/transforming-cervical-cancer-screening-and-management-new-guidelines-new-tests-a-case-based-discussion/14676/
Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.
CME credits: 0.25
Valid until: 30-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/talking-rare-epidemiology-and-pathogenesis-of-apol1-mediated-kidney-disease/14781/
End-stage kidney disease (ESKD) is at least 3x higher among African Americans compared to Americans of European descent. Carriers of APOL1 variants with chronic kidney disease (CKD) are associated with more rapid disease progression and an increased risk of kidney failure. Join Drs. Martin Pollak and Susanne Nicholas as they discuss the epidemiology and possible mechanisms of APOL1 kidney disease, as well as recent clinical evidence for therapies in development that can potentially prevent rapid disease progression.
CME credits: 0.25
Valid until: 28-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-bone-health-in-postmenopausal-post-fracture-patients/14662/
Life-altering secondary fractures are a harsh reality, but Medicare studies show, and orthopedic surgeons agree, that knowledge has not translated into prevention. Why is there clinical inertia in providing preventative interventions related to secondary fragility fractures? Join Drs. Andrea Singer and Susan Bukata as they provide a cogent medical approach to preventing these fractures and a roadmap for when and how to use available therapies based on their mechanisms of action.
CME credits: 0.25
Valid until: 28-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/alloimmune-neutropenia-of-the-fetus-and-newborn/13910/
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.
CME credits: 0.50
Valid until: 21-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/utilization-and-management-of-antibody-drug-conjugates-in-metastatic-breast-cancer-the-relationship-between-adcs-and-her2/14552/
New data for sequencing antibody-drug conjugates (ADCs) in HER2 metastatic breast cancer have hit the conference circuit. Listen as Drs. William Gradishar, Javier Cortés, and Hope Rugo dissect the data surrounding ADCs in different types of HER2 metastatic breast cancer. Make sure you’re up to date and offering your patients the best care.
CME credits: 0.25
Valid until: 20-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-in-patients-with-ovarian-cancer-multidisciplinary-patient-centered-care/14565/
Follow along as Dr. Floortje Backes walks us through a patient case and demonstrates the shared decision-making process of selecting an appropriate maintenance treatment regimen for advanced ovarian cancer.
CME credits: 0.50
Valid until: 20-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/treating-iron-deficiency-in-patients-with-hfref-a-review-of-the-recent-data-for-iv-iron-replacement-therapy/13508/
Symptoms from iron deficiency can greatly affect the overall quality of life of our patients with heart failure. Recent clinical evidence from the IRONMAN trial explores the use of IV iron replacement in patients with chronic heart failure. Join Drs. Javed Butler, Stefan Anker, Piotr Ponikowski, and Robert Mentz as they discuss the clinical trial design and outcomes from IRONMAN compared to the current body of evidence for managing iron deficiency in this setting.
CME credits: 1.00
Valid until: 19-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/when-to-start-using-sglt2i-in-hfref-initiating-guideline-recommended-treatment-options/14735/
What are the benefits of SGLT2 inhibitors (SGLT2i) in heart failure? What clinical challenges can physicians face when initiating guideline recommended therapy in heart failure? And what unanswered questions with SGLT2i in heart failure remain? Three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure.
This course consists of the following:
- The clinical challenges of initiating guideline recommended therapy in HF - Prof. John McMurray, MD - Glasgow, UK
- Benefits and evolving insights on SGLT2i in the spectrum of LVEF - Prof. Carolyn Lam, MD, PhD - Singapore
- Expanding evidence on SGLT2i: Where are we now and what can we expect? - Prof. Scott Solomon, MD - Boston, MA, USA
CME credits: 1.00
Valid until: 19-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/clinical-dilemmas-in-heart-failure-weighing-the-balance-of-raasi-and-hyperkalemia/14740/
Optimizing RAASi therapy in patients with heart failure, while managing hyperkalemia can be challenging. Three experts talk about this clinical dilemma and present new therapeutic options that could achieve better outcomes in patients with heart failure.
This course consists of the following:
- Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure - Prof. Andrew Coats, MD - Coventry, UK
- Hyperkalemia in heart failure: Why should we care? - Clara Bonanad Lozano, MD, PhD - Valencia, Spain
- Potassium binding as RAASi enabling therapy: applying recent insights into practice - Aaron Wong, MD - Bridgend, UK
CME credits: 1.00
Valid until: 19-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/innovative-therapeutic-approaches-in-hypertrophic-cardiomyopathy/14744/
Hypertrophic cardiomyopathy (HCM) is more than just a thickened heart. This series of three presentations provides insights into the etiology and pathogenesis of this complex disease, how to make the diagnosis, and the therapeutic options.
Dr. Antonis Pantazis starts his presentation off with a scientific definition of HCM and explains what distinguishes it from other conditions that feature a “thick heart.” Dr. Michelle Michels highlights the importance of a thorough work-up in patients with LV hypertrophy to make the correct diagnosis. Prof. Iacopo Olivotto discusses the study results of mavacamten, a drug specifically designed for treating HCM.
This course consists of the following:
- Unhiding hypertrophic cardiomyopathy, a call for action - Antonis Pantazis, MD - London, UK
- Hypertrophic cardiomyopathy: making the diagnosis - Michelle Michels, MD, PhD - Rotterdam, the Netherlands
- Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape? - Prof. Iacopo Olivotto, MD - Florence, Italy
CME credits: 0.25
Valid until: 14-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/medical-management-of-endometriosis-gnrh-antagonists/14145/
Are you currently considering GnRH antagonists as first-line therapy, or are you waiting for patients to fail other endometriosis treatment approaches first? Drs. Andrea Lukes and Lee Shulman discuss how the advent of effective GnRH antagonists is evolving the care of endometriosis. Are you ready to provide patients with the clinical outcomes they seek while balancing the benefits of medical and surgical approaches?
CME credits: 0.75
Valid until: 12-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/virtual-ibd-clinic-surgical-and-pharmacological-therapeutics/14036/
It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Sauk presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.
CME credits: 0.75
Valid until: 12-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/virtual-ibd-clinic-updates-in-diagnostic-therapeutic-and-prognostic-strategies/14035/
The management of inflammatory bowel disease (IBD) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Sushila Dalal presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.
CME credits: 0.50
Valid until: 12-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/spanning-the-spectrum-of-vvc-diagnosing-and-managing-acute-and-recurrent-disease/14660/
For affected women, acute vulvovaginal candidiasis (VVC) brings with it a significant health burden, and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved diagnosis, management, and quality of care. Join Dr. Michael Krychman as he dissects the barriers to managing VVC and RVVC and provides insights on diagnosis and management based on guidelines, plus an overview of innovative therapeutic agents. The unique qualities of the current and emerging therapeutic interventions may well represent a significant step forward in how you manage these challenging infections.
CME credits: 0.50
Valid until: 12-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/long-acting-reversible-contraceptives-their-critical-role-in-addressing-todays-reproductive-health-landscape/14661/
Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARCs), are the most effective reversible contraceptive methods. The major advantage of LARCs compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term, effective use. In addition, after the device is removed, the return of fertility is rapid. Join Dr. David Eisenberg has he discusses when LARCs should be recommended as a first-line contraceptive choice and when they should not. He further details how to approach a shared decision-making discussion with patients about their contraceptive options.
CME credits: 0.50
Valid until: 12-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/mental-health-and-menopause-patient-centric-approaches/14477/
Optimizing the management of comorbid depression and menopause is a significant clinical challenge. When the darkness begins to set in, are you able to hear your patients’ needs and deliver life-changing treatment?
Join Dr. Jennifer Payne as she provides concrete tips and explores the latest guidelines and research on therapies that improve vasomotor symptoms, mood, and perimenopausal depression. Get ready to offer new hope to your patients as you help them cool off and begin to see the dawn of a new day.
CME credits: 0.75
Valid until: 12-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/endoshare-2022-a-patient-centered-evidence-based-approach-to-managing-endometriosis-pain/14478/
Endometriosis is challenging to diagnose, with approximately 6 to 11 years from symptom onset to definitive diagnosis and treatment. Many medical providers are not adequately familiar with the disease, and this, coupled with historically limited medical options, has resulted in surgical approaches often being considered as the first treatment option. Join us as Dr. Hugh Taylor discusses how this landscape is changing to one in which safe and effective medical options can now offer improved outcomes for our patients with endometriosis.
CME credits: 0.75
Valid until: 12-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/lets-discuss-postpartum-depression-screening-diagnosis-and-management/14600/
This animated Women’s Health 2022 lecture features a discussion between Drs. Jennifer Payne and Anita Clayton who clearly highlight the importance of screening for perinatal and postpartum depression (PPD). Our experts delve into the critical importance of proactively diagnosing and treating women during the various stages of pregnancy and review the latest therapies that specifically target PPD. Find out how these therapies compare to traditional antidepressants and how PPD treatment can improve the health and quality of life for patients and their families. What changes can you implement into your clinical practice to improve maternal and infant health?
CME credits: 0.75
Valid until: 12-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-medical-management-of-uterine-fibroids-achieving-patient-centered-goals-and-outcomes/14458/
By the age of 50, ultrasound imaging demonstrates that 70%-80% of women have fibroids. Uterine fibroids are associated with disability similar to other chronic diseases. They can even lead to lower vitality and social function than are experienced by women with breast cancer. Fibroid-related hysterectomies account for 45% of all US hysterectomies, but a surgical approach is no longer one size fits many. Join Dr. Andrew Kaunitz as he describes the clinical presentations of fibroids and how newly emergent medical options greatly improve fibroid-related symptoms, provide time to consider other alternatives, and can be used to bridge the transition to menopause.
CME credits: 0.25
Valid until: 06-12-2023
Claim your CME credit at https://reachmd.com/programs/cme/hemolytic-disease-of-the-fetus-and-newborn-hdfn-what-pediatric-providers-need-to-know-when-managing-hemolytic-disease-in-newborns-hdn/13799/
What are the essential steps in managing hemolytic disease of the fetus and newborn (HDFN)? How soon after “the cord has been cut” does newborn care transfer from the maternal-fetal medicine specialist and ob-gyn to the pediatric team? At a recent satellite symposium of the American Academy of Pediatrics, Dr. James Bussel, Dr. Kara Markham, and Bethany Weathersby presented the latest data regarding current and emerging practice patterns and highlighted the critical need for improved understanding and multidisciplinary collaboration in the area of HDFN. Tune in to hear Dr. Markham summarize how diagnosis, care, and treatment have evolved—plus insights on how these might change the way you practice.
CME credits: 0.25
Valid until: 30-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-the-treatment-of-locally-advanced-squamous-cell-carcinoma-of-head-and-neck-enhancing-antitumor-activity-through-inhibitor-of-apoptosis-protein-antagonism/14129/
There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.
CME credits: 0.50
Valid until: 30-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-care-for-patients-with-advanced-hepatocellular-carcinoma-current-standards-and-future-directions-with-immunotherapy/14482/
Combination immunotherapy (IO) is revolutionizing the management of advanced hepatocellular carcinoma (HCC). Listen in as Dr. Richard Finn and Dr. Peter Galle break down the most recent data around emerging strategies for using IO to treat your patients with HCC. What impact will these advances have on your clinical practice?
CME credits: 0.25
Valid until: 30-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/treating-iron-deficiency-in-heart-failure-are-all-iv-iron-supplements-the-same/13515/
Patients with heart failure are at increased risk for iron deficiency which leads to poor outcomes and quality of life. Several intravenous iron formulations are available to clinicians, yet iron deficiency remains undertreated. Join Dr. Giuseppe Rosano, Dr. Pieter Martens, and Dr. Kamyar Kalantar-Zadeh as they discuss differing iron formulations and the current body of evidence for managing iron deficiency in patients with heart failure.
CME credits: 0.25
Valid until: 23-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/alloimmune-thrombocytopenia-in-the-fetus-and-newborn/13909/
Program Chairman:
As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.
CME credits: 0.25
Valid until: 22-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/medical-management-of-uterine-fibroids-gnrh-antagonists/14144/
GnRH antagonists are revolutionizing the medical management of uterine fibroids. Drs. Al-Hendy and Shulman discuss how medical myomectomy with GnRH antagonists is revolutionizing care by bridging gaps during 3 different stages of patients’ lives.
CME credits: 0.25
Valid until: 21-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-in-second-line-and-potential-considerations-in-first-line-agc-and-gej-cancers/14038/
HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.
CME credits: 0.25
Valid until: 18-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/direct-from-the-heart-failure-clinic-novel-device-therapy-for-patients-with-hfref/14473/
Despite the use of guideline-directed medical therapy (GDMT), many heart failure (HF) patients may experience worsening symptoms and disease progression. There is now an FDA-approved device that works with GDMT and uses the baroreflex to improve HF-related physiological effects and clinical consequences. Tune in to keep up with baroreflex activation therapy, its mechanism of action, and the associated improved patient outcomes.
CME credits: 0.25
Valid until: 16-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-critical-role-of-addressing-patient-fertility-desire-in-the-treatment-of-uterine-fibroids-and-endometriosis/14143/
Fertility preservation is a significant clinical concern for all women of reproductive age diagnosed with endometriosis or uterine fibroids (UF). Drs. Elizabeth Stewart and Lee Shulman discuss how the advent of GnRH antagonists is affecting how we approach these 2 conditions. Management trends are evolving beyond reflexive, prophylactic surgery, so are you ready to change with the times?
CME credits: 0.50
Valid until: 15-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
CME credits: 0.25
Valid until: 11-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/personalizing-treatment-in-cushings-disease/14397/
Cushing’s disease is complex, and individualized approaches require the consideration of many patient factors. You and your patient also need to know what to expect in terms of therapeutic response and speed of recovery. Tune in as Drs. Maria Fleseriu and Irina Bancos address these challenges and more!
CME credits: 0.50
Valid until: 04-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-care-of-patients-with-msi-hdmmr-or-her2-colorectal-cancers/14480/
In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
CME credits: 0.25
Valid until: 02-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/evaluating-your-current-options-in-the-treatment-of-nsclc-with-metex14-skipping-mutations/14089/
Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendations on appropriate therapy selection for your patients with advanced NSCLC harboring MET exon 14 skipping mutations.
CME credits: 0.25
Valid until: 02-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/patient-centered-discussions-and-shared-decision-making-in-the-management-of-nsclc-with-metex14-skipping-mutations/14088/
Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!
CME credits: 0.50
Valid until: 01-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/menopause-matterslets-start-paying-attention-to-racial-and-ethnic-differences-addressing-patient-needs/14520/
This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion.
Addressing Patient Needs
CME credits: 0.50
Valid until: 01-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/menopause-matterslets-start-paying-attention-to-racial-and-ethnic-differences-current-and-emerging-treatment-approaches/14519/
This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion.
Current and Emerging Treatment Approaches
CME credits: 0.50
Valid until: 01-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/menopause-matterslets-start-paying-attention-to-racial-and-ethnic-differences-overview-of-disparities/14518/
This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion.
Overview of Disparities
CME credits: 0.25
Valid until: 31-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/retina-clinic-emerging-treatment-options-in-diabetic-retinopathy/13985/
Can we apply the new, more durable treatments in diabetic macular edema and neovascular age-related macular degeneration to the treatment of our patients with diabetic retinopathy? Join Dr. Peter Campochiaro and Dr. Roger Goldberg as they discuss ways these new approaches could benefit even more patients.
CME credits: 0.25
Valid until: 31-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/why-icis-have-revolutionized-cancer-care/14456/
Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!
CME credits: 0.25
Valid until: 31-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/heart-failure-grand-rounds-3-things-you-need-to-know-about-cardiac-contractility-modulation/14396/
Cardiac contractility modulation (CCM) is a novel, approved, implantable device that significantly improves heart failure symptoms, exercise tolerance, and quality of life while reducing the rate of heart failure hospitalizations. Find out why you should consider sending your patients with NYHA Class III heart failure who are not responding to guideline-directed medical therapy directly to an electrophysiologist for device implantation.
CME credits: 1.00
Valid until: 28-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/prosecutions-arguments/14244/
tbd
CME credits: 1.00
Valid until: 28-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/opening-statements/14243/
tbd
CME credits: 1.00
Valid until: 28-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/closing-arguments/14250/
tbd
CME credits: 1.00
Valid until: 28-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/defenses-arguments/14245/
tbd
CME credits: 0.25
Valid until: 27-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/targeting-the-fc-receptor-pathway-to-treat-red-blood-cell-alloimmunization/13908/
Program Chairman:
How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.
CME credits: 0.25
Valid until: 25-10-2023
Claim your CME credit at https://reachmd.com/programs/project-oncology/management-tools-for-early-stage-lung-cancer/13232/
Lung cancer screenings have shown to be effective in detecting lung cancer earlier. So what are the current guidelines? To discuss this question and give their own experiences with lung cancer screenings and the management of early-stage lung cancer are expert pulmonologists, Drs. Septimiu Murgu and Janani Reisenauer. Dr. Murgu is from the University of Chicago, and Dr. Reisenauer is from the Mayo Clinic.
CME credits: 1.00
Valid until: 19-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/challenging-cases-in-ckd-anemia-the-kidneys-and-heart-as-linked-parts/14128/
Anemia in chronic kidney disease (CKD) is persistently undermanaged because current treatments have been linked with an increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance.
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to provide an alternative treatment paradigm for patients with CKD-related anemia. Physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the data supporting their use in appropriately selected patients.
CME credits: 0.25
Valid until: 19-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/factors-that-delay-diagnosis-of-uterine-fibroids-and-endometriosis-the-demographic-divide/14142/
Join Drs. Linda Bradley and Lee Shulman as they discuss factors contributing to disparities in care for patients with endometriosis and/or uterine fibroids. They offer practical tips to overcome the disproportionate disease burden that especially impacts women of color. Cut through the noise to clearly hear each patient’s voice. Your clinical impact may be profound.
CME credits: 0.50
Valid until: 17-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/imaging-in-the-diagnosis-and-management-of-adpkd/13876/
This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD.
CME credits: 0.50
Valid until: 14-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/reducing-morbidity-and-mortality-in-patients-with-ckd-in-t2d-new-late-breaking-data/14165/
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
CME credits: 0.25
Valid until: 13-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/covid-19-differentiating-disease-course-and-updates-on-treatment/14090/
Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.
CME credits: 0.25
Valid until: 13-10-2023
Claim your CME credit at https://reachmd.com/programs/cme/covid-19-updates-on-best-practices-to-improve-outcomes/14091/
Newer therapeutic options are now available to treat COVID-19. Don’t panic! Drs. Charles Vega and Paul Auwaerter are here to help you successfully integrate these therapeutics into your practice. Find out how to identify patients that are at risk for severe disease and select the appropriate treatment for the patient in front of you.
CME credits: 0.50
Valid until: 30-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/clinical-innovation-in-aml/14103/
Developments over the last few years have brought dramatic changes to the treatment landscape of acute myeloid leukemia (AML). While new therapies mean more opportunities to individualize care, clinicians are also faced with new challenges and must quickly evaluate patients, order appropriate molecular tests, assess risk, and differentiate the efficacy, safety, and applicability of novel treatments and combinations. Join Drs. Courtney DiNardo and Marina Konopleva for a discussion of how to untangle the data to determine which treatment is right for each patient in the increasingly complex clinical setting of AML.
CME credits: 0.25
Valid until: 29-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/5-things-you-need-to-know-in-cervical-cancer-new-and-emerging-agents/14102/
The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials, including antibody-drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.
CME credits: 0.25
Valid until: 28-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/beyond-a1c-practical-strategies-for-managing-obesity-in-patients-with-t2d/14131/
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
CME credits: 0.25
Valid until: 28-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-what-weve-learned-about-implantable-anti-vegf-technology/13988/
What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to optimize success and minimize patient risk.
CME credits: 0.25
Valid until: 22-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/retina-clinic-current-treatment-options-in-dme/13984/
Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and Dr. Mark Barakat as they discuss patient management approaches based on the latest clinical data.
CME credits: 0.50
Valid until: 23-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/management-of-adpkd/13878/
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
CME credits: 0.25
Valid until: 15-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/indolent-systemic-mastocytosis-ism-tools-to-diagnose-ism/13994/
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
CME credits: 0.50
Valid until: 15-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/why-weight-loss-should-be-the-primary-goal-of-treatment-in-type-2-diabetes-care/14130/
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
CME credits: 0.25
Valid until: 15-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-a-closer-look-at-implantable-anti-vegf-technology/13987/
Whether you’re a medical or surgical retina specialist, the port delivery system (PDS) is a practice-changing treatment modality. How can you smoothly incorporate continuous anti-VEGF delivery technology into your clinical practice? Join Dr. SriniVas Sadda and Dr. John Kitchens as they discuss how the PDS fits into our treatment arsenal.
CME credits: 0.25
Valid until: 15-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/experts-discuss-longevity-and-durability-with-tavr/13997/
Data are limited on the incidence and factors associated with structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) and surgery for severe aortic stenosis in patients of all risk levels. The lifetime management of these patients requires an understanding of bioprosthetic valve durability and failure. Tune in for new evidence evaluating the 5-year incidence, outcomes, and predictors of hemodynamic SVD in patients undergoing TAVR and surgery that will support best practices for treatment selection.
CME credits: 0.50
Valid until: 14-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/improved-patient-outcomes-needed-stat-for-anemia-in-chronic-kidney-disease/14037/
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
CME credits: 0.25
Valid until: 09-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/maximally-tolerated-or-suboptimal-therapy-clinical-perspectives-on-rechallenging-raasi-therapy/13262/
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
CME credits: 0.25
Valid until: 09-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/retina-clinic-current-treatment-options-in-namd/13983/
With the availability of multiple novel treatment options, how do we decide which is best for each patient with neovascular age-related macular degeneration? Join Dr. Arshad Khanani and Dr. Carl Danzig as they discuss their approach to treatment based on the latest clinical evidence.
CME credits: 0.25
Valid until: 08-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/a-look-behind-the-curtain-exploring-lower-risk-mds-rs-mdsmpn-rs-t/13992/
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
CME credits: 1.00
Valid until: 06-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/sars-cov-2-variants/13442/
Like other viruses, SARS-CoV-2 evolves over time. Certain variants have gained widespread attention because of their rapid emergence within populations and evidence for transmission or clinical implications; per the CDC, these are considered variants of concern. Clinicians may be challenged to optimize use of COVID-19 vaccines and therapeutics in the clinical context of SARS-CoV-2 variants given the complex nature of the variants and the ever-evolving data surrounding them. Because of the significance associated with SARS-CoV-2 variants, clinicians require education on the latest data and clinical recommendations regarding these variants.
CME credits: 1.00
Valid until: 06-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/immunosenescence-and-inflammaging-role-of-aging-as-a-risk-factor-for-severe-covid-19/13440/
Our understanding of the spectrum of COVID-19 as well as optimal management tactics continue to develop. In light of the ever-changing data and clinical recommendations surrounding COVID-19, clinicians are challenged to stay abreast of current treatment-related information with the potential to impact clinical decision-making. To mitigate the overall health burden associated with this devastating pandemic, healthcare professionals must be up to date on the latest practice-changing information regarding recommended therapeutic strategies, which include monoclonal antibodies, for high-risk patients in the outpatient setting. As such, an educational initiative surrounding COVID-19 outpatient treatments is warranted.
CME credits: 1.00
Valid until: 06-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/treatments-for-outpatients-with-mild-to-moderate-covid-19/13441/
Normal functions of the immune system include defense against infections. As the immune system ages and these capabilities decline, however, there is increased susceptibility to infections. Individuals of any age can acquire SARS-CoV-2 infection, although adults of middle age and older are most commonly affected, and older adults are more likely to have severe disease. Older age is also associated with increased COVID-19-related mortality. There is a need for knowledge regarding the harmful effects of the aging immune system (immunosenescence) and the role of chronic inflammation among elderly populations to facilitate enhanced clinical monitoring of at-risk patients. As such, an educational activity is needed to provide up-to-date coverage of the knowledge regarding immunosenescence in the context of COVID-19 to help optimize patient outcomes.
CME credits: 1.00
Valid until: 30-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/shifting-paradigms-for-assessment-and-management-of-lower-risk-myelodysplastic-syndromes-genomics-risk-stratification-and-novel-therapies/13788/
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with cytopenias, suboptimal production of mature erythrocytes, and substantial risk for progression to acute myeloid leukemia.
The classification of MDS and MDS/myeloproliferative neoplasm (MPN) overlap syndromes continue to evolve, making them difficult for clinicians to define and raising important new considerations for diagnosis, assessment, risk stratification, and treatment. The presence of ring sideroblasts (RS) and mutations in the SF3B1 gene correlate with favorable outcomes and help define specific disease subtypes.
In this video-based educational activity, an interview-style expert faculty panel will provide their perspectives and insights on the latest trends and emerging research in low-risk MDS, including guideline-directed diagnostic workup, RS evaluation and SF3B1 testing and their implications, currently approved and novel emerging treatment strategies for managing lower risk MDS, and strategies to mitigate and manage treatment-related adverse events.
CME credits: 1.00
Valid until: 30-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/improved-outcomes-in-mcrpc-with-psma-directed-diagnostics-and-therapies/13789/
Prostate cancer–specific antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).
In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.
CME credits: 0.50
Valid until: 25-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/evolving-perspectives-in-pik3ca-related-overgrowth-spectrum-diagnosis-treatment/13790/
PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.
The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.
Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.
CME credits: 0.50
Valid until: 24-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/update-on-botulinum-toxins-for-aesthetic-indications-duration-anatomy-and-other-patient-centric-considerations/13852/
The injection of botulinum toxin type A products can diminish unwanted facial wrinkles and improve appearance. Do you fully understand how to use these products? Tune in as Dr. Jason Bloom and Dr. Carolyn Jacob take us through the pharmacologic similarities, differences, and duration of effect for the 4 FDA-approved neuromodulators and demonstrate specific injection techniques for the masseter, platysma bands, “bunny lines,” and the glabellar complex.
CME credits: 0.25
Valid until: 16-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/looking-beyond-diabetes-the-role-of-sglt2i-and-mras-in-cardiorenal-disease/13259/
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
CME credits: 0.50
Valid until: 15-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/beyond-pulmonary-hypertension-month-diagnosing-treating-pah/13843/
Join Dr. John Russell as he speaks about diagnosing and treating pulmonary arterial hypertension using the latest pharmacologic and medical management strategies with Dr. Valerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan.
CME credits: 0.50
Valid until: 31-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-her2-treatment-paradigm-for-breast-cancer/13918/
This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment strategies for patients with HER2+ breast cancer.
CME credits: 0.50
Valid until: 31-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/clinical-case-challenge-navigating-the-her2-treatment-paradigm-for-breast-cancer/13919/
This Clinical Case Challenge is designed to help improve clinical decision making for providers caring for patients with HER2+ breast cancer.
CME credits: 1.00
Valid until: 29-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/underserved-pah-populations-why-dont-we-connect/13718/
Many pulmonary arterial hypertension (PAH) patients remain undiscovered, undiagnosed, and underserved. The reasons for this are many-fold, but central to the treatment of these patients is a need to make PAH care more accessible, affordable, and attractive. The COVID-19 pandemic has further exacerbated the need to connect with not only undiscovered PAH patients, but even those currently under physician care. That’s why this program explores myriad aspects of finding means to discover, connect with, and manage the disease of these underserved PAH patients in our general population. Key explorations brought to light in the program include the burdens many patients and physicians face with the financial costs to care, the prejudices many experience or perceive, and the lack of education and awareness of patients and healthcare providers alike. Part of the solution to these modern-day issues centers on the education of physicians, reducing medical and ancillary costs to patients, and making the most of the developing practices of telemedicine.
CME credits: 1.25
Valid until: 19-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-optimizing-timeliness-of-diagnosis-treatment-of-patients-with-lung-cancer-during-global-crises/13389/
A multidisciplinary panel including a medical oncologist, a thoracic surgeon, and an interventional pulmonologist will discuss the role of lung cancer teams in their thoracic oncology practices. The panelists will review their management of patients with lung cancer during the COVID-19 pandemic, including the impact of delayed procedures and telemedicine on patient outcomes.
CME credits: 0.25
Valid until: 15-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/personalizing-nsclc-the-optimal-applicability-of-ngs-and-liquid-biopsy/13834/
There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.
CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-for-patients-with-relapsed-or-refractory-cllsll/13797/
The landscape of treatment for CLL is rapidly evolving, with promising results from trials examining chemotherapy-free regimens in the frontline setting. While these targeted approaches utilizing BTK or BCL-2 inhibitors have largely displaced chemoimmunotherapy in frontline management of CLL, there remains a clinically significant fraction of patients who will require subsequent therapy after developing drug intolerance or progressive disease. Join Drs. Andrew Lipsky and Jacob Soumerai as they strategize which targeted therapeutic options for relapsed/refractory CLL likely offer each individual patient the safest and most effective clinical outcome.
CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/tackling-adverse-events-associated-with-disruption-of-b-cell-receptor-signaling-a-multispecialty-approach/13796/
Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent’s unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.
CME credits: 1.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/updates-on-clinical-trials-in-oncology-radiation/13390/
Two internationally known medical and radiation oncologists will discuss ongoing and recent clinical trials and offer their perspectives on how they will impact thoracic oncology practice. The panelists will also discuss current guidelines for managing patients with advanced lung cancer and emphasize the role of tissue and blood biomarkers.
CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/state-of-the-union-a-targeted-approach-in-first-line-treatment-of-cllsll/13795/
The process of matching the most optimal first-line therapy to patients with CLL has recently undergone a paradigm shift. Along with a widening focus on targeted agents, untangling key patient- and disease-centric parameters adds complexity to this shared decision. Join Drs. Susan O’Brien and Timothy Call as they offer clarity to this first-line decision process—a clarity that you can readily take into the clinic.
CME credits: 0.25
Valid until: 29-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-updates-from-asco-2022/13825/
A plethora of new data for multiple myeloma were presented at ASCO 2022. Hear Dr. Shaji Kuman and Dr. Maria-Victoria Mateos discuss the most relevant findings and which emerging strategies look promising for patients.
CME credits: 0.25
Valid until: 29-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-novel-targets-for-multiple-myeloma/13824/
There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.
CME credits: 0.25
Valid until: 29-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-optimizing-treatment-selection-in-relapsed-or-refractory-multiple-myeloma/13823/
Patients with multiple myeloma inevitably experience disease relapse, which is challenging. Rapid therapeutic advances have heralded an increasing number of efficacious targeted strategies and combination therapies for patients after a first relapse or in those with heavily pretreated disease. However, selecting the optimal regimen requires a individualized approach. Hear how Dr. Amrita Krishnan and Dr. Morie Gertz translate the evolving clinical data into their clinical practices and what factors influence their choices to improve durable responses and outcomes for patients with relapsed/refractory multiple myeloma.
CME credits: 0.25
Valid until: 29-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-newly-diagnosed-multiple-myeloma/13822/
Significant progress has been made with induction and initial treatment of multiple myeloma, leading to longer and deeper remissions for patients. Yet, how do you decide which regimen is best? Hear how Dr. Monique Hartley-Brown and Dr. Shonali Midha navigate the treatment of their newly diagnosed patients and what factors they consider when selecting a regimen.
CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/patients-as-partners-frontline-management-of-multiple-myeloma/13435/
Frontline management of patients with newly diagnosed multiple myeloma is complicated by a multitude of current and newer agents, and navigating the guidelines can be confusing. Tune in as Drs. Caitlin Costello and Ravi Vij provide insight into the newer agents and different administration modalities so that you can address your patients’ questions.
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/her2-directed-adcs-in-gastric-cancer/13889/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/her2-directed-adcs-breast-cancer/13881/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/trop2-directed-adcs-in-breast-cancer/13882/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/her3-directed-adcs-in-breast-cancer/13885/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/her2-directed-adcs-in-lung-cancer/13886/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/trop2-directed-adcs-in-lung-cancer/13887/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/her3-directed-adcs-in-lung-cancer/13888/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/nectin-4-directed-adcs-in-bladder-cancer/13890/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 22-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/trop2-directed-adcs-in-bladder-cancer/13891/
HER2-Directed ADCs in Breast Cancer
CME credits: 1.00
Valid until: 17-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/maximizing-ph-care-using-risk-assessment-to-improve-outcomes/13717/
In the management of the pulmonary arterial hypertension (PAH) patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, based on the registries, from which the modern risk assessment models have been developed, it’s clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there’s a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy and lung transplantation.
CME credits: 0.25
Valid until: 17-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/updates-in-vasomotor-symptom-treatment/13592/
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
CME credits: 0.25
Valid until: 16-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/new-horizons-in-the-medical-management-of-endometriosis-the-role-of-gnrh-antagonists-a-voice-of-patientvoice-of-provider-curriculum/13565/
Despite its profound impact, endometriosis remains critically undermanaged. This program provides highlights from a live symposium at the annual meeting for obstetrics and gynecology professionals and is based on patient & provider surveys. Join Dr. Ayman Al-Hendy to explore management gaps, the role of GnRH antagonists in addressing deficits, and the latest research, which he presented with Drs. Andrea Lukes and Lee Shulman—you might just alter your current practice patterns.
CME credits: 0.25
Valid until: 10-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/how-do-i-optimize-gdmt-with-new-therapies-in-my-patients-following-a-worsening-hf-event/13610/
Recent clinical trial data and subsequent approval of novel therapies have expanded the treatment armamentarium. These advances have the potential to improve long-term patient outcomes, but also make the choice of therapy more complex. This activity aims to educate clinicians managing patients with HFrEF already on guideline-directed medical therapy (GDMT) who continue to be at high risk of rehospitalization to recognize the clinical characteristics of worsening heart failure and to select appropriate HF treatment strategies including novel classes of agents in heart failure.
CME credits: 0.25
Valid until: 07-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/contraceptive-continuity-of-care-during-the-covid-19-pandemica-voice-of-patient-curriculum/13696/
In-office delivery of sexual and reproductive healthcare (SRH) services was markedly restricted for 2 years during the COVID-19 pandemic. Now, in-office access to these services has begun to improve. What have we learned since 2020 that can prepare us for future periods of reduced access? Join Dr. Mitchell Creinin as he discusses SRH service strategies initiated during the pandemic that remain useful even in times of full in-office access.
CME credits: 1.25
Valid until: 31-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimal-tissue-acquisition-handling-and-processing-ngs-and-pd-l1-testing/13391/
Expert pathologists and a medical oncologist will discuss current guidelines and their own practices regarding the role of liquid biopsy and comprehensive genetic and PD-L1 testing in the management of advanced lung cancer. The panelists will also explore various strategies for optimizing the quantity and quality of cytology and small volume biopsy specimens.
CME credits: 0.50
Valid until: 31-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/reducing-cardiovascular-risk-with-pcsk9-inhibitors-addressing-challenges-and-improving-outcomes/13698/
Two lipid experts will 1) provide an overview of the landscape of nonstatin, LDL-C-lowering therapy, 2) explain current guideline recommendations, 3) describe the evidence with ezetimibe and PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), 4) discuss cardiovascular risk reduction with PCSK9 inhibitors in a variety of very high risk ASCVD patient populations, and 5) emphasize the need to incorporate PCSK9 inhibition early in acute coronary syndrome patients to facilitate best patient outcomes.
CME credits: 0.50
Valid until: 27-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/empowering-clinicians-to-optimize-patient-outcomes-addressing-global-challenges-in-the-use-of-immunotherapy-in-nsclc/13564/
In the first-line management of non-small cell lung cancer, the use of immune checkpoint inhibitors (ICI) as monotherapy, as dual ICI, in combination with chemotherapy, or not at all is broadly dependent on which biomarkers are identified. While the choice of therapy is generally based on the level of expression of 1 or more biomarkers (eg, PD-L1, TMB), other factors often complicate this decision. Join us as Drs. Luis Paz-Ares and Kristen Marrone tackle these complexities by providing both foundational and clinical guidance to help you help your patients.
CME credits: 0.25
Valid until: 26-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimal-standards-of-care-for-second-line-her2-positive-advanced-gastric-and-gej-cancers/13685/
HER2 expression is a crucial biomarker when selecting treatment for patients with advanced gastric and gastroesophageal junction (GEJ) cancers. Until recently, there were limited therapeutic options. Join this lively conversation to enhance your knowledge related to emerging data and optimal treatment selection for patients with HER2-positive gastric and GEJ cancers.
CME credits: 1.00
Valid until: 20-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/bronchoscopy-ebus-tbna-and-ct-guided-biopsy/13392/
Two internationally known interventional pulmonologists will discuss current guidelines and their own experiences regarding sampling of lung lesions and mediastinal adenopathy. Specifically, the panelists will discuss the pros and cons of various diagnostic strategies and sampling techniques, including transcutaneous and bronchoscopic biopsies. This interactive webinar will offer the opportunity for learners to ask questions prior to and during the event. Learning is augmented by a few follow-up quizzes weeks after the webinar, a strategy proven to improve knowledge gain and retention.
CME credits: 1.00
Valid until: 19-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/lets-examine-collaborative-patient-management-in-ascvd-risk-reduction/13659/
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
CME credits: 0.50
Valid until: 19-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/qad-addressing-challenges-in-alzheimers-disease-from-early-identification-to-new-treatment-considerations/13485/
Alzheimer’s Disease (AD) is a progressive disease that presents challenges when it comes to the early diagnosis and treatment of patients. That’s why this two-part series will help answer your specific questions while providing expert insights into these challenges.
In this first activity, a panel of esteemed faculty will examine the case of a patient who was diagnosed early with mild cognitive impairment (MCI) due to AD, prior to dementia. Using this patient case, faculty will delve into both the importance of early identification of AD and how to detect it early. The panel will then discuss the pathobiology of AD and potential treatments in development to target this pathology. Finally, the panel will explore current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment. Throughout this activity, we will gather questions from clinicians like you who care for patients living with dementia, and then in part two of this series, we will answer some of the questions generated from this first activity.
CME credits: 0.50
Valid until: 29-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/protecting-adults-from-pneumococcal-disease-through-vaccination/13203/
Pneumococcal disease can cause pneumonia, meningitis, and sepsis, and can be a serious complication of influenza. Pneumococcal disease is serious and can be deadly; in the US, more than 150,000 adults are hospitalized with pneumococcal pneumonia each year, and about 1 in 20 individuals who get pneumococcal pneumonia will die. According to the 2017 National Health Interview Survey, pneumococcal vaccination coverage among adults age 65 years and older was 69%, well below US public health goals. The changing recommendations for pneumococcal vaccination in adults can make the vaccination assessment process challenging for healthcare professionals. This activity is based on the latest CDC recommendations and includes practical strategies to implement pneumococcal vaccination.
CME credits: 0.25
Valid until: 29-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/focus-on-the-new-menopause-management-horizon-improving-outcomes-through-managed-care/13273/
Are you ready to see what is on the horizon to more effectively navigate vasomotor symptoms (VMS)? Join Drs. Dunn, Owens, and Nelson as they discuss highlights from a symposium held at AMCP 2022 featuring the latest data on the impact of menopause and evolving treatments options. They provide guidance, context, and recommendations for the medical management of VMS beyond estrogen. The nonhormonal treatment options that are currently being studied represent a new horizon for both patients and payers.
CME credits: 0.75
Valid until: 27-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/bridge-to-understanding-your-connection-to-advancements-in-psoriasis-and-psa-treatments/13521/
There's good news for patients and clinicians dealing with the challenges of psoriasis or psoriatic arthritis (PsA). Novel and emerging therapies exist that can help improve symptoms, and slow or prevent disease progression. In this fast-paced, clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the American Academy of Dermatology (AAD) Annual Meeting that support using novel biologic and targeted synthetic agents for psoriasis and PsA. As part of the discussion, they also examine a patient case illustrating how you can optimize treatment plans, integrate the latest guideline recommendations in your practice, and encourage shared decision making with your patients.
CME credits: 0.25
Valid until: 26-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/best-practices-for-taking-a-sexual-history-destigmatizing-prep-care/13303/
Sexual histories are a vital part of ensuring a patient’s well-being. Nonetheless, many providers are uncomfortable taking a sexual history for an individual who may be at increased risk for acquiring HIV. The ability to offer a preventative medication for HIV acquisition is a cornerstone for informed consent for sexual health. Join Dr. Richard Elion as he takes us through a patient-clinician dialogue demonstrating how to take a sexual history that is complete, respectful, and nonjudgmental.
CME credits: 0.25
Valid until: 22-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/novel-clinical-approaches-in-multiple-myeloma-car-t-cell-therapy/13429/
Two newly approved BCMA-directed CAR T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are providing patients with the prospect of deep and durable remissions. Maximizing the potential of CAR T cell therapy can provide improved length and quality of life for patients with multiply relapsed multiple myeloma. Join us as Dr. Sagar Lonial and Dr. Noopur Raje discuss the available treatment options, current applications of the clinical data, and strategies to improve care for your patients with multiple myeloma who may be candidates for CAR T cell therapy.
CME credits: 3.50
Valid until: 20-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/adopting-the-new-therapeutic-lineup-to-manage-ascvd-central/13254/
Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
CME credits: 0.25
Valid until: 19-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-emerging-role-of-her2-erbb2-mutations-in-nsclc/13695/
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
CME credits: 0.50
Valid until: 17-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/non-covalent-btk-inhibitors-for-b-cell-malignancies-mclcll-setting-the-stage-for-future-use/13384/
During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated.
This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …
CME credits: 0.25
Valid until: 15-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/alzheimers-disease-tools-for-early-diagnosis/13288/
Are you familiar with available and developing tools for assessing Alzheimer’s disease (AD)? Correctly using these tools can lead to a vital earlier diagnosis which can improve outcomes for our patients. Tune in to hear Dr. Richard Isaacson and Dr. Michael Weiner take us through some of these assessment tools and they ways in which they can help us reach a true diagnosis of AD.
CME credits: 0.25
Valid until: 15-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/managing-and-monitoring-mds-mds-related-effects-and-progression-to-aml/13518/
MDS is a very heterogenous clonal bone marrow disorder with a high risk for anemia and progression into acute myeloid leukemia. Dr. Amer Zeidan and Dr. Amy DeZern discuss how to appropriately monitor and treat patients with higher-risk MDS.
CME credits: 0.25
Valid until: 15-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/iron-deficiency-anemia-in-patients-presenting-with-abnormal-uterine-bleeding-the-role-of-oral-iron-supplementation/13577/
How ready are you to go beyond simply ordering CBCs and recognizing anemia? Join Drs. Martin and Shulman as they discuss the latest developments in oral and IV iron therapies. Learn how you may take a more active role in managing iron deficiency anemia, focusing on abnormal uterine bleeding.
Participating in this activity will ensure that you are prepared to address the goals with your patients by improving access and adherence to efficacious and convenient therapies.
CME credits: 0.25
Valid until: 14-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-hypertrophic-cardiomyopathy-the-potential-role-of-cardiac-myosin-inhibition/13287/
—Breaking News—Commentary on HCM-related Late-Breaking Abstracts presented at ACC.22 in April has been added to the start of the program. The rest of the program will cover the following topics: Why do we need new therapies in hypertrophic cardiomyopathy (HCM), and will newer and emerging cardiac myosin inhibitors improve the standard of care for patients with HCM? What differences can we expect regarding patient outcomes and quality of life with these new therapies? Join Dr. Ahmad Masri and Dr. Deepak Bhatt as they explore how newer cardiac myosin inhibitors go beyond traditional medical management (that only addresses the macro-pathophysiology and disease symptoms) to actually treat HCM at the cellular level.
CME credits: 0.25
Valid until: 08-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/a-new-light-in-higher-risk-mds-emerging-treatment-options/13517/
New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans.
Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML.
https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/state-of-the-union-car-t-cell-therapy/13658/
Patients with multiple myeloma (MM) whose disease has relapsed multiple times have historically poor outcomes. CAR T cell therapy is a novel therapeutic option for those patients and can provide prolonged responses and improved outcomes. However, the treatment is complex, and careful planning is needed to effectively incorporate these treatments into practice. Drs. Thomas Martin and Larry Anderson discuss CAR T cell therapies for MM with a focus on patient selection, accessibility of treatment, and management of patients after administration.
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/having-productive-conversations-with-patients-at-high-risk-for-hiv/13304/
The CDC’s 2021 update to their PrEP guidelines recommend that PrEP should be offered to all individuals who want or need it. Although PrEP is both safe and extremely effective, persistence to PrEP in the long-term is low, at about 40% at 2 years. Join Drs. Wohl and Hightow-Weidman as they discuss the challenges associated with increasing PrEP uptake and how the emergence of a long-acting injectable PrEP formulation could result in improved long-term persistence.
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-uc/13566/
There are over a half dozen newer and emerging classes of agents for ulcerative colitis. This abundance is great news for our patients, but it also increases the complexity of treatment. Listen in as Dr. Neil Nandi and Dr. Jean-Frederic Colombel explore the roles that these agents will play in the evolving treatment landscape.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
CME credits: 0.50
Valid until: 30-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/adjuvant-treatment-of-early-nonsmall-cell-lung-cancer-in-the-era-of-immunotherapy/13453/
Standard of care treatment for resectable early-stage NSCLC usually includes surgery in combination with neoadjuvant or adjuvant platinum-based chemotherapy; however, metastatic disease often develops. To lower the risk for recurrence, an area of active research is the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for early-stage NSCLC. Several immune checkpoint inhibitors are now being investigated in early-stage NSCLC, with promising results reported, suggesting a role for the use of neoadjuvant and adjuvant therapy with immune checkpoint inhibitors in early-stage NSCLC.
This educational activity will review the role of immunotherapy in early-stage NSCLC as adjuvant treatment, recent clinical data and the latest advances for immune checkpoint inhibitors as adjuvant treatment, and recent and ongoing clinical trials for adjuvant and neoadjuvant immunotherapy for the treatment of early-stage NSCLC so that clinicians are better able to integrate emerging data and new treatment options into clinical practice and inform, educate, and refer patients to clinical trials when appropriate.
CME credits: 0.50
Valid until: 30-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/improving-interprofessional-management-of-sickle-cell-disease-with-disease-directed-therapies/13250/
A common complication of sickle cell disease (SCD), vaso-occlusive crisis (VOC), is characterized by the sudden onset of severe pain and is the most common reason for hospital visits in patients with SCD. Vaso-occlusion is caused by the adhesion of sickled erythrocytes and leukocytes to the endothelium, resulting in vascular obstruction and tissue ischemia. In addition to severe pain, long-term complications of vaso-occlusion may include damage to muscle and/or bone, in addition to vital organs such as the liver, spleen, kidneys, and brain. Vaso-occlusion and VOCs are associated with decreased organ function and can result in life-threatening complications such as acute chest syndrome, pulmonary hypertension, renal failure, and stroke. SCD can also have a profound effect on the quality of life for children and adults.
With increased understanding of the pathophysiology of VOCs, novel therapies that target the pathologic process of vaso-occlusion may reduce cell adhesion and inflammation, leading to decreased incidence of VOCs and prevention of end-organ damage. This educational activity will review the burden of SCD, including VOCs, acute chest syndrome, and end-organ damage in adults and pediatric sickle cell patients, as well as efficacy and safety data of established and novel therapies that target SCD-related complications for …
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-updates-on-durable-vegf-suppression/13278/
Multiple new and novel strategies are now available to treat patients with neovascular age-related macular degeneration and diabetic macular edema. What are these strategies, and how should they be used in everyday practice? Hear Dr. Caroline Baumal and Dr. Carl Regillo discuss the latest data and how they are adopting these new approaches into their retina patient care.
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-latest-surgical-techniques-for-anti-vegf-delivery/13279/
New technology has arrived that provides prolonged delivery of anti-VEGF therapy and with it comes new techniques for vitreoretinal surgeons. Find out what steps you need to take to ensure both successful implantation and refill-exchange of the port delivery system. Dr. Fernando Arevalo discusses these critical details with Dr. W. Lloyd Clark, one of the leading pioneers of this technology.
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-new-data-for-namd-and-dme-in-vascular-integrity/13280/
Second-generation intravitreal agents that incorporate new pathogenic targets have emerged for the treatment of retinal diseases. What are these targets, and how should these new medicines be used in clinical practice? Join Dr. Diana Do and Dr. John Wells as they discuss novel mechanisms for therapeutic control of neovascular age-related macular degeneration and diabetic macular edema and how to incorporate these new agents into clinical practice.
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-with-hematologic-malignancies-understanding-classifying-and-stratifying-mds/13282/
In order to effectively treat the MDS patient in front of us, we first need to classify their disease and understand its risk stratification category. Hear what Dr. David Sallman and Dr. Jacqueline Garcia have to say about MDS prognosis and risk stratification to better understand each patient’s disease progression.
CME credits: 0.25
Valid until: 30-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/new-perspectives-in-managing-hf-and-hk-the-cardiorenal-angle/13261/
RAASi therapy is a critical component of heart failure management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. This is especially evident in our patients with chronic kidney disease. So how can we simultaneously maintain optimal therapy and manage hyperkalemia? Join Dr. Mikhail Kosiborod and Dr. Austin Stack as they discuss a patient case and make sure you’re staying up to date with the evolving data, guidelines, and practices.
CME credits: 0.25
Valid until: 25-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/weighing-the-evidence-a-case-based-review-in-ulcerative-colitis/13439/
The proliferation of new classes of therapies for ulcerative colitis is affecting how we decide which treatments are most appropriate for our patients who are first- or second-line non-responders. This creates not only new challenges, but also new opportunities for all community gastroenterologists. Dr. Neil Nandi and Dr. David Rubin walk us through a case to highlight some of these challenges.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
CME credits: 0.25
Valid until: 25-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/strategies-to-improve-patient-communication-about-the-vaginal-ph-modulator/13300/
Are you ready to apply the latest counseling techniques to address the contraceptive revolution?
Join nurse practitioners Patty Cason and Joely Pritzker as they briefly review the history of contraceptive counseling and then use case vignettes to illustrate how shared decision-making techniques will support the appropriate use of nonhormonal contraceptive options, such as the vaginal pH modulator (VPM).
Participating in this activity will ensure that you are ready to effectively counsel patients on their many options so that each patient’s reproductive and sexual health goals can be met.
CME credits: 0.25
Valid until: 25-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/hypertrophic-cardiomyopathy-the-3-things-you-need-to-know/13286/
What if a patient has fatigue, dyspnea, chest pain, palpitations, presyncope, left ventricular afterload, and diastolic dysfunction? Is it heart failure? Is it left ventricular hypertrophy due to arterial hypertension? Is it aortic stenosis? Did you even consider hypertrophic cardiomyopathy? Join Dr. Ahmad Masri and Dr. Steve Ommen as they discuss the challenges of HCM diagnosis and why you should get to know HCM!
CME credits: 0.25
Valid until: 17-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/rethinking-benzoyl-peroxide-in-acne-and-rosacea/13289/
Do you ever wish you could mix the unmixable when it comes to treatment selection? Microencapsulation is the answer! This new technology preserves the advantages of BPO while minimizing limitations for patients with acne and rosacea. Tune in to our chapterized panel discussion with Drs. Linda Stein Gold, Julie Harper, and Neal Bhatia and view 3D animation revealing how microencapsulation works.
CME credits: 0.25
Valid until: 17-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/case-review-rethinking-benzoyl-peroxide-in-rosacea/13292/
Drs. Neal Bhatia and Jeff Sugarman discuss how the new formulation of benzoyl peroxide can change our treatment armamentarium for rosacea. Find out how microencapsulation technology stabilizes BPO and improves outcomes for patients.
CME credits: 0.25
Valid until: 17-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/case-review-understanding-benzoyl-peroxide-combination-treatment-in-acne/13290/
Microencapsulation technology is allowing us to combine agents that were previously incompatible. One new formulation is preserving the advantages of BPO while minimizing limitations and improving adherence for patients with acne. Join Dr. Linda Stein Gold and Dr. Hilary Baldwin as they walk through a case scenario to demonstrate how the new formulation of BPO and tretinoin fits into clinical practice.
CME credits: 0.25
Valid until: 15-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/sharpening-the-focus-identifying-treatment-strategies-for-diabetic-retinopathy/13265/
A main goal in the treatment of diabetic retinopathy is to intervene early enough to prevent vision loss. New data are giving us new tools for our armamentarium and helping us define what constitutes “early”—and if there’s such a thing as “too early.” Join us to take a closer look at the data surrounding the management of NPDR and CI-DME with good vision and hear our panelist of experts explain how the data translate into clinical care.
CME credits: 0.25
Valid until: 14-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/overcoming-vaccine-hesitancy-improving-clinician-and-patient-communication/13245/
Vaccine hesitancy is a very challenging, and often tiring topic, for clinicians to address. Join Dr. Rachel Caskey in an engaging clinician-patient dialogue as she uses a dynamic and presumptive approach to overcome common vaccination challenges. What communication pearl will you use with your patients?
CME credits: 0.50
Valid until: 07-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/modifying-treatment-strategies-to-address-poor-response-in-major-depressive-disorder/13386/
This Expert Exchange webcast is designed to help clinicians achieve better outcomes in patients with MDD who have an inadequate initial treatment response.
CME credits: 0.25
Valid until: 28-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/clarifying-the-value-of-anti-egfr-therapy-in-metastatic-colorectal-cancer/13269/
Even with the recent advances in therapeutic options for patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC), they still have an uphill climb ahead of them.
How will the new standard of care in the second-line setting address global challenges and unmet needs regarding molecular profiling and treatment sequencing options?
Join us as 3 experts, Dr. Scott Kopetz, Dr. Elizabeth Smyth, and Dr. Elena Elez, untangle these new advances in treatment and offer their insights on how diagnostic testing can improve patient outcomes.
CME credits: 0.25
Valid until: 28-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/what-you-need-know-about-strategies-treating-npdr/13177/
The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?
Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.
CME credits: 0.25
Valid until: 28-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mras-latest-evidence-of-cardiorenal-protection-in-ckd-and-t2d/13298/
Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.
CME credits: 0.25
Valid until: 28-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/saving-sight-what-you-might-be-missing-in-your-patients-with-diabetes/13161/
With the increasing prevalence of diabetes in the United States, more individuals are at risk of losing their vision due to diabetic retinopathy every day. Fortunately, research is improving our understanding of this disease. But what does the latest information mean for our patients?
Hear Dr. Susan Bressler, Dr. Mark Dunbar, and Dr. Ruth Weinstock share their perspectives as multidisciplinary specialists treating these patients. Find out what the evidence shows and how timely referral, early diagnosis, and appropriate treatment can prevent the vision-threatening complications of diabetes.
CME credits: 0.50
Valid until: 25-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/raising-the-bar-in-psa-integrating-structural-assessment-to-improve-long-term-outcomes/13301/
Integrating routine assessments of psoriatic arthritis (PsA)-related structural progression has proven challenging in clinical practice. Join Drs. Sergio Schwartzman, Philip Mease, and April Armstrong as they discuss evidence that frequent monitoring of PsA structural progression permits earlier intervention with effective therapies as well as provides indications for when to switch to another class of agent. They also address which therapeutic agents have been shown to impact PsA structural progression in clinical trials and provide insight into how best to incorporate collaborative treatment strategies across disciplines. These practices are likely to improve outcomes for patients with PsA, so be sure to stay informed.
CME credits: 0.25
Valid until: 25-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/psignposts-addressing-health-disparities-in-psoriatic-arthritis/13294/
There is often a delay in the diagnosis of psoriasis and/or psoriatic arthritis for people with skin of color. Among the multiple factors that cause this disparity are a low index of suspicion for such a diagnosis in skin of color and a lack of familiarity with the morphology of these conditions in richly pigmented skin. Join Drs. William Mencia and Andrew Alexis as they address pathways to overcoming these systemic and experiential healthcare barriers.
CME credits: 0.25
Valid until: 22-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/potassium-binders-as-enablers-of-raasi-therapy-diamond-topline-results/13260/
The DIAMOND trial recently released topline results, adding to the growing clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. So what do the data mean for our patients? Join Dr. Stefan Anker and Dr. Javed Butler as they discuss the value of these results and make sure you’re staying up to date with the evolving data, guidelines, and practices.
CME credits: 0.25
Valid until: 11-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-vaginal-ph-modulator-a-revolutionary-approach-to-contraception/13299/
Are you ready for the contraceptive revolution? Are you applying the latest information on contraceptive efficacy, recent clinical trial data, and sexual satisfaction when counseling your patients on contraceptive options? Join Dr. David Portman, Dr. David Eisenberg, and Ms. Patty Cason as they discuss the novel mechanisms of action of cutting-edge, non-hormonal contraceptive options, such as the vaginal pH modulator (VPM). Participating in this activity will ensure that you are prepared to discuss sexual and reproductive goals with your patients and confirm that your patients’ goals are being met.
CME credits: 0.25
Valid until: 08-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/high-risk-hfref-who-will-benefit-most-from-novel-therapies/13297/
Have you started using newly approved therapies when caring for your patients with heart failure with reduced ejection fraction (HFrEF)? Tune in to hear Drs. Javed Butler and Shelley Zieroth discuss strategies you can use to determine the best treatment approaches for your most challenging patients. A 3D mechanism of action animation is included to help you understand the workings of novel classes of agents in heart failure. Make sure you get with the guidelines, because guideline-directed medical therapy really does work.
CME credits: 0.25
Valid until: 31-01-2023
Claim your CME credit at https://reachmd.com/programs/cme/misconceptions-benefits-and-disadvantages-of-the-newer-oral-gnrh-antagonists-in-the-management-of-uterine-fibroids-and-endometriosis/13247/
Surgery has long been the default choice when managing uterine fibroids and endometriosis. However, over the past few years, reliable and durable medical interventions have emerged, notably GnRH antagonist therapy. Clinical trial data for GnRH antagonists highlight both their safety and efficacy for a broad demographic of patients. Join Drs. Lee Shulman and Ayman Al-Hendy as they discuss the “how” and the “why” of a paradigm shift that is occurring, changing our focus from surgery to first-line medical intervention for uterine fibroids and endometriosis.
CME credits: 0.50
Valid until: 21-01-2023
Claim your CME credit at https://reachmd.com/programs/cme/seeing-beyond-the-symptoms-early-diagnosis-and-treatment-of-dry-eye-and-meibomian-gland-dysfunction/13178/
Dry eye disease is one of the most common ophthalmic complaints; it results from the activity of various pathways and is considered a multifactorial disease. An important factor that contributes to the onset of dry eye disease is meibomian gland dysfunction. Meibomian gland dysfunction causes a disruption in the tear film lipid layer, which affects the rate of tear evaporation. This evaporation leads to tear hyperosmolarity, eventually triggering the onset of dry eye disease. Dry eye disease and meibomian gland dysfunction are strongly associated with each other, such that many of their risk factors, signs, and symptoms overlap. In this educational podcast, our expert faculty will review the association between dry eye disease and meibomian gland dysfunction, and highlight best practices for assessment, diagnosis, and management.
CME credits: 1.00
Valid until: 18-01-2023
Claim your CME credit at https://reachmd.com/programs/cme/advances-standard-care-tnbc-addressing-health-disparities-and-integrating-adcs-treatment/13107/
For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States.
This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.
CME credits: 1.00
Valid until: 16-01-2023
Claim your CME credit at https://reachmd.com/programs/cme/hemophilia-a-strategies-for-improving-long-term-holistic-management-adherence-and-quality-of-life/13065/
Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII.
However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data.
In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.
CME credits: 0.25
Valid until: 07-01-2023
Claim your CME credit at https://reachmd.com/programs/cme/new-insights-into-the-management-of-ckd-in-t2d-the-role-of-mra-therapies/13097/
Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.
In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.
CME credits: 0.50
Valid until: 06-01-2023
Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-for-whos-at-risk-preventing-and-managing-tumor-lysis-syndrome-and-neutropenia-in-cll/13144/
Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes.
A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.
CME credits: 0.50
Valid until: 04-01-2023
Claim your CME credit at https://reachmd.com/programs/cme/reimagining-alzheimers-disease-new-thinking-new-choices/13132/
Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. It is the most common cause of dementia worldwide and its’ prevalence continues to grow in part because of the aging world population. AD is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria including fluid and imaging biomarkers. Until recently, current therapies were limited to delaying cognitive decline in some patients, but not treating the underlying causes of the disease nor halting the progression of the disease. This program discusses recent advances in our understanding of the clinical evaluation for early and accurate diagnosis, newly approved and emerging disease-modifying therapies, as well as non-pharmacological strategies for the management of patients with AD.
CME credits: 0.25
Valid until: 14-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/new-perspectives-on-managing-dr-applying-the-latest-strategies-into-clinical-practice/13098/
Are you aware of the latest data that adds to our understanding of the management of diabetic retinopathy (DR)? Listen in as Dr. Avni Finn and Dr. Jay Sridhar discuss what those data are and the impact they have on the early referral and timely treatment of patients with DR. Make sure you’re properly using all of the resources in your armamentarium to save your patients’ sight.
CME credits: 0.25
Valid until: 30-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-integration-of-immune-checkpoint-inhibitors-as-initial-therapy-for-advanced-disease/13147/
Medical innovation in the treatment of lung cancer is at an all-time high. However, the gap between recent developments and their adoption into clinical practice continues to expand for community oncologists as the plethora of scientific and clinical data for the treatment of NSCLC rapidly emerges. Dr. Mark Socinski and Dr. Sandip Patel go through the selection and management of immune checkpoint inhibitors for patients with advanced NSCLC who do not have an actionable mutation.
CME credits: 0.25
Valid until: 30-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/considerations-when-using-a-potassium-binder-in-patients-with-ckd/13068/
Determining the optimal strategies for treating patients with chronic kidney disease (CKD) can be challenging. After decades of waiting, exciting and rapid progress in renin-angiotensin-aldosterone system (RAAS) inhibition is being made, but these therapies can lead to hyperkalemia. The trick is to sustain optimal therapy in the patient without interruption or reduction. Are you familiar with novel potassium binders and recent changes in guideline-directed medical therapy surrounding their use? Tune in because these resources are offering new therapeutic opportunities for your patients with CKD.
Join Drs. Murray Epstein and Gates Colbert to ensure you’re up to date on the latest treatment options for your patients with CKD.
CME credits: 0.25
Valid until: 30-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-clinical-case-challenges-in-nsclc/13181/
With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.
CME credits: 0.50
Valid until: 30-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/navigating-her2-treatment-paradigm-gastric-cancer/13180/
This Clinical Case Challenge is designed to assess a learner’s ability to implement appropriate treatment HER2 strategies for patients with gastric cancer.
CME credits: 0.50
Valid until: 30-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/latest-lessons-learned-rapid-review-of-chest-vte-and-chest-covid-vte-guidelines/13079/
Physicians are challenged in adopting the latest clinical guidelines and integrating new and existing treatment advances into practice when managing patients with VTE.
CME credits: 1.00
Valid until: 29-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/a-new-chapter-for-oral-precision-therapies-in-thyroid-cancer-ret-inhibitors/13137/
Although multi-kinase inhibitors (MKIs) have been the standard of care for the treatment of thyroid cancer, they produce excessive “off-target” clinical adverse effects and toxicity that limit their use in some patients, leading to drug discontinuation or dose reduction. The introduction of RET inhibitors into the thyroid cancer treatment landscape offers novel, efficacious therapies for patients who previously had limited treatment options.
This online, on-demand educational activity will review RET alterations in thyroid cancer, molecular diagnostic testing, and recent and emerging clinical data on novel therapies targeting RET-altered or RET-driven thyroid cancer. A Virtual Case Clinic Video Exercise will highlight and demonstrate the translation of these RET-targeted therapies into real-world clinical practice for the treatment of patients with thyroid cancer.
CME credits: 0.25
Valid until: 30-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/new-perspectives-on-the-management-of-hfref-iron-deficiency-and-cardiac-remodeling/13143/
Iron deficiency (ID), independent of anemia status, is common in heart failure with reduced ejection fraction (HFrEF). In normal cardiac physiology, contractility increases disproportionally to heart rate; however, in HFrEF and concomitant ID, this response is impaired. Additionally, HFrEF patients with ID who receive cardiac resynchronization therapy (CRT) exhibit diminished cardiac reverse remodeling after CRT implant.
In this discussion, Drs. Martens and van der Meer discuss how physicians can work to improve reverse cardiac remodeling, the force-frequency relationship, and quality of life in patients with HFrEF and ID receiving CRT.
CME credits: 0.25
Valid until: 30-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-guidelines-and-the-future-direction-of-immunotherapy-in-nsclc/13165/
The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.
CME credits: 0.25
Valid until: 30-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-improving-outcomes-for-patients-with-ret-positive-nsclc/13163/
RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option. Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.
CME credits: 0.25
Valid until: 28-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/eyes-wide-open-new-strategies-managing-diabetic-retinopathy/13128/
When it comes to diabetic retinopathy, studies and new data are constantly being published. Are you up to date with the progress being made? Join Dr. Diana Shechtman and Dr. Carolyn Majcher for a discussion on the latest data around the treatment of nonproliferative diabetic retinopathy and how these advances affect the management of your patients.
CME credits: 0.25
Valid until: 31-01-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-raasi-therapy-the-role-of-personalized-medicine/13124/
Hyperkalemia is common in chronic heart failure and is associated with an increased risk of hospitalization and death. The incidence is further elevated in those with chronic kidney disease, and the presence of hyperkalemia can often lead to clinical delay and suboptimal dosing of RAAS inhibitors in these patients.
Join the discussion as Drs. George Bakris and Giuseppe Rosano examine the management of hyperkalemia in patients with HF and provide individualized approaches for optimizing RAASi therapy. Collaboration between nephrologists and cardiologists is key, and these experts make sure to stress the strong connection between the heart and kidneys when managing these patients.
CME credits: 1.00
Valid until: 29-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/it-pah-or-ph-due-lung-disease-andor-chronic-hypoxia/13174/
It can be very challenging to differentiate between WHO Class 1 Pulmonary Arterial Hypertension and WHO Class 3 Pulmonary Hypertension due to Lung Disease or Chronic Hypoxia. Despite similar clinical manifestations, these two conditions are characterized by different hemodynamic definitions and etiologies. Through the use of 2 case studies, clinicians can learn about the diagnosis and management of PAH versus PH due to lung disease or chronic hypoxia.
CME credits: 0.25
Valid until: 29-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/unravel-global-clinical-complexities-in-head-and-neck-cancers-identifying-approaches-to-improve-outcomes-with-manageable-toxicities/13056/
Formulating individualized treatment plans for patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) is increasingly essential and increasingly complex. Newer regimens have become the standard of care because of their efficacy in overall survival and reduced toxicities. So how do we deploy them now that they’re in our treatment armamentarium?
Join Drs. Joël Guigay and Kevin Harrington as they explore the role of IO as the standard of care in SCCHN and discuss the potential of taxanes to reduce dependence on fluorouracil-based chemotherapeutic regimens. Tune in to make sure you’re meeting the needs of your patients’ with SCCHN.
CME credits: 0.50
Valid until: 29-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/advances-treatment-neurogenic-detrusor-overactivity/13188/
This Expert Exchange webcast is designed to enhance clinicians’ awareness of advances in the pharmacotherapeutic armamentarium for treating NDO in the pediatric population.
View the Advances in the Treatment of Neurogenic Detrusor Overactivity Clinical Compendium here: https://cdn.reachmd.com/uploads/clinicalcompendium_ndo_v2_final.pdf
CME credits: 0.25
Valid until: 29-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-role-of-rapid-acting-agents-for-the-treatment-of-mdd/13090/
Depression can cause a multitude of symptoms, many of which are associated with impairment that, if not treated appropriately, can go on for months or even years. With traditional antidepressants having a longer time to onset, the role of rapid-acting agents can greatly improve the quality of life for patients with major depressive disorder (MDD). Dr. Michael Thase and Dr. Sagar Parikh discuss the clinical diagnosis of MDD and the role of emerging neuroactive steroids. Tune in and fasten your seat belt for faster results!
CME credits: 0.50
Valid until: 28-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/navigating-her2-treatment-paradigm-gastric-cancer/13179/
This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment HER2 strategies for patients with gastric cancer.
CME credits: 0.50
Valid until: 28-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/how-long-is-too-long-evolving-literature-on-long-term-anticoagulation-therapy-after-vte/13069/
Although evidence corroborates the safety and efficacy of managing low-risk patients with VTE in outpatient settings through prophylactic extension, the majority of this subtype is still being treated in hospital settings.
CME credits: 0.25
Valid until: 28-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/improving-the-standard-of-care-in-community-based-her2-positive-metastatic-breast-cancer/13108/
HER2 is overexpressed and/or amplified in about 20% of breast cancers and signifies aggressive tumor behavior. New anti-HER2 therapies are improving the outlook for advanced or metastatic disease with targeted therapeutics, but while physicians now have a multitude of therapies to choose from, patient-specific characteristics and sequencing still present a challenge.
Tune in to enhance your knowledge and skills with this lively panel discussion examining 2 different patient cases with metastatic breast cancer (mBC). Explore optimal treatment selection based on patient-specific characteristics and ensure that you’re keeping up with the rapidly evolving landscape of HER2+ mBC. Find out what changes can make in your practice today to improve the lives of your patients.
Note that this program follows a previous case-based simulation activity titled “Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer.” This panel discussion analyzes choices made in that simulation and expands on optimal recommendations. If you haven’t participated in the simulation and would like to put yourself to the test, you can find the link to the activity in the related section.
Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about …
CME credits: 0.25
Valid until: 28-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/normalizing-mufc-cushings-disease/13120/
The primary goals in the medical management of Cushing’s disease are to normalize cortisol levels and reduce or eliminate the associated comorbidities, physical features, and symptoms for our patients. With recently approved therapies and more in development, it really is an exciting time in this treatment space! Tune in to hear Dr. Eliza Geer discuss novel medical options and how we should remember the importance of looking at patient outcomes to make sure we’re addressing Cushing’s disease holistically.
CME credits: 0.25
Valid until: 27-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/flip-the-coin-have-catheter-directed-therapies-found-their-place-in-pe-management/13070/
High risk patients and those with identifiable symptoms are not routinely receiving prophylaxis treatment that could prevent the development of VTE.
CME credits: 1.00
Valid until: 27-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/real-world-experience-diagnosing-and-managing-pnh-special-patient-populations/13167/
In a “how I do it” clinical commentary, Dr. Jamile Shammo and Dr. Ilene Weitz share their real-world experience in the diagnosis and management of PNH in special patient populations. This case-based activity includes clinical scenarios and treatment strategies to improve patient outcomes.
CME credits: 1.00
Valid until: 23-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/practical-guidance-community-oncologist-incorporating-advances-therapy-metastatic-tnbc-focus-trop2/13157/
Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC.
What are the latest data with these ADCs? Why is TROP2 an effective target in TNBC? How do we best incorporate these TROP2-targeted ADCs into TNBC care? This expert-led recording from a series of national visiting lecture series updates clinicians on how recently approved and investigational ADCs overcome current challenges in TNBC treatment. This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations. The activity includes excerpts from the live question and answer session as well as downloadable resources to improve care for your patients with TNBC.
CME credits: 0.25
Valid until: 23-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/parkinsons-disease-psychosis-watchful-waiting-vs-proactive-treatment/13105/
Hallucinations and delusions cause a significant number of hospitalizations and nursing home admissions for our patients with Parkinson’s Disease. Listen to Dr Kevin Black share his approach to timely diagnosis and evidence-based management that can improve the daily lives of these patients and their caregivers.
Kevin Black, MDProfessor of Psychiatry, Neurology, Radiology, and Neurobiology
Washington University in St Louis School of Medicine
St Louis, Missouri
CME credits: 0.25
Valid until: 21-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/update-on-treatment-options-for-narcolepsy/13110/
Tune in to hear about new treatments for patients with narcolepsy. Data were recently presented at the American College of Chest Physicians Annual Meeting, and Drs. Clete Kushida and Lois Krahn are breaking it down for you: they examine the evolving treatment landscape and dive into the latest research on currently available and emerging pharmacologic options including the expanding range of oxybate therapies. Join us and find out why it’s such an exciting time to be caring for patients with narcolepsy.
CME credits: 0.25
Valid until: 21-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/medical-management-of-uterine-fibroids-and-endometriosis-the-emerging-value-proposition-surrounding-the-new-oral-gnrh-antagonists/13083/
By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.
CME credits: 1.00
Valid until: 20-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/identifying-and-managing-cancer-therapy-induced-interstitial-lung-disease-ild-and-pneumonitis/12929/
Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors.
Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.
CME credits: 0.25
Valid until: 21-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/panel-discussion-on-aha-symposium-clinical-rundown3-hot-topic-sessions-on-ascvd-risk-reduction/13091/
This CME Roundtable highlights key takeaways and late-breaking data shared at a symposium held at the AHA annual meeting. Hear updated management strategies, new data, and guidelines to help you manage patients with established ASCVD who are at an increased risk of myocardial infarction, stroke, and death.
CME credits: 0.25
Valid until: 20-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-bladder-cancers-all-about-sequencing-in-locally-advanced-or-metastatic-urothelial-carcinoma/13164/
It's critical that we select and sequence appropriate therapeutics to provide our patients with the best possible outcomes. Dr. Petrylak and Dr. Siefker-Radtke provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma. With so many new treatment options now available and a cure becoming a real possibility, we invite you to tune in to find out if your treatment strategies are on target.
CME credits: 0.25
Valid until: 17-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-applying-the-right-therapy-to-the-right-patient-in-ret-positive-nsclc/13130/
With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you’re identifying everyone who can benefit from these newer therapies.
CME credits: 0.50
Valid until: 16-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/the-future-of-heart-failure-management-rethinking-approaches-to-care/13089/
In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.
Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.
CME credits: 0.50
Valid until: 15-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/synergy-of-guideline-directed-medical-therapies-in-heart-failure-to-optimize-patient-outcomes/13115/
Renin-angiotensin-aldosterone system inhibition (RAASi) is the foundation of guideline-directed medical therapy (GDMT) for heart failure patients. However, due to practice gaps, a significant proportion of the population requiring its use do not experience the benefits of RAASi therapy, which is especially true for patients with comorbid conditions. Hyperkalemia is a common adverse effect of RAASi therapy that needs to be anticipated and mediated so that the optimal dosing of necessary medications can occur. Maximizing GDMT in the face of hyperkalemia remains a key clinical challenge that, if not handled properly, can result in increased morbidity and mortality.
In this activity, Drs. Javed Butler, Mikhail Kosiborod, and Matthew Weir review a patient case and discuss different treatment approaches to optimize GDMT while managing hyperkalemia. Tune in to make sure you’re doing all you can to improve outcomes for your patients with heart failure and comorbid conditions.
CME credits: 0.50
Valid until: 15-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-her3-expression-in-advanced-solid-tumors/12956/
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
*Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.
CME credits: 0.75
Valid until: 08-12-2022
Claim your CME credit at https://reachmd.com/programs/cme/addressing-the-unique-needs-of-women-with-migraine/13076/
Women with migraine have unique needs that often remain undermanaged. Have you taken a critical look at the standard of care and how current treatment strategies have recently shifted? Groundbreaking research on the calcitonin gene-related peptide (CGRP) pathway has led to the development of new medications that act on the specific cascade of inflammatory response associated with migraine. Also called gepants, the CGRP receptor antagonists confer clinical benefit to patients who seek better control of their migraines.
Tune in to this Women’s Health 2021 program to hear our experts, Drs. Peter Goadsby and Kathleen Mullin, discuss the diagnosis of migraine with a focus on the recent evolution of acute and preventive treatment strategies and the role of gepants. Are you doing all you can to ensure that your patients’ needs are optimally addressed?
CME credits: 1.00
Valid until: 29-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinical-playbook-team-based-integration-adcs-metastatic-nsclc/12841/
One area of recent progress in the treatment of non–small cell lung cancer (NSCLC) is the development of HER2 targeted therapies for the rare, emerging genetic variant, ERBB2 (HER2) mutations. In fact, the NCCN lists ERBB2 (HER2) mutations as an emerging biomarker to identify novel therapies for patients with metastatic NSCLC. The HER2-directed antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki are now listed as available targeted agents with activity against HER2 mutations. ADCs with other targets such as Trop-2 and HER3 are now also under investigation and showing promise in NSCLC. ADCs have the potential to increase treatment choices for patients with mNSCLC.
For practicing clinicians, this evolution of HER2-directed therapy and ADCs will add to the complexity of NSCLC treatment. This activity will review the emerging role and potential application of ADCs in mNSCLC, including HER2 as a target in NSCLC, biomarker testing, HER2-, HER3-, and TROP2-targeted ADCs, available clinical data on safety and efficacy, evidence-based guideline recommendations, and how newer targeted agents may fit into the treatment paradigm for patients with mNSCLC.
CME credits: 0.75
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/individualizing-management-of-endometriosis-pain-current-evidence-potential-new-strategies-and-ongoing-research/13096/
How confident are you in determining which of your patients with endometriosis are suitable candidates for medical intervention? Do you ask about each patient’s goals and preferences? Have you heard about the paradigm shift occurring in the medical management of endometriosis?
While medical management of endometriosis is often a secondary consideration to surgery, it should often be the first line of treatment. Join Dr. Anita Nelson as she discusses long-standing and novel medical strategies for managing endometriosis. Find out how you can use shared decision-making strategies to help you provide more options to your patients. Join us and take an important first step that can improve outcomes and quality of life for your patients while enabling them to make educated decisions about their immediate and long-term treatment.
CME credits: 0.50
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-postpartum-depression-what-you-need-to-know/13085/
Listen in as Dr. Anita Clayton takes us through the importance of screening for postpartum depression (PPD) and reaching an early diagnosis in the perinatal and postnatal stages of pregnancy. This Women’s Health 2021 lecture also covers the exciting new agents that are targeted specifically for PPD. Find out how they compare to the traditional antidepressants and how they can improve the quality of life for your patients with PPD.
CME credits: 0.75
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-medical-management-of-uterine-fibroids-achieving-patient-centered-goals-and-outcomes/13078/
In this Women’s Health 2021 lecture, Dr. Anita Nelson discusses why uterine fibroids are such a high priority for both women and their clinicians. Listen in as she shares strategies to engage patients in discussions about their fibroid symptoms and their preferences for treatment. Dr. Nelson also evaluates the latest evidence on the mechanisms of action, safety, and efficacy of the newer class of therapies that are now available and can improve the quality of life for women with fibroids.
CME credits: 0.25
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-how-would-you-treat-case-based-learning-in-egfr-mutant-nsclc/13067/
FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!
CME credits: 0.25
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/perspectives-on-new-directions-in-the-management-of-postpartum-depression/13059/
In this panel discussion, Drs. Anita Clayton, Jennifer Payne, and Nancy Byatt walk us through two clinical cases of postpartum depression. Listen in as they discuss optimal strategies to screen, diagnosis, and treat patients, as well as go over the newer class of medications specifically targeted at treating PPD.
CME credits: 0.25
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/factors-that-delay-diagnosis-of-uterine-fibroids-and-endometriosis-the-demographic-divide/13036/
Hear from Dr. Erica Marsh and Dr. Lee Shulman as they discuss the burden, prevalence, and treatment of uterine fibroids and endometriosis and the disproportionate impact these conditions have on vulnerable populations. Learn how to prioritize early diagnosis and treatment to improve outcomes for your patients; as well as evaluating barriers to proper diagnosis and treatment
Our experts offer strategies to guide discussions beyond surgical treatment approaches to include pharmacotherapeutic options such as GnRH agonists and new oral GnRH antagonists. Open communication with patients allows them to carefully consider symptom severity, risks, and fertility preferences to optimize treatment outcomes and patient satisfaction. Tune in to make sure that you’re really doing all you can for your patients.
CME credits: 0.25
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-all-about-antiangiogenics-and-tkis-current-roles-and-future-directions-in-egfr-mutant-nsclc/13019/
In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.
CME credits: 0.50
Valid until: 23-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/best-practices-use-long-acting-injectables-bipolar-disorder-part-1/12971/
This Expert Exchange webcast is designed to help clinicians determine the appropriate time to initiate LAI therapy in patients with bipolar disorder, and how to discuss that treatment decision with patients.
CME credits: 0.25
Valid until: 23-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/applying-key-updates-esc-hfa-managing-heart-failure/13026/
Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.
In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.
CME credits: 0.50
Valid until: 23-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/best-practices-use-long-acting-injectables-bipolar-disorder-part-2/12982/
This patient-provider role play webcast is designed to provide clinicians with effective communication strategies for discussing long-acting injectable antipsychotics with patients in a variety of scenarios.
CME credits: 1.00
Valid until: 21-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-selection-and-side-effect-management-braf-mutant-melanoma/13042/
Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials.
In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.
CME credits: 0.25
Valid until: 17-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/managing-hk-in-hf-navigating-the-evolving-clinical-landscape/13029/
There is a substantial gap between the guideline recommendations for treatment and the real-world prescribing patterns of RAASi therapy. This disconnect results in worse cardiorenal outcomes and higher mortality in patients receiving suboptimal dosing. This is particularly true in patients with CKD who develop hyperkalemia, which constitutes the major barrier to optimal therapy.
In this activity, Drs. Ferdinand and Metra discuss how best to manage comorbidities, optimize RAASi therapy, and improve the long-term care for our patients with heart failure.
CME credits: 0.50
Valid until: 17-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/tryptase-testing-in-chronic-mast-cell-disorders-and-acute-settings/13017/
Are you familiar with the role of serum tryptase testing in diagnosing idiopathic anaphylaxis and mastocytosis? What role does serum tryptase play in the ongoing management of patients who have anaphylactic reactions to insect venom, and are there different considerations when a patient has a known trigger? Expert faculty Dr. Phil Lieberman shares his insights on serum tryptase testing in clinical practice and its importance in assessing mast cell disorders and anaphylaxis. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.
Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and anaphylaxis. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. To help physicians provide optimal evaluation and management, it is essential that they be knowledgeable regarding the appropriate use of tryptase testing in these clinical settings. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ …
CME credits: 1.00
Valid until: 09-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/where-are-new-targets-severe-asthma-looking-upstream-inflammatory-cascade/12973/
In this session, National Jewish Health faculty experts will discuss a new paradigm of severe asthma pathophysiology and potential treatment targets that may impact patients with non-allergic and non-eosinophilic as well as eosinophilic severe asthma. This session will explore new understanding of the immunology of severe asthma, new potential targets for treatment, and emerging data on novel therapies that may improve outcomes for your patients with severe asthma.
CME credits: 1.00
Valid until: 08-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/patient-case-studies-on-the-emerging-treatment-strategies-for-the-management-of-chronic-cough/12948/
The diagnosis and management of chronic cough can be challenging. Only an estimated 50% of patients with chronic cough are accurately diagnosed. Recent advances in the understanding and management of refractory chronic cough, have led to the development of novel therapies and ongoing clinical studies. In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough; and finally, summarize the current guidelines and emerging treatment strategies for the management of patients with chronic cough.
CME credits: 1.00
Valid until: 02-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/evolving-management-strategies-braf-mutant-metastatic-colorectal-cancer/13015/
Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC.
This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.
CME credits: 0.25
Valid until: 29-10-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-gu-cancers-clinical-considerations-prostate-cancer-global-perspectives/12993/
Prostate cancer is the second most common cancer in incidence and the fifth most frequent cause of cancer-related mortality in men worldwide. With the broader availability of PSA screenings, the incidence of disease is only rising.
This lively discussion focused on prostate cancer is designed to help you keep pace in GU cancers. You will enhance your knowledge and skills related to targeted therapy in patients with metastatic castrate-resistant prostate cancer, discover relevant biomarkers in prostate cancer, follow a patient case example, and hear about the latest clinical trial data presented at ASCO and ESMO 2021.
The prostate cancer landscape is rapidly evolving, so tune in to find out what changes you can make in your daily practice today.
CME credits: 0.25
Valid until: 29-10-2022
Claim your CME credit at https://reachmd.com/programs/cme/osteoporosis-pivotal-role-orthopedic-surgeons-can-play-optimizing-bone-health-their-postmenopausal-post-fracture-patients/12949/
While there’s growing awareness among orthopedic surgeons that osteoporosis is the underlying cause of fractures, there is often a disconnect between this recognition and action in the form of treatment to prevent subsequent fractures. In this discussion, Drs. Andrea Singer, Paul Anderson, and Susan Bukata address the pathophysiology of osteoporosis and the need to identify patients at risk for additional fractures. Osteoporosis treatment (including pharmacotherapy) can play a critical role in preventing future fractures, but physicians must first recognize that fracture is a sentinel event and treat it as a call to action.
CME credits: 0.50
Valid until: 27-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/tryptase-testing-clinical-utility-and-application-during-covid-19-vaccination-reactions/12955/
What is the risk of anaphylaxis following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19)? Are you familiar with the role of serum tryptase testing in patients with a suspected anaphylactic reaction? Expert faculty, Dr. Cem Akin, discusses serum tryptase testing and its importance in assessing anaphylaxis in response to COVID-19 vaccination. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.
Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and SARS-CoV-2 vaccination. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ appropriate use of tryptase testing across acute and follow-up care settings.
CME credits: 0.25
Valid until: 27-10-2022
Claim your CME credit at https://reachmd.com/programs/cme/making-case-iron-replacement-therapy-hfref-clinical-and-pharmacoeconomic-impact/12990/
Assessing iron deficiency is a crucial aspect of heart failure (HF) that warrants close clinical consideration, especially because it remains underdiagnosed and undertreated.
In this expert panel discussion, we examine data from AFFIRM-HF supporting the importance of correcting iron deficiency in patients with HF. Find out how treating iron deficiency can change the natural history of heart disease, lead to cost savings, and improve patients’ lives.
CME credits: 0.50
Valid until: 22-10-2022
Claim your CME credit at https://reachmd.com/programs/cme/real-world-cases-the-itch-clinic-treatment-of-chronic-kidney-disease-associated-pruritus-in-hemodialysis-patients/12945/
At least 25% of patients with chronic kidney disease (CKD), and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This case-based program will apply the foundational information presented in the first program of this 2-part series to real-world patients.
CME credits: 1.00
Valid until: 15-10-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinicians-update-omega-3s-ascvd-risk-reduction/12991/
Join Drs. Chilton and Nelson as they discuss recent omega-3 fatty acid (OM-3) outcomes trial results and how to apply those results along with evidence-based guidelines to reduce ASCVD risk. Tune in to hear about the use of OM-3s including dietary supplement OM-3s that are readily available in pharmacies and online, so you can keep your patients informed!
CME credits: 0.25
Valid until: 15-10-2022
Claim your CME credit at https://reachmd.com/programs/cme/guidelines-practice-key-updates-2021-hfsa/12927/
Rapid initiation and up-titration of guideline-directed medical therapy (GDMT) is critical to achieve optimal patient outcomes in heart failure. This is particularly important in patients with multiple comorbidities and in pivotal situations to avoid stopping or lowering the dose of any of the four critical medicines that these patients must receive.
Drs. Javed Butler, Ileana Piña, and Giuseppe Rosano will recap the data and the views that were presented at a symposium held in conjunction with the Heart Failure Society of America’s 2021 annual scientific meeting.
CME credits: 0.25
Valid until: 30-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/hot-topics-in-hcv-a-multidisciplinary-online-minicurriculum-activity-3-anticipating-the-impact-of-the-covid-19-pandemic-on-vulnerable-populations/12749/
The COVID-19 pandemic has taken a disproportional toll on already vulnerable persons, yet substance use, psychosocial comorbidities, and preexisting disparities in access to care may translate to an even greater adverse impact among persons with chronic HCV. This educational activity offers up-to-date information on the impact of COVID-19 on the normal and HCV-infected liver, practical strategies for optimizing telehealth-delivered HCV care, and other recommendations for engaging vulnerable populations in HCV care during times of reduced service capacity.
CME credits: 0.25
Valid until: 30-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/hot-topics-in-hcv-a-multidisciplinary-online-minicurriculum-activity-2-the-dual-realities-of-the-opioid-epidemic-and-rising-maternal-hcv-rates-what-the-obgyn-needs-to-know/12748/
With alarming increases in the incidence of maternal HCV, your obstetrics and gynecology (OB/GYN) practice plays a critical role in screening of all pregnant patients and engaging HCV-infected women who otherwise may not seek medical care. This educational activity will provide practical tactics for implementing Centers for Disease Control and Prevention (CDC) screening guidelines at the practice level, insights for destigmatizing behavioral risk inquiries and harm-reduction discussions, current recommendations for postpartum HCV treatment, and evolving perspectives on HCV treatment during pregnancy.
CME credits: 0.25
Valid until: 30-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/narcolepsy-awakening-new-day-its-management/12838/
Excessive sleepiness is a common, highly impactful problem not commonly reported and frequently misdiagnosed by physicians. While prevalence reports of narcolepsy vary, patients often do not seek medical advice for their symptoms or, if they do, they receive inaccurate diagnoses. Because of this, it’s possible that more than 1 in 2000 people are living with narcolepsy. It may even take 10 to 15 years to be diagnosed, during which time these patients are impaired. What signs and symptoms are both clinicians and patients missing?
Tune in to hear a patient, Julie Flygare, JD, recount her bizarre symptoms and receive clinical tips on how to improve your identification of overlooked sleep disorders and narcolepsy. Drs. Zee, Doghramji, and Kuritzky provide their clinical insight and expertise on this serious medical condition that continues to be grossly misdiagnosed, underdiagnosed, and undermanaged. By improving your ability to detect, accurately diagnose, and appropriately manage narcolepsy, you can improve the quality of life and health outcomes for your patients. Find out what subtle signs and red flags you need to be on the lookout for and what exciting therapies are now available for these patients.
CME credits: 0.50
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/expanding-contraceptive-choices-for-women-the-vaginal-ph-modulator/13055/
Many women prefer to use a nonhormonal contraceptive. They also want the freedom to self-administer on demand and want assurances that the contraceptive is safe, effective, and has received FDA approval. One such contraceptive is a self-administered, hormone-free gel that functions as a vaginal pH modulator. Join Dr. David Eisenberg as he describes the evolution of this vaginal pH modulator and the clinical trials leading to FDA approval. Even more significant is patient acceptance, which was remarkably high for this contraceptive. In fact, approximately 9 out of 10 women participating in the clinical trials indicated they would continue using the vaginal pH modulator and also recommend this novel method to their friends.
CME credits: 0.75
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/a-closer-look-at-women-atherosclerosis-and-lipids-what-is-different/13077/
Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.
CME credits: 0.50
Valid until: 02-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/managing-vulvovaginal-candidiasisriding-wave-therapeutic-change/13040/
The global burden of acute vulvovaginal candidiasis (VVC) and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved solutions and quality of care for affected women. Join Dr. Paul Nyirjesy as he dissects the barriers to managing VVC and RVVC in your clinical practice and provides both diagnostic and therapeutic guidance inclusive of newly emerging and novel agents. These agents have unique qualities that may well represent a significant step forward in how you manage this challenging infection.
CME credits: 0.25
Valid until: 20-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/evolving-pharmacologic-intervention-for-methamphetamine-use-disorder-a-focus-on-adapt-2/12907/
Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the ADAPT-2 clinical trial supporting the combination of extended release naltrexone and high dose bupropion to reduce methamphetamine use for patients with moderate to severe methamphetamine addiction. These important data from ADAPT-2 offer a significant therapeutic advance for methamphetamine use disorder that can be taken into the clinic.
CME credits: 0.50
Valid until: 30-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/shining-a-new-light-on-the-contraceptive-patch/13075/
Our patients express a number of misperceptions about combined hormonal non-LARC contraceptives such as the contraceptive patch, vaginal rings, and oral contraceptive pills. How well do you explain the advantages and disadvantages of these different options to your patients? How often have you prescribed what appeared to be a good contraceptive method for your patients only to have them be dissatisfied and become nonadherent?
Join Dr. Brooke Faught in this Women’s Health 2021 lecture as she tackles these issues and offers insights into how to discuss the full range of combined hormonal non-LARC contraceptive options with your patients using shared decision-making strategies. Remember, each patient’s needs, goals, and cultural background are important factors in a patient-centric approach to the choice of contraception.
CME credits: 0.75
Valid until: 29-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/itch-clinic-treatment-chronic-kidney-disease-associated-pruritus-hemodialysis-patients/12840/
At least 25% of patients with chronic kidney disease (CKD) and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life, and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This first program will review the epidemiology, consequences, evaluation, pathophysiology and available and emerging treatments for CKD-aP; a second case-based program will apply the information to real-world patients.
CME credits: 1.50
Valid until: 28-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/demystifying-continued-pharmacologic-therapy-hfref-pivotal-opportunities-improve-patient-outcomes/12902/
Recent guideline updates and publications are leading to changes in care in patients with heart failure with reduced ejection fraction (HFrEF). What clinical evidence is driving recent changes to guideline directed medical therapy (GDMT) in HFrEF, and what real-world data exists that may impact the landscape of care and patient outcomes?
CME credits: 0.25
Valid until: 22-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/a-new-normal-covid-19-and-hf-in-clinical-trials/12776/
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.
CME credits: 0.25
Valid until: 20-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/hot-topics-in-hcv-a-multidisciplinary-online-minicurriculum-activity-1-treating-hepatitis-c-in-primary-care-you-can-you-should/12747/
Armed with Centers for Disease Control and Prevention (CDC) guidelines for HCV universal screening and risk-based testing — and an understanding of the simplicity of prescribing and managing direct-acting antiviral (DAA) therapies — primary care providers (PCPs) will be well equipped to step up and provide comprehensive HCV care and cure. This educational activity offers practical tips and tactics to prepare PCPs for their central role in eliminating HCV.
CME credits: 0.50
Valid until: 17-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/rcc-treatment-strategies-in-a-favorable-risk-patient/12798/
Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
CME credits: 0.25
Valid until: 31-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/figaro-dkd-and-fidelity-analysis-key-takeaways/12827/
Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!
CME credits: 0.50
Claim your CME credit at https://reachmd.com/programs/cme/a-novel-therapeutic-approach-in-myeloid-malignancies-targeting-the-neddylation-pathway/11694/
Please note: This activity is no longer available for continuing education credit.
There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and developing strategies based on the evolving implications of this research will allow for greater understanding of their potential impact on management and health outcomes of patients with MDS, CMML, and AML.
CME credits: 0.25
Valid until: 31-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinical-guide-role-iron-hf-pathophysiology/12796/
Iron deficiency is an extremely common comorbidity for 50% to 70% of our patients with heart failure in both the acute and chronic settings. It’s associated with poor exercise capacity, poor quality of life, and increased morbidity and mortality. In hospitalized patients with acute heart failure, iron deficiency is often present independent of anemia.
With that in mind, join Drs. Robert Mentz and Peter van der Meer as they discuss the impact of iron deficiency on patients with heart failure. Find out why it’s time to shift our perception of iron deficiency from a marker of disease outcome to a treatment target.
CME credits: 0.50
Valid until: 30-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-4-emerging-therapies/12680/
This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.
CME credits: 0.50
Valid until: 30-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/state-union-advances-management-muc/12764/
Bladder cancer is the sixth most common malignancy in the United States. Many of these patients present with multiple comorbidities which creates a considerable challenge for clinicians when determining an appropriate treatment plan. Until recently, platinum-based chemotherapy was the only viable systemic therapy option for patients with locally advanced or metastatic urothelial cancer (mUC); however, the majority of these patients eventually relapse and need subsequent lines of therapy. Patients are then left with limited treatment options and often poor outcomes, contributing to a largely unmet need that prompted investigation into new and promising therapeutic options.
This chapterized activity is designed to update clinicians who treat locally advanced or metastatic urothelial cancer on new clinical trials and the treatment guidelines that align with the identified unmet need of subsequent treatment options for this patient population. Drs. Arjun Balar and Daniel Petrylak focus on enhancing the knowledge and skills of clinicians through case-based content to demonstrate individualized patient treatment plans and enable participants to further incorporate changes into their clinical practice. Join us to find out why the future is bright for our patients with mUC.
CME credits: 0.25
Valid until: 27-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/counseling-your-patients-at-risk-of-hdfn/12763/
OB-GYN clinicians can improve how they communicate with their patients about hemolytic disease of the fetus and newborn or HDFN. Strategies include encouraging patients to talk about their feelings when learning about this condition and communicating with them in terms that are not overly complex. In this program, Drs. Lee Shulman and Michelle Owens discuss how to break things down for the patient in front of you and explain how to use a read-back approach. This tactic ensures that your patient has absorbed what was discussed and also allows you to identify gaps in her understanding that can be addressed with further counseling.
CME credits: 0.50
Valid until: 27-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/rcc-treatment-strategies-in-a-poor-risk-patient/12797/
Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
CME credits: 0.25
Valid until: 26-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/elevated-creatinine-and-aki-are-not-synonymous-optimal-raasi-therapy-always-goal/12773/
When treating patients with heart failure and chronic kidney disease, RAASi therapy should be continued if at all possible. One thing to keep in mind is that an elevation in serum creatinine does not always represent acute kidney injury. In this activity, Drs. George Bakris, Biykem Bozkurt, and Robert Toto examine a case study and discuss transient changes in serum creatinine with hyperkalemia. Join us to find out how and why you should avoid RAAS blockade interruption in these patients.
CME credits: 0.25
Valid until: 26-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-raasi-therapy-patients-hyperkalemia-role-potassium-binders/12767/
It is well understood that RAASi therapy is critical in the management of patients with heart failure. However, hyperkalemia is common in these patients, and its presence often leads to suboptimal RAASi dosing, which in turn results in poorer patient outcomes. Join Drs. Javed Butler and Giuseppe Rosano as they look at a case presentation and discuss the hows and whys of optimal RAASi dosing in patients with heart failure and recurrent hyperkalemia.
CME credits: 1.00
Valid until: 24-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/practicing-precision-alk-and-ros1-rearrangement-positive-nsclc-testing-targets-and-treatments/12757/
Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.
The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated.
This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.
CME credits: 1.00
Valid until: 24-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/recognizing-and-treating-alpha-1-antitrypsin-deficiency-aatd/12765/
Alpha-1 antitrypsin deficiency (AATD) is a common yet underdiagnosed genetic disorder. Led by 2 AATD experts, this activity will address the most current information on the screening, diagnosis, and treatment of this potentially fatal disorder. AATD primarily affects the lungs and liver and requires a multidisciplinary care approach. Faculty will review patients who are at risk for AATD, its clinical manifestations (including similarities with COPD), and possible consequences to the lung and liver. Current treatment involves augmentation therapy with IV administration of AAT; there are ongoing investigations into other potential treatments. Patient cases will help clinicians apply the foundational information to clinical practice.
CME credits: 0.50
Valid until: 15-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-3-management/12679/
This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.
CME credits: 1.00
Valid until: 07-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/emerging-treatment-strategies-management-patients-chronic-cough/12741/
The diagnosis and management of chronic cough can be challenging. In fact, only an estimated 50 percent of patients with chronic cough are accurately diagnosed. Recent advances in the understanding and management of refractory chronic cough have led to the development of novel therapies and ongoing clinical studies. In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough and summarize the current guidelines and emerging treatment strategies for the management of patients with chronic cough.
CME credits: 0.50
Valid until: 04-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12678/
This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.
CME credits: 0.50
Valid until: 04-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12677/
This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.
CME credits: 0.50
Valid until: 30-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/horizon-achieving-durable-vegf-suppression-namd-and-dme/12662/
One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use?
Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice.
CME credits: 0.25
Valid until: 30-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/future-narcolepsy-therapy-its-likely-impact-disease-burden-and-patient-outcomes/12743/
While gaps in care remain, the future is bright for patients with narcolepsy. Data from cutting-edge clinical trials were recently presented at 2021 Virtual Sleep, the 35th Annual Meeting of the Associated Professional Sleep Societies, and Drs. Clete Kushida and Michael Thorpy are ready to break it down for you. Join them as they examine the main barriers to timely diagnosis and treatment and then dive into the latest research on currently available and emerging pharmacologic therapies. Tune in to stay up to date on the latest progress and research on the management of patients with narcolepsy.
CME credits: 0.25
Valid until: 30-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/act-fast-case-study-postexposure-influenza-prophylaxis/12734/
Post-exposure influenza prophylaxis should be a top-of-mind discussion with patients receiving an influenza diagnosis. Unfortunately, it remains an underused means to reduce secondary infections in at-risk households. Join Drs. Cassandra Donnelly and Charles Vega as they examine an extended patient case and offer practical strategies to overcome common clinical barriers surrounding post-exposure influenza prophylaxis, including how to match the right patient with the right antiviral treatment.
CME credits: 0.25
Valid until: 30-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/updates-head-and-neck-cancer-treatment-integrating-checkpoint-inhibitor-therapy-improve-outcomes/12701/
Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.
CME credits: 0.25
Valid until: 30-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/horizon-strategies-surgical-success-durable-anti-vegf-delivery-namd-and-dme/12660/
The quest for durable VEGF-suppression in neovascular AMD and diabetic macular edema has led to significant advances in the operating room for surgical retina specialists. What are these new methods, and what do surgeons need to know to ensure a successful procedure? Listen to pro tips from Drs. Carl Awh and Peter Campochiaro and see demonstrations of the new techniques. How will your patients benefit from the introduction of durable VEGF suppression into clinical practice?
CME credits: 0.25
Valid until: 28-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/hdfnnew-understandings-risk-diagnosis-and-therapeutic-approaches/12710/
Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical.
Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.
CME credits: 1.00
Valid until: 26-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/advanced-practice-perspectives-cdk-46-inhibitors-paving-way-hr-her2-negative-early-breast-cancer/12698/
Endocrine therapy is currently the cornerstone of treatment for advanced hormone receptor–positive (HR+) breast cancer in both pre- and postmenopausal patients. However, not all advanced HR+ breast cancers respond to first-line endocrine therapy, and those that do respond eventually relapse. Agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, have been approved by the US Food & Drug Administration (FDA) for the treatment of HR+/human epidermal growth factor receptor 2–negative (HER2−) advanced/metastatic breast cancer. Now, CDK 4/6 inhibitors are being investigated for the treatment of early stage HR+, HER2- breast cancer.
This web-based, on-demand, activity will feature interprofessional perspectives and expert insights on the latest emerging evidence for CDK 4/6 inhibitors in the adjuvant setting for early breast cancer. The faculty panel will also provide their perspectives and best practice recommendations for improving adherence and side effect management. Case-based discussion will provide practical approaches for integrating CDK 4/6 inhibitors into real-world clinical practice for the treatment of early stage HR+, HER2- breast cancer.
Since the date of this activity’s recording, an exciting and practice changing advancement has occurred with the Food and Drug Administration’s (FDA) recent approval of abemaciclib with endocrine …
CME credits: 1.25
Valid until: 27-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/abcs-ctd-pah-algorithms-team-based-approach-and-combination-therapy/12739/
John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series.
CME credits: 0.25
Valid until: 26-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinicians-update-omega-3s-ascvd-risk-reduction/12718/
More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!
CME credits: 0.50
Valid until: 16-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/evolving-landscape-chronic-lymphocytic-leukemia-selecting-and-managing-targeted-therapy/12643/
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy associated with different cytogenetic, immunophenotypic, and morphological profiles. This diversity has resulted in varying clinical courses and responses to therapy and underscores the importance of individualizing therapy. The availability of targeted therapies has dramatically transformed the CLL therapeutic landscape, providing options for personalized treatments within both the newly diagnosed and relapsed/refractory (R/R) settings.
In this educational activity, faculty members review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or R/R CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.
CME credits: 0.50
Valid until: 15-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-ldl-c-management-post-mi-patient/12664/
Cholesterol guidelines recommend nonstatin, LDL-C-lowering therapies in very high risk ASCVD patients if LDL-C goals are not achieved (ESC/EAS dyslipidemia guideline) or if LDL-C is above a specific threshold of 70 mg/dL (AHA/ACC cholesterol guideline). Unfortunately, a substantial number of patients with ASCVD do not achieve LDL-C targets, and nonstatin, LDL-C-lowering therapies are underutilized. Therefore, patients such as those who have experienced an acute coronary syndrome (ACS) remain at increased risk for another major cardiovascular event. Patients with a recent ACS are especially vulnerable to a recurrent cardiovascular event. Nonstatin, LDL-C-lowering therapy with PCSK9 inhibitors and ezetimibe has demonstrated reductions in cardiovascular risk after an ACS. PCSK9 inhibitors have demonstrated robust LDL-C lowering to very low LDL-C levels, with no increase in adverse safety events and with additional cardiovascular risk reduction. Analyses of cardiovascular outcome trial data with PCSK9 inhibition have indicated particularly potent cardiovascular risk reduction in patients with a recent ACS; utilizing PCSK9 inhibitors in these patients enables clinicians to greatly improve their patients’ clinical outcomes. Significant LDL-C reductions, rapid LDL-C goal attainment, and safety have been observed in very early (in-hospital) use of PCSK9 inhibitors. In this educational initiative, lipid expert Dr. Marc Sabatine will discuss guideline …
CME credits: 0.25
Valid until: 15-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/raasi-therapy-diabetes-and-hyperkalemia-halting-therapy-not-only-option/12714/
In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.
CME credits: 0.25
Valid until: 14-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/riding-wave-change-cervical-cancer-screening-managing-patients-light-risk-using-extended-genotyping/12697/
Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.
CME credits: 0.25
Valid until: 13-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/act-fast-understanding-flu-prevention-and-treatment-risk-populations/12717/
Antiviral agents are underutilized against influenza in clinical practice, a failure that places many patients, especially those with comorbidities, at high risk for influenza-associated complications. Join Drs. Cassandra Donnelly and Charles Vega as they explore management strategies for patients with symptomatic influenza, compare and contrast clinical applications for the available antiviral agents, and reflect upon the increasing use of these agents as post-exposure influenza prophylaxis.
CME credits: 0.50
Valid until: 09-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/changing-treatment-paradigms-in-type-1-diabetes-role-of-anti-cd3-targeted-therapy-screening-for-islet-autoantibodies-in-children-and-adolescents-to-preventdelay-t1d/12695/
Experts in the immunopathology of type 1 diabetes review data showing that clinical presentation is preceded by an asymptomatic phase, characterized by the presence of one or more islet autoantibodies. Screening children for islet autoantibodies during the two preclinical stages can identify those with multiple autoantibodies and high-risk antibody phenotypes who may be candidates for preventive interventions before developing dysglycemia or the clinical onset of type 1 diabetes.
CME credits: 0.25
Valid until: 07-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/how-adcs-are-transforming-her2-metastatic-breast-cancer-discover-the-latest-clinical-trend/12690/
While HER2+ breast cancers are traditionally associated with a poor prognosis, the development of HER2-directed treatment strategies has led to substantial and durable survival improvements, even in patients with metastatic disease. Nonetheless, a percentage of these patients will not respond to certain therapies, and many may become resistant within a year of treatment.
In this chapterized activity, Dr. Javier Cortes and Dr. Sara Hurvitz discuss optimal therapy selection based on individual patient characteristics as well as strategies to manage potential adverse events associated with current treatment options for HER2+ metastatic breast cancer.
CME credits: 0.25
Valid until: 30-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-on-new-therapy-combinations-for-hfref-raising-clinician-awareness/12691/
Is it possible to reduce the nearly 60% one-month rehospitalization rates in patients with worsening heart failure? Dr. Paul Armstrong and Dr. Justin Ezekowitz discuss new therapeutic combinations including soluble guanylate cyclase (sGC) stimulators, as well as the practical applications of new evidence that was presented at the 2021 annual ACC meeting that may change how physicians approach treating their patients with worsening heart failure. Don’t miss out on new information about how sGC stimulators may benefit your patients.
CME credits: 0.50
Valid until: 30-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/calibrating-covid-19-interplay-disease-modifying-therapy-and-vaccination-patients-multiple-sclerosis/12656/
The emergence of COVID-19 has created an unprecedented medical emergency that both raises new questions and presents updated information each day. This issue is even more pressing for patients with conditions such as multiple sclerosis (MS) who have altered immune systems from both chronic illness and disease modifying therapies (DMTs). While the advent of vaccines has revived hope for a return to normal life, vaccination is not always straightforward for those on or planning to start immunosuppressive therapies such as MS DMT. In this activity, Drs. Claire Riley and Robert Bermel discuss guidance outlined by the National Multiple Sclerosis Society (NMSS) and approaches to implementing these considerations in routine practice.
CME credits: 0.25
Valid until: 29-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/applying-clinical-trial-data-on-newer-chcs-into-real-world-patient-care/12689/
The effort to reduce the estrogen concentration in combination oral contraceptives (COCs) and strike the right balance between efficacy and safety appears to be never-ending. However, a recently FDA-approved estetrol/drospirenone COC formulation offers some unique properties not seen in current COC formulations. Join us as Dr. Jeffrey Jensen and Dr. Lee Shulman discuss if this estetrol/drospirenone COC formulation will allow physicians to better address these efficacy and safety issues.
CME credits: 0.75
Valid until: 27-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12675/
This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).
CME credits: 0.25
Valid until: 16-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/meeting-future-global-challenges-case-based-presentations-management-nsclc/12600/
For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC.
CME credits: 0.25
Valid until: 16-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/potassium-binders-facilitate-continued-raasi-therapy-helpful-tips-for-clinicians/12567/
There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fraction. RAASi therapy improves both morbidity and mortality outcomes, and its use is now recommended in published guidelines. However, the achievement of target dosing is often limited or interrupted due to the development of hyperkalemia.
In this case-based activity, Drs. Javed Butler and Ileana Piña discuss the importance of optimizing RAASi therapy in patients with heart failure and how the use of potassium binders can help accomplish this goal. They will also review the risks and benefits of potassium binders, in addition to both short- and long-term use of these agents in the treatment of patients with heart failure.
CME credits: 0.25
Valid until: 14-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/applying-data-patient-care-case-review-follicular-lymphoma/12661/
Recent clinical trial evidence supports the use of available and emerging options in relapsing/refractory follicular lymphoma. In this case-based activity, Dr. Loretta Nastoupil and Dr. John Leonard discuss the importance of testing for EZH2 mutations in follicular lymphoma, choosing the appropriate treatment option for each patient, and how to minimize risk to improve patient outcomes.
CME credits: 0.50
Valid until: 13-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/improving-quality-care-patients-harboring-alk-nsclc/12631/
The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.)
Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on …
CME credits: 0.25
Valid until: 11-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/contraception-focus-vaginal-ph-modulation/12608/
A new form of contraception based on vaginal pH modulation is available. In this activity, Dr. Eisenberg reviews the risks and benefits of the hormone-free, user-controlled gel, and Dr. Portman provides his perspective on clinical trial results within the context of the “creeping Pearl Index.”
CME credits: 0.50
Valid until: 30-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-familial-hypercholesterolemia-diagnosis-treatment-and-management/12554/
According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly diagnosed due to gaps in screening, recognition and classification of FH. If not identified and aggressively treated from an early age, individuals with FH have a 20-fold increased life time risk of heart disease compared to the general population. However, with optimal treatment, an affected individual’s lifetime risk of cardiovascular disease approaches the risk found in the general population. Although the clinical symptoms are not as pronounced in cases of heterozygous FH, both homozygous (HoFH) and heterozygous FH (HeFH) patients still have an elevated risk of developing coronary heart disease at some point in their life. Early diagnosis and treatment for both HoFH and HeFH can significantly reduce the risk of coronary heart disease or delay its onset. Both homozygous and heterozygous FH are serious conditions that require special attention and treatment.
CME credits: 0.25
Valid until: 04-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/critical-review-data-follicular-lymphoma/12625/
Follicular lymphoma (FL) is an incurable neoplasm that is frequently associated with relapse and refractory (R/R) disease. In this activity, Drs. Loretta Nastoupil and Gilles Salles will review the role of EZH2 modulation in FL and explain the role that EZH2 inhibition can play in R/R disease. They will also discuss the many available oral therapeutic options and emerging therapies on the horizon, recent data from those clinical trials, and where these therapies will fit into clinical practice.
CME credits: 0.50
Valid until: 31-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/changing-treatment-paradigms-type-1-diabetes-role-anti-cd3-targeted-therapy-anti-cd3-monoclonal-antibodies-preventdelay-onset-type-1-diabetes/12599/
Experts in the immunopathology of type 1 diabetes consider the potential role of monoclonal antibodies, disease modifying agents, and other agents to prevent or delay the onset of clinical disease. Particular emphasis will be placed on the CD3 cell surface marker and anti-CD3 monoclonal antibodies, which has been shown to slow progression to clinical type 1 diabetes in high risk persons.
CME credits: 0.25
Valid until: 28-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/understanding-differences-between-strength-and-reduce-it-omega-3-fatty-acid-clinical-trials-and-epadha/12618/
In 2019, the REDUCE-IT trial studying eicosapentaenoic acid (EPA), a purified form of omega-3 fatty acid, was published and demonstrated a dramatic 25% reduction in major cardiovascular events. In 2020, the STRENGTH trial that used a carboxylic acid formulation of combined EPA and docosahexaenoic acid (DHA), was surprisingly neutral and the study was halted for futility. A recent post hoc analysis of the STRENGTH study failed to show a difference in the primary endpoint in the highest tertile group receiving the EPA/DHA carboxylic acid treatment. Why did these two major omega-3 clinical trials studying patients with elevated triglyceride levels have disparate results? What does this mean for our patients? Join two experts, Drs. Michael Miller and Brian Olshansky, as they assess the different trials and offer their perspective on the clinical and scientific implications of the results.
CME credits: 0.25
Valid until: 27-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/uterine-fibroids-focus-on-medical-management/12569/
In this activity, Dr. Linda Bradley reviews risk factors for uterine fibroids, the use of TVS,
CME credits: 0.25
Valid until: 26-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/understanding-emerging-options-managing-vasomotor-symptoms/12565/
In this activity, Dr. Nanette F. Santoro explains risk factors for vasomotor symptoms, reviews current medical options for this bothersome problem, and describes the mechanism of action of a new class of nonhormonal agents: selective neurokinin-3 receptor antagonists.
CME credits: 0.50
Valid until: 26-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/should-epa-be-another-e-abcs-cvd-risk-prevention-straight-talk-experts/12348/
This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join Drs. Erin D. Michos, James A. Underberg, and Nathan D. Wong for a deep dive into these hot topics: new pathways to manage high risk in ASCVD, differential biological effects of omega-3 fatty acids, and practical considerations to manage ASCVD risk.
CME credits: 0.25
Valid until: 21-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-durable-suppression-addressing-health-disparities/12568/
Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.
CME credits: 0.25
Valid until: 20-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/therapy-gaps-identifying-new-targets-management-nsclc/12515/
Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small cell lung cancer (NSCLC), MET exon 14 skipping alterations are a primary oncogenic driver in approximately 3% to 4% of these patients, often with a poor outcome. Join us as Dr. Paul Paik and Dr. Viola Zhu discuss the importance of testing patients for MET gene aberrations and their relevance in the management of NSCLC, especially as related to recently approved and emerging therapies for patients harboring a MET gene aberration.
CME credits: 0.25
Valid until: 19-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-addressing-health-disparities-and-other-barriers-optimal-outcomes/12526/
Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.
CME credits: 0.25
Valid until: 19-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/creating-personalized-care-relapsedrefractory-follicular-lymphoma/12578/
The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease setting has shown efficacy. In this activity, Drs. Matasar and Nastoupil discuss the role of EZH2 in the pathobiology of FL, emphasize the need to test for mutations in EZH2 in FL, and explore the potential of targeting EZH2 in different settings of FL treatment.
CME credits: 0.25
Valid until: 17-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-and-patient-selection-braf-v600e-mutated-metastatic-colorectal-cancer/12437/
BRAF mCRC is a very aggressive subset of colon cancer and, until recently, treatment options have been very limited. With a new standard of care on the rise, a critical challenge remains: How will emerging regimens be utilized in daily clinical practice?
Join us as 2 experts, Dr. Scott Kopetz and Dr. Julien Taieb, examine strategies to enhance the personalized management of patients with BRAF V600E-mutated mCRC.
CME credits: 0.50
Valid until: 14-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-patient-outcomes-in-acromegaly/12456/
Acromegaly is a rare disorder caused by excess growth hormone production and is associated with increased morbidity and mortality. Delays in the diagnosis and initiation of therapy or the provision of suboptimal therapy often negatively impact the quality of life of these patients. Join us for this expert interview with Dr. Susan Samson and Dr. Kevin Yuen who offer insights to help you overcome the complex medical challenges often faced when managing patients with acromegaly, including strategies to apply the latest guidelines and the 2020 consensus statement into clinical practice.
CME credits: 0.25
Valid until: 13-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/advanced-her2-positive-gastric-cancer/12507/
Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers for clinicians to manage. One of the many challenges to optimizing patient outcomes is a relative lack of familiarity with practice standards regarding HER2-positive disease. While HER2 is an oncogenic driver in gastroesophageal cancers, it does not appear to act as a predictive biomarker in quite the same way as it does in breast cancer. However, there are ways to fully optimize anti-HER2 therapy in gastroesophageal cancers. Join us as Dr. Daniel Catenacci and Dr. Yelena Janjigian demystify HER2-positive gastroesophageal cancers and provide insights for the integration of personalized therapeutic approaches for these patients.
CME credits: 0.75
Valid until: 10-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-abreast-development-vaccines-prevent-covid-19-what-clinicians-need-know/12629/
With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of SARS-CoV-2 is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines close to approval. This podcast will provide clinicians a review of up-to-date safety and efficacy information on vaccine candidates in late-stage development, and steps to prioritize patients who would benefit most from vaccination once available.
CME credits: 1.00
Valid until: 09-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/change-story-preventing-missteps-invasive-fungal-infections/12501/
Have you ever wondered what went wrong in the management of invasive fungal infections? Through a storytelling approach Dr. James Lewis & Dr. George Thompson discuss a clinical story and identify where medical misses may have occurred. Supportive evidence will be provided on how care should have been provided and strategies for clinicians to apply in their practice.
CME credits: 0.25
Valid until: 30-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/updates-muscular-dystrophy-focus-lgmd/12478/
Dr. Colin Quinn and Dr. Matthew Wicklund discuss the genetic and pathophysiologic underpinnings of limb girdle muscular dystrophy, as well as the use of appropriate diagnostic tests for accurate identification of LGMD.
CME credits: 0.25
Valid until: 07-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-womens-cancer-clinical-considerations-endometrial-cancerglobal-perspectives/12500/
Therapeutic choices for many women with advanced endometrial cancer are being driven by our understanding of the mismatch repair (deficient/proficient) and microsatellite (instable/stable) status of their tumors. Join us as Dr. Richard Penson and Dr. Ana Oaknin discuss the global perspective surrounding the recent emergence of immunotherapy agents in the management of recurrent or metastatic endometrial cancer. Find out how to manage the toxicities of these newer therapies and discover just how critical a role molecular testing plays in selecting which patients receive a particular therapeutic strategy.
CME credits: 0.25
Valid until: 07-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/expert-insights-managing-patients-ckd-hyperkalemia-and-continued-raasi-therapy-through-case-study-approach/12523/
Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.
CME credits: 0.25
Valid until: 06-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-womens-cancer-targeting-advanced-endometrial-cancer/12479/
Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.
Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.
CME credits: 0.50
Valid until: 01-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/managing-chronic-hepatitis-b-integrating-eastern-philosophies-with-western-approaches/12495/
Experts in chronic hepatitis B within Asian communities discuss prevention, screening and management options to reduce the number of new cases and the risk of progression to cirrhosis, hepatic failure, and hepatocellular carcinoma. Experts also will consider the integration of Western and Eastern Medicine approaches to treatment and how cultural perceptions and community stigmatization of persons of Asian descent with chronic HBV infection can create barriers to diagnosis and care.
CME credits: 0.25
Valid until: 30-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/updates-muscular-dystrophy-focus-dmd/12458/
Dr. Crystal Proud and Dr. Edward Smith discuss the relationship of DMD genetics and pathophysiology and explain the importance of early diagnosis of Duchenne Muscular Dystrophy and the challenges associated with making this diagnosis.
CME credits: 0.50
Valid until: 30-04-2022
Claim your CME credit at https://reachmd.com/programs/cme/type-1-diabetes-the-role-of-anti-cd3-targeted-therapy/12503/
Experts in the immunopathology of type 1 diabetes discuss the epidemiology, non-genetic and genetic risk factors, and progression from preclinical to clinical stages of this disease. The discussion will emphasize the breakdown of immune tolerance that precedes type 1 diabetes and the subsequent pathogenetic role of islet autoantibodies responsible for its clinical manifestations.
CME credits: 0.50
Valid until: 30-04-2022
Claim your CME credit at https://reachmd.com/programs/cme/advances-angiostatic-treatment-retinal-disease-demystifying-novel-therapeutic-targets/12490/
Current challenges in the treatment of neovascular retinal disease include the tremendous burden of treatment and suboptimal response to treatment in many cases. Strides have been made recently toward therapies that deliver increased efficacy vs traditional first-line therapies, a decreased treatment burden, or both. To achieve these ends, next-generation treatment strategies target multiple angiogenic cellular pathways at once. In this activity, experts in retinal disease treatment use custom animations to discuss the mechanisms of action of various novel treatment strategies. The latest clinical trial data for faricimab and OPT-302, two molecules currently in phase 3 clinical trials for the treatment of retinal disease, are also presented.
CME credits: 0.75
Valid until: 28-04-2022
Claim your CME credit at https://reachmd.com/programs/cme/pulse-points-prostate-cancer-embracing-advances-parpi-combinations/12472/
During recent years, advances in the understanding of the underlying genetic events and biology in prostate cancer development, including the DDR and MMR pathway alterations, have yielded new avenues for clinical exploration. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair, such as mutations in BRCA1/2 and ATM, are associated with response to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition.
PARP inhibitors are now gaining FDA approvals for the treatment of patients with mCRPC, and ongoing clinical trials are evaluating these PARP inhibitors as monotherapy or in combination with other treatments such as androgen pathway inhibitors. The National Comprehensive Cancer Network (NCCN®) is now recommending germline testing and molecular biomarker analysis, including tumor testing for HRR mutations, and to consider tumor testing for MSI or dMMR for metastatic disease. PARP inhibitors for the treatment of mCRPC in patients harboring germline and somatic BRCA/ATM mutations, and in combination with androgen pathway inhibition, are poised to propel the management of mCRPC toward a more personalized approach.
In this activity, expert faculty will review, discuss, and provide their expert insights on recent and emerging practice-changing advancements with PARP inhibitors for the treatment of mCRPC, with a …
CME credits: 0.25
Valid until: 23-04-2022
Claim your CME credit at https://reachmd.com/programs/cme/liquid-and-tissue-biopsy-treatment-nsclc-focus-met-gene-aberrations/12465/
Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.
CME credits: 0.75
Valid until: 15-04-2022
Claim your CME credit at https://reachmd.com/programs/cme/fight-covid-19-neutralizing-mabs/12403/
As of February 2022, information originally presented in the original broadcast has been updated. Due to the rise of the omicron variant, two combination therapies no longer carry EUA: bamlanivimab+eteseviman and casirivimab+imdevimab.
Neutralizing monoclonal antibodies (mAbs) first received emergency use authorization (EUA) in November 2020 for treating at-risk patients with COVID-19, and the field has continued to evolve since that time. This presentation provides an update in the latest evidence showing reduced severe illness and hospitalization in patients treated with neutralizing mAbs. This presentation will also answer your questions from multidisciplinary expert perspectives in identifying EUA-appropriate patients and administering outpatient infusion therapies: Robert Gottlieb, MD, PhD; Marilyn Bulloch, PharmD, BCPS, FCCM; and Tesha Seabra, MSN, RN.
CME credits: 1.00
Valid until: 13-04-2022
Claim your CME credit at https://reachmd.com/programs/cme/portrait-bipolar-i-depression-visualizing-improved-patient-care-world-bipolar-day/12362/
Bipolar depression remains a burden for patients living with bipolar I disorder. Therefore, faculty experts came together on World Bipolar Day in a call to action to the healthcare community to improve the diagnosis and treatment of bipolar I depression. In this 60-minute activity previously aired as a live broadcast, faculty review the diagnosis and treatment of a patient case, discussing the utility of tools in diagnosis and strategies to overcome common clinical challenges. An overview of treatments recommended for bipolar I depression is also provided.
CME credits: 0.25
Valid until: 31-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/time-vision-critical-role-early-diagnosis-and-referral-neovascular-amd-and-rvo/12304/
Early diagnosis and early treatment of age-related macular degeneration (AMD) and retinal vein occlusion (RVO) can be critical to preserving a patient’s vision. How can optometrists, who are on the frontlines of eye care, diagnose and refer patients early in the disease process to ensure the best visual outcomes for patients? Join the discussion with Dr. Dunbar and Dr. Shechtman to find out more about how time is vision for these patients.
CME credits: 0.25
Valid until: 31-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/neovascular-amd-and-rvo-distinguishing-the-differential/12361/
Correctly identifying retinal diseases early on is essential in preserving your patients’ vision. How do physicians distinguish key pathological features to identify early neovascular age-related macular degeneration (AMD) and retinal vein occlusion (RVO) before macular edema leads to permanent vision loss?
In this activity, Drs. Kaiser and Pieramici discuss these key pathologies in AMD and RVO and when further evaluation with advanced imaging is necessary—for these patients, time is vision.
CME credits: 0.25
Valid until: 31-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-vision-outcomes-namd/12320/
Age-related macular degeneration (AMD) is the most common cause of blindness in adults over the age of 50 years. Anti-VEGF therapy has markedly improved vision outcomes in patients with neovascular AMD, but what else can we do to maximize long-term vision in these patients? Drs. Do, Haller, and Singh discuss the key role of fluid in the treatment of wet AMD, dosing interval data from clinical trials, and the importance of patient expectations when selecting therapy.
CME credits: 0.25
Valid until: 31-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/seeing-eye-eye-case-series-treatment-strategies-rvo/12323/
Retinal vein occlusion (RVO) can lead to macular edema, which is the main cause of vision loss. Accordingly, retina specialists know that time is vision and prompt intervention is critical to good outcomes in patients with RVO.
Join our discussion with Drs. Campochiaro, Khurana, and Scott to discover strategies to use with your patients before and during treatment and throughout maintenance to improve visual acuity while minimizing side effects.
CME credits: 0.25
Valid until: 31-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/namd-and-rvo-understanding-the-impact-on-patient-lives-and-the-need-for-timely-diagnosis-and-referral/12386/
Approximately 2 million individuals in the United States are living with age-related macular degeneration (AMD), and another 1.6 million are living with retinal vein occlusion (RVO). These numbers are increasing daily due to an aging population and prevalence of risk factors. There have been many advances in treatment, but what else can you be doing to prevent vision loss in your patients?
In this activity, Dr. Emily Chew speaks with Drs. Neil Bressler, Joseph Coney, and Steven Ferrucci to examine the evidence around early diagnosis, referral, and treatment of AMD and RVO and the impact of these diseases on patients’ lives.
CME credits: 0.25
Valid until: 31-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/time-vision-early-recognition-and-management-neovascular-amd-and-rvo/12279/
For patients with retinal vascular disease, time is vision. But there are key components that can help you diagnose early neovascular age-related macular degeneration and retinal vein occlusion before permanent vision loss occurs. Drs. Michael Ip and Christina Weng discuss warning signs, risk factors for progression, and the steps you can take to ensure early diagnosis and improved outcomes for your patients.
CME credits: 0.25
Valid until: 31-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/reducing-estrogen-dosing-in-chc-the-quest-to-balance-safety-with-tolerability/12426/
Physicians continue to seek the safest and most effective formulations for combined hormonal contraceptives (CHCs). The goal is to ensure that the patient’s chosen option optimizes the many benefits of estrogen but also reduces its adverse events—particularly those that are cardiovascular and thromboembolic in nature. Lower estrogen concentrations do not always mean better; sometimes better means better. But just like in a game of beach limbo, we have to ask: How low can you go?
Join us as Dr. Lee Shulman and Barbara Dehn, a nurse practitioner with vast contraception counseling and prescribing experience, discuss the dynamics of a new, lower-strength estrogen with the potential for use in combined oral contraceptives.
CME credits: 1.00
Valid until: 30-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/advocating-action-hcc-delivering-impartial-and-personalized-care/12205/
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Additionally, liver cirrhosis and hepatic dysfunction often complicate treatment. Advances in the understanding of the molecular pathogenesis of HCC have broadened the potential for effective molecular targeted therapies, and advances in immune checkpoint inhibitor therapy are now transforming the way clinicians treat HCC.
Of particular concern, HCC incidence and mortality rates have risen among American Indian/Alaska Native, Hispanic, and black populations in the United States in recent years. Incidence of HCC is also expected to increase in older populations due to hepatitis C, a risk factor for development of HCC, among other comorbid conditions such as cirrhosis, obesity, diabetes, and non-alcoholic steatohepatitis, which are also on the rise. Screening and surveillance of these conditions that contribute to the development of HCC occur less often in many Hispanic and black populations, which can delay diagnosis and leave them ineligible for curative resection or transplantation due to advanced disease, leading to worse prognosis.
In this activity, the expert faculty will review health disparities, inequities, and …
CME credits: 0.25
Valid until: 31-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/practical-guidance-surveillance-and-reporting-hemophilia/12299/
Dr. Shannon Meeks and Dr. Jonathan Roberts give an overview of the treatments used for the management of hemophilia A and discuss the safety and efficacy of these treatments. Using a patient case, they illustrate the pharmacovigilance process and explain how to implement this important reporting structure into everyday practice.
CME credits: 0.25
Valid until: 31-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/new-therapies-offer-improved-outcomes-in-hfref-management/12347/
Finding the optimal treatment strategy for patients with worsening heart failure with reduced ejection fraction (HFrEF) can be challenging, and long-term outcomes are poor. Can newer therapies and novel mechanisms of action finally help close the treatment gap for these patients? Join Drs. Javed Butler and Paul Armstrong as they explore these new mechanisms of action and provide practical insights into incorporating newly approved therapies into an overall HFrEF treatment plan.
CME credits: 0.25
Valid until: 31-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/what-you-need-know-about-pharmacovigilance-novel-hemophilia-treatment/12331/
Pharmacovigilance begins after clinical trials end and new therapies enter everyday practice. Due to the rarity of hemophilia, participation in clinical trials has necessarily been small, and so monitoring the safety of new hemophilia treatments is especially important. Continued surveillance of adverse drug reactions (ADRs) after approval is a responsibility that falls on all members of the care team.
Dr. Shannon Meeks and Dr. Cindy Leissinger discuss the importance of safety surveillance and monitoring for novel hemophilia A therapeutics. To give a better understanding of pharmacovigilance, this activity includes animation that breaks down the process and illustrates where your ADR reports go and what happens next.
CME credits: 0.25
Valid until: 27-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/biostimulators-and-anatomy/12377/
The differences between biostimulators and dermal fillers are simple yet critically important to their safe and successful use. With the help of 2D animation, Dr. Joel Cohen presents different techniques to optimize results in patients and minimize the risk of adverse effects.
CME credits: 0.25
Valid until: 30-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/latest-clinical-considerations-non-small-cell-lung-cancer-global-approach/12363/
Are dMMR and MSI-H both markers that will soon replace or work in conjunction with PD-L1 when determining immunotherapy for patients with metastatic NSCLC? Accurate testing and treatment selection is critical in identifying patients who will benefit from these therapies. Dr. Federico Cappuzzo, Dr. Solange Peters, and Professor Yi-Long Wu discuss emerging data from the recent WCLC, ESMO, and ASCO virtual conferences and offer their international and regional perspectives on the evolving use of immunotherapies in advanced NSCLC.
CME credits: 0.25
Valid until: 30-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/case-challenges-in-the-management-of-ibd/12355/
Follow Dr. Sunanda Kane and Dr. Neil Nandi as they explore a personalized and proactive treat-to-target strategy to achieve long-term remission in this clinical case scenario of a patient with IBD. Would you make the same decisions?
CME credits: 0.25
Valid until: 30-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/overcoming-barriers-young-adult-vaccination-call-action-frontline-providers/12407/
Adherence to CDC vaccination recommendations is a public health issue and a topic of great concern for clinicians. According to the World Health Organization, vaccines ultimately reduce the burden of infectious disease and have the potential to save 2 to 3 million lives a year worldwide independent of their impact on morbidity. Join us as Drs. E.J. Mayeaux and Paul Doghramji discuss the challenges we’re all facing to overcome vaccine hesitancy and improve vaccine uptake, especially during the COVID-19 pandemic.
CME credits: 0.25
Valid until: 30-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-womens-cancers-ovarian-cancer-io-parp/12337/
Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon.
CME credits: 0.25
Valid until: 29-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/neuromodulator-dosing-upper-face/12300/
Dr. Joel Cohen and Dr. Jason Bloom discuss the importance of neuromodulator selection and accurate dosing for the glabella and upper face. Dr. Bloom takes us through a patient demonstration of optimal injection techniques and dosing while addressing strategies to minimize the risk for adverse events.
CME credits: 0.25
Valid until: 29-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-womens-cancers-updates-triple-negative-breast-cancer/12302/
Our understanding of the biology of triple-negative breast cancer (TNBC) is leading to the development of more targeted therapies. Dr. Peter Schmid and Dr. Javier Cortés discuss the role of immunotherapies in the treatment of metastatic TNBC and how to determine if your patient is eligible for combination immunotherapies.
CME credits: 0.25
Valid until: 29-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/evolving-strategies-management-her2-positive-early-stage-breast-cancer/12412/
Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increased risk for recurrence and need further improvements in therapy options.
In this activity, Drs. Charles Geyer and Hope Rugo discuss how the management of HER2-positive early-stage breast cancer has evolved, the continued quest to reduce the burden of therapy on patients—and how subcutaneous approaches are achieving this—and other challenges in the treatment continuum.
CME credits: 0.25
Valid until: 29-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/new-viewpoints-in-the-management-of-ibd/12354/
New and emerging therapeutic targets will add to the existing portfolio of available biologics and small molecule therapies available in IBD. Join Dr. Russel Cohen and Dr. Neil Nandi as they explore the role of these targets in addressing the various unique IBD phenotypes that lead to loss of response over time, as well as provide practical insights into selecting the right therapy at the right time for your patient.
CME credits: 0.25
Valid until: 19-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/achieving-long-term-success-in-the-management-of-ibd/12353/
Achieving remission and long-term success in IBD is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation, and that do not possess broad immunosuppressive properties. Join Dr. Gary Lichtenstein and Dr. Neil Nandi as they break down their therapeutic recommendations and patient care approaches. Learn how to develop treatment plans that incorporate early, more aggressive use of targeted therapies and to select the right treatment for the right patient.
CME credits: 0.25
Valid until: 17-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/initial-and-subsequent-dmt-choices-in-the-management-of-multiple-sclerosis/12350/
Treatment goals for patients with multiple sclerosis continue to be refined as more and better disease-modifying drugs emerge from clinical trials and we accrue findings from real-world data. Nonetheless, the decision to match a patient with a particular drug agent has become more complex as we strive to achieve our treat-to-target goals and optimize patient outcomes.
Drs. Coyle and Oh discuss how clinicians can best approach the medical management of patients with multiple sclerosis, both in the short and long term. The goal is to apply best clinical evidence while personalizing a patient’s therapy, thus offering the patient as normal a life as possible.
CME credits: 0.25
Valid until: 17-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/goals-of-managing-ibd-treating-to-target/12352/
Treat-to-target is the current standard for the management of IBD, and as such it is imperative to understand what those targets are, what strategies will help you achieve them, and the importance of integrating a patient-focused therapeutic plan. Join Dr. Miguel Regueiro and Dr. Neil Nandi as they explore practical approaches to defining therapeutic success and provide listeners with solutions and recommendations to ultimately improve long-term IBD patient outcomes.
To view and download the Crohn's and Colitis Foundation's appeal letters referenced in this program, click here!
CME credits: 0.25
Valid until: 10-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-considerations-for-therapeutic-decisions-in-multiple-sclerosis/12332/
While we are witnessing an impressive expansion in the multiple sclerosis treatment landscape, we cannot lose sight of the fact that a critical component of care is the incorporation of best clinical evidence into the personalized management of each patient.
Join us as Drs. Coyle and Williams discuss how bringing shared decision-making into the management of multiple sclerosis can help us to not only achieve our treat-to-target goals, but also improve patient outcomes and satisfaction.
CME credits: 0.50
Valid until: 08-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/spotlight-new-guidelines-identify-and-manage-aortic-stenosis/12303/
New guidelines on valvular heart disease from the American Heart Association and the American College of Cardiology have recently been published. In this activity, Dr. Latib and Dr. Kohnstamm discuss the etiology of aortic stenosis, as well as apply the new ACC/AHA guidelines to clinical practice.
CME credits: 0.25
Valid until: 25-02-2022
Claim your CME credit at https://reachmd.com/programs/cme/multiple-myeloma-newsflash-emerging-data-2020-ash-annual-meeting/12245/
A 15-minute synopsis of the top hematology research in multiple myeloma presented at the 2020 ASH Annual Meeting. Learn about potential practice-changing data placed in a real-world context by a myeloma expert. This activity is an opportunity to stay up to date on the rapidly evolving myeloma landscape and to enhance your management and care strategies for patients with multiple myeloma.
CME credits: 0.25
Valid until: 26-02-2022
Claim your CME credit at https://reachmd.com/programs/cme/new-chcs-native-estrogen-with-specific-actions-in-tissues-nest/12283/
The estrogen component of combined oral contraceptives in part helps to suppress FSH and folliculogenesis, stabilizes the endometrium, minimizes unscheduled bleeding, and supports progestin activity. Nonetheless, there are downsides to estrogen, including an increased risk for cardiovascular and thromboembolic adverse events such as pulmonary embolism and deep vein thrombosis.
Join Drs. Lee Shulman and Andrew Kaunitz as they envision a better oral contraceptive—one formulated with a high NEST activity estrogen that has less potential to increase the risk of thromboembolic events while maintaining good cycle control.
CME credits: 0.25
Valid until: 26-02-2022
Claim your CME credit at https://reachmd.com/programs/cme/neuromodulator-dosing-duration/12266/
What does the future hold for aesthetics? The 4 four available neuromodulators share a similar mechanism of action and efficacy profiles, but they each have their own unique characteristics, and now an emerging agent is about to enter the scene. Dr. Joel Cohen and Dr. Carolyn Jacob discuss the subtle differences among neuromodulators and the importance of dosing for duration, specifically for the glabella and upper face. They also explore potential adverse events and strategies to minimize your patients’ risks.
CME credits: 0.50
Valid until: 25-02-2022
Claim your CME credit at https://reachmd.com/programs/cme/personalizing-prophylaxis-hemophilia-and-b-new-era-treatment-and-management/12152/
Hemophilia A and hemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX). While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies. The preferred treatment option for patients with hemophilia is replacement therapy. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are currently available and newer strategies are on the horizon. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these therapies have the potential to address and individualize the needs of patients.
Click here to access patient information on hemophilia from the CDC.
CME credits: 0.25
Valid until: 31-03-2022
Claim your CME credit at https://reachmd.com/programs/cme/advancing-acne-care-applying-current-knowledge-patient-needs-and-emerging-evidence-improve-outcomes/12262/
Depression, anxiety, failure to thrive, unemployment, low self-esteem, and suicidal ideation. What could possibly be contributing to all of these consequences? The culprit is acne—didn’t expect that, did you? Hear from dermatologists Dr. Andrew Alexis and Dr. Linda Stein Gold as they discuss the proper assessment of acne, its location—particularly beyond the face—and the differences to keep in mind when assessing skin of color. Faculty also examine the role that selective retinoid therapies play in treating acne and preventing the development of both the physical and psychological scars associated with this condition.
CME credits: 0.50
Valid until: 26-02-2022
Claim your CME credit at https://reachmd.com/programs/cme/emerging-antipsychotic-strategies-bipolar-i-disorder-and-schizophrenia-translating-findings-clinical-trials-individual-patients/12258/
Dr. Leslie Citrome and Dr. Christoph Correll discuss the clinical trial data of current and emerging antipsychotic therapy for bipolar I disorder and schizophrenia. They provide insight on how to apply this clinical data into everyday practice and explore the best strategies to improve patient-centric issues for people coping with these illnesses.
CME credits: 1.00
Valid until: 18-02-2022
Claim your CME credit at https://reachmd.com/programs/cme/connecting-care-multidisciplinary-panel-discussion-use-neutralizing-monoclonal-antibodies-ambulatory-patients-covid-19/12226/
Hear from a multidisciplinary, interprofessional panel of experts on COVID-19 infusion therapies with virus-neutralizing monoclonal antibodies (mAbs). This activity features a clinical discussion of the Emergency Use Authorization criteria and data from real-world use of mAbs in ambulatory patients. Learn how this treatment reduces the chance of patients with COVID-19 developing severe illness and what could be done to effectively implement the outpatient delivery of mAbs to patients with COVID-19 in your practice.
CME credits: 1.00
Valid until: 12-02-2022
Claim your CME credit at https://reachmd.com/programs/cme/challenging-cases-pah-deeper-dive/12246/
Pulmonary Arterial Hypertension is a progressive disease and is associated with poor clinical outcomes. This first live webinar provides an in-depth discussion of the new thresholds for the diagnosis of PAH, and differential diagnostic considerations, along with the emerging data on the optimal management of patients with PAH. This activity provides a case discussion on the clinical application and effective strategies to integrate the emerging data into treatment regimens to improve outcomes for individuals with this highly complex disease.
CME credits: 0.75
Valid until: 03-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/virtual-ibd-clinic-disease-management-and-surgery/11489/
It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Hudesman presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.
CME credits: 0.75
Valid until: 03-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/virtual-ibd-clinic-diagnosis-and-medical-treatment/11442/
The management of IBD remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Anita Afzali presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.
CME credits: 0.50
Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-common-questions-management-hemophilia/10839/
Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life.
Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices.
AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when …